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ABSTRACT 
 
 
Background: In England and Wales over 5000 people die each year with a sudden 
death of ill-defined or unknown cause. 
 
Aims: To explore the hypothesis that the use of drugs that can cause prolongation of 
the QT interval on the electrocardiograph are associated with an increased risk of 
sudden death from cardiac arrhythmia. 
 
Methods: A community based, matched case control study used post mortem and 
primary care datasets. Cause of death was most likely due to cardiac arrhythmia. 789 
cases were matched to 2357 controls for age, sex and cardiovascular disease at the GP 
practices. The International Registry for Drug-Induced Arrhythmias “Arizona” 
classification was used to separate drugs according to strength of QT prolongation. 
 
Results: Conditions significantly associated with sudden death were used in the 
adjusted analysis. Overall risks were doubled for the registry drugs that were 
considered to pose the greatest risk but with considerable variation. The association 
with sudden death increased with concomitant use of registry drugs. Drugs used for 
psychiatric purposes were consistently strongly associated with sudden death. 
 
Conclusion: Arizona registry classification is a poor predictor of sudden death. The 
linkage of the general practice research database to mortality data has the potential for 
a much larger sample for further study. 
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  0 INTRODUCTION 
 
This thesis describes a matched case-control study that identified and quantified 
associations between sudden cardiac death (SCD) from presumed cardiac arrhythmia 
and medications that prolong the QT interval on the electrocardiograph.  
 
The background (Chapter 1) puts the study into context with previous work.  
 
Chapter 2 states the aims of the study. 
 
Chapter 3, the methods, describes in detail the design of the study, and the definition 
and selection of cases and controls and how information was obtained. It defines drug 
exposure as the independent variable. The process of obtaining ethical approval is 
described. There are short sections on matching and strategy for analysis.  
 
Chapter 4 explores methodological issues relevant to this thesis. A reliability study 
measured the level of agreement between the two nurses that gathered the data. A 
comparison of surgeries that granted access to medical researchers with those that did 
not was done investigating whether they were single or multi handed and indices of 
deprivation for the catchment areas of surgeries. The third methodological study 
quantified the level of agreement between causes of death on mortality files and post 
mortem reports.  
 
Chapter 5 describes the results of the case-control study with particular emphasis on 
associations between SCD and medications that can prolong the QT interval. 
 
 1
Chapter 6 discusses the findings of the thesis and attempts to put them into context 
with contemporary work by other researchers. 
 
My role on the study 
Before I started working on the study, the protocol had been written, ethical approval 
obtained and section 60 approval had been granted by the Department of Health for 
access to patient records. 
 
I was employed as a research nurse to gather the data and also expressly to do an 
MPhil. I designed the database for the study and wrote all of the queries and reports. I 
planned and undertook all of my own analysis. To aid timely submission of my MPhil 
I used the data collected up to October 2006 whilst the case-control study continued 
for a longer period and thus had a larger number of cases.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 2
1 BACKGROUND 
 
1.0 Introduction to the background section 
 
This chapter describes the epidemiology of sudden cardiac death (SCD) in the United 
Kingdom and worldwide and explores cardiological conditions that lead to SCD. 
There is a substantial section on medications that can directly and indirectly prolong 
the QT interval. Cases in this thesis had a post mortem report and there are sections 
that examine the accuracy of death certification and post mortem reporting in the UK 
and beyond. 
 
When researchers write about sudden cardiac death they do not always mean the same 
thing. There are many definitions of sudden cardiac death, the broadest including 
death from myocardial infarction as well as arrhythmia. Narrower definitions exclude 
myocardial infarction and acute precipitating causes. 
 
1.1 The epidemiology of sudden cardiac death 
 
Search strategy 
I used the medical database medline 1950 to April 6th 2009. The search strategy used 
the keywords “sudden” “cardiac” and “death” limited to epidemiology and gave 1553 
references. A further limit to abstracts gave 1233 references of which there were 1049 
articles in the English language. There were 264 full text articles. I used relevant 
papers and references to other relevant papers were followed up and incorporated into 
this thesis.  
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I used the Critical Skills appraisal Programme1 (CASP) appraisal tool as a framework 
for evaluating studies although I did not do it formally as one would do for a 
systematic review. I reviewed case control and cohort studies from the major 
researchers investigating the association with sudden cardiac death and medication 
and I have quoted relevant study results. I have commented on the quality of relevant 
studies in my thesis with respect to the CASP guidelines.  
 
 
1.1.1 Definition of sudden cardiac death 
There are many definitions of sudden cardiac death (SCD) and there is ambiguity in 
the definition of SCD in clinical and public health practice. It is a matter of debate as 
to when an unexpected death should be called ‘sudden’ and how the cardiac origin of 
the death should be ascertained2. This background section will explore various broad 
definitions of sudden cardiac death as well as the much narrower definition of sudden 
cardiac death that defines the cases in this thesis. 
 
Typically SCD is broadly defined as follows: ‘Natural death due to cardiac 
causes, heralded by abrupt loss of consciousness within one hour of the onset of acute 
symptoms or within 24 hours of having been observed alive and symptom free; pre-
existing heart disease may have been known to be present, but the time and mode of 
death are unexpected3 4. In practice, numerous criteria have been used to define 
sudden cardiac death in the medical literature. Sudden cardiac death is witnessed in 
only two thirds of cases making the diagnosis and time of onset difficult to establish5. 
 
One broad definition of SCD used by Zheng et al was to define SCD as deaths 
occurring out of the hospital or in the emergency room or as "dead on arrival" with an 
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underlying cause of death reported as a cardiac disease (ICD-9 code 390 to 398, 402, 
or 404 to 429)6. This analysis was based on 719,456 cardiac deaths among adults age 
35 years or older in 1998 of which 456,076 were classified as sudden cardiac death. 
 
In a letter to the editor Angelini pointed out that if SCD denotes any unexpected, 
cardiac death (which, by inference, would have been prevented by a pacemaker or an 
implantable defibrillator), it seems unreasonable to assume that SCD accounted for 
63.6% of cardiac deaths in 1998, as claimed by Zheng7. He concluded that “what 
would indeed be important to identify is premature arrhythmic death”. He stated that 
without consistent electrocardiographic monitoring and post mortem data, death 
certificates will not elucidate the true incidence of this event. 
 
In this thesis the cases were people that had died from a presumed sudden cardiac 
arrhythmic death not due to an acute precipitating event such as a myocardial 
infarction. Every case had a post mortem report and individuals were excluded from 
being a case if there was evidence that death was due to any non cardiac cause or if 
they had an acute cardiac event that could trigger an arrhythmia such as a fresh 
coronary artery thrombus. This is an uncommon definition of SCD. In the section 
describing the epidemiology I will be using the broader definition of SCD based on 
the International Classification of Diseases version 10 codes. 
. 
1.1.2 Incidence of SCD in the UK 
 
The National Service Framework 2005 estimated the number of sudden cardiac deaths 
each year in the United Kingdom (UK) at 100,0008. A prospective survey of 83 
coroners jurisdictions in England estimated that the frequency of deaths in apparently 
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healthy adults age 16 to 64 seen alive within 12 hours of death for whom there was no 
medical history of cardiac disease and for whom the post mortem report showed either 
a cardiac or no identifiable cause of death was 11 in 100,0009. An estimated 400 
sudden cardiac deaths in the UK each year that occur in people under the age of 30 
years are unexplained and thought to have a genetic basis8. 
 
 
1.1.3 Incidence Worldwide 
 
Various estimates exist for the magnitude of sudden cardiac death in the general 
population of the United States. Figures based on primary cardiac arrest from first 
responder agencies and from death certificate data give estimates ranging from 
184,000 to greater than 400,000 per year4. Thus in the general population of the 
United States the incidence of sudden cardiac death is about 1 death per 1000 head of 
population per year and as described below this figure holds for other developed 
nations. 
 
A prospective cohort study using an integrated primary care database in the 
Netherlands reported an annual incidence of sudden out of hospital cardiac arrests of 
0.92 cases per 1000 person-years (95% Confidence interval (CI): 0.85, 0.99). The 
study population comprised 249,126 subjects with a mean follow up of 2.54 years. In 
this period 4,892 deaths were identified, 582 of which were classified as (probable) 
sudden cardiac death10. 
 
It has been estimated that in the developed world sudden cardiac death is the largest 
cause of natural death accounting for 12-18% of total mortality and 50% of cardiac 
mortality. These figures are based on retrospective studies that may be an over-
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estimate as described below. Sudden cardiac death accounted for 5.6% of the annual 
mortality of a population of 660,486 residents of Multnomah County, Oregon 
according to a prospective study4 .Between 1 February 2002 and 31 January 2003, 353 
residents suffered sudden cardiac death (incidence 53 of 100,000, median age 69 
years, 57% male). An assessment of the validity of death certificate-based 
retrospective surveillance was made by comparing it with the prospective study 
results. It was found that retrospective death certificate-based surveillance 
significantly overestimated sudden cardiac death (1007 cases, incidence 153 of 
100,000, median age 81 years, 51% male). 
 
Sudden cardiac death rates were overestimated by 47% when derived from death 
certificates in a study that compared out of hospital sudden cardiac deaths derived 
from death certificates with physician adjudicated sudden cardiac deaths in the 
Framingham Heart Study from 1959 to 199911. 
 
 
1.1.4 Incidence of sudden cardiac death by gender 
 
The incidence of SCD is higher in men than in women, with men two to four times 
more affected than women when age is adjusted for. Most studies of primary cardiac 
arrest have reported a threefold higher incidence in men compared with women12 but 
these studies have looked at data retrospectively. Prospective studies may reduce the 
sex discrepancy as shown in a study that found 43% of 353 sudden cardiac death 
cases were female4. A prospective study in the Netherlands that classified 582 people 
as having probable sudden cardiac death estimated the risk to be 2.3 fold higher in 
men than in women 10. 
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1.1.5 Change in sudden cardiac death rates over time 
 
Temporal trends of the 358 sudden cardiac deaths in the original and offspring cohorts 
of the Framingham heart study from 1950 to 1999 have been examined. From the 
periods 1950-1969 to 1990-1999 sudden cardiac death rates decreased by 49%, (95% 
CI (28 %,  64%)). This decrease was seen in men and women, in subjects with and 
without a prior history of coronary heart disease, and in smokers and non-smokers13.  
 
The trend in subjects with and without heart disease may be evidence that the 
improvements in primary and secondary prevention have resulted in the decreasing 
occurrence of this event. Interventions aimed at reducing the frequency and severity 
of myocardial ischaemia, such as thrombolytic therapy and coronary artery bypass 
grafting, have been associated with decreased incidence of sudden cardiac death and 
reduced overall cardiac mortality5.  
 
 
1.1.6 Circumstances of sudden cardiac deaths 
 
In the prospective study that identified 353 sudden cardiac deaths in the residents of 
Multnomah County Oregon 52% of them were witnessed. 82% of cardiac arrests took 
place at home of which 46% were witnessed. The place of death did not vary 
significantly when stratified by age or gender 4 
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1.1.7 Onset of symptoms to death 
 
Experience from ambulatory and coronary care unit monitoring indicates that the 
underlying mechanism in most sudden deaths is ventricular fibrillation14. This finding 
is supported by a study that showed that of 133 persons with spontaneous cardiac 
arrest attended by paramedics within 10 minutes, 100 (75%) had ventricular 
fibrillation as the initial rhythm and 33 (25%) had extreme bradycardia or asystole. 
The latter group of arrhythmias was characterised by sinus arrest or severe sinus 
bradycardia (90%) and complete A-V block (10%)15.  
 
 
1.1.8 Chances of survival from cardiac arrest 
 
For those who suffer out-of-hospital cardiac arrest due to heart disease, survival rates 
are low, even in the setting of witnessed arrests in persons with ventricular fibrillation. 
ospital discharge rates of 20% have been reported from urban centres with the ability 
to provide rapid-response defibrillator equipped emergency medical services. Survival 
is highest when cardiopulmonary resuscitation (CPR) is started early, possibly 
because definitive procedures such as defibrillation, medications and intubation can 
be effectively applied16. However, national averages of successful resuscitation from 
out-of-hospital cardiac arrest due to heart disease are only between 1% and 2%5. This 
discrepancy could in part be due to people dying because they do not get prompt 
expert treatment.   
A prospective community study over the two years 1994 and 1995 in the United 
Kingdom health districts of Brighton, South Glamorgan and York concluded that the 
chance of surviving a cardiac arrest in the community depends on whether it is 
witnessed and if so by whom and if there is a resuscitation attempt 17. The main 
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outcome measure was survival to reach hospital and for 30 days after cardiac arrest in 
1290 people less than 76 years of age. People whose cardiac arrests were witnessed by 
a doctor or paramedic had the greatest chance of survival with 35 out of 101 (35%) 
surviving. Out of 200 cardiac arrests witnessed by other members of the public 15 
(7.5%) survived. Home cardiac arrests totalled 464 with 15 (2.0%) surviving. There 
were 525 cardiac arrests unwitnessed and none survived. The study found that there is 
an increased chance of surviving a cardiac arrest if it is witnessed by a person that is 
trained in the technique of resuscitation.  
 
A prospective study in North America4 also found that the survival rate was better if 
the sudden cardiac death occurred outside the home. This is likely to be related to a 
higher chance of the out-of-home sudden cardiac death being a witnessed event (70% 
of out of home SCDs were witnessed compared with 46% of in home SCDs).  The 
study also found that there were no differences between genders with respect to 
overall survival rate. 
 
 
 
1.1.9 Strategies to prevent sudden cardiac death 
 
A prospective study of sudden cardiac arrest in casinos where trained security officers 
used automated external defibrillators in 105 cases with ventricular fibrillation 
resulted in a survival rate of 74% when defibrillation was started no later than 3 
minutes after a witnessed collapse and 49% when defibrillation was started after more 
than 3 minutes18. A literature review concluded that early defibrillation is critical to 
improving survival and public access to defibrillation offer hope that further 
improvements in survival can be achieved.19 The complexity of trigger mechanisms 
makes it difficult to achieve a reliable identification of high-risk patients. The number 
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of sudden cardiac deaths could be reduced by, firstly in patients with known heart 
disease by developing new methods to identify those who are at risk, secondly treat 
patients that do not have a diagnosis of heart disease according to risk factors for 
coronary disease and thirdly, improve the success rate of resuscitation by putting 
greater emphasis on the training of laypersons in basic and advanced life support 
techniques. 
 
 
1.2 Causes of Sudden Cardiovascular Death 
 
 
1.2.1 Post-Mortem findings 
 
Cardiac arrhythmia was the most common cause of death in a study that evaluated the 
post mortem reports of four hundred and forty five sudden cardiac deaths, all of whom 
had evidence of at least moderate atherosclerosis20. Extensive coronary 
atherosclerosis is by far the most common pathological finding in patients who die 
suddenly21. One study concluded that coronary artery disease accounts for as much as 
80% of sudden cardiac deaths22. Zheng et al found that of those people who were 
classified as dying of a sudden cardiac death, coronary heart disease (ICD-9 codes 
410-414) was the underlying cause on 62% of death certificates. These conclusions 
were reached from an analysis of United States vital statistics mortality data from 
1989 to 19986. It has been shown that in nearly two thirds of cases, three coronary 
arteries showed more than 75% luminal obstruction23. The arteries with extensive 
atherosclerosis in victims of sudden cardiac death were the left anterior descending 
(96%), right coronary (79%), left circumflex (66%), and left main stem (34%). 
Vascular obstruction was generally found in both proximal and distal segments of the 
epicardial coronary arteries. In a study of 90 hearts, healed infarcts in the absence of 
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acute infarction were found in 37 (41%) and no infarct in 34 (38%) of sudden 
coronary deaths24. 
 
Post mortem studies of sudden cardiac death give consistent findings in line with an 
American study of the Framingham population which concluded that 85% of people 
greater than 40 years old that died from cardiac arrest had coronary artery disease, 
10% had other structural cardiac abnormalities for example cardiomyopathy, 
hypertrophy or valvular disease leaving 5% with no macroscopic structural cardiac 
abnormality25. 
 
A study of 215 post mortem reports of sudden cardiac death cases in Southampton, 
England found that 51% had a previous MI26. 
 
An investigation of sudden cardiac deaths in London, England stated that at least 4% 
of sudden deaths are unexplained at autopsy and concluded that over half of sudden 
arrhythmic deaths (SADS) were likely to be due to inherited heart disease27. These 
SADS are a subset of those dying from SCD. 
 
 
1.2.2 The problem of unrecognised heart disease 
 
In approximately 40% to 50% of cases of cardiac arrest in the community there is no 
history of heart disease. The examination of the Framingham heart study data showed 
that 173 (48%) of the 358 sudden cardiac deaths were in subjects not treated for 
preceding coronary heart disease13. Thus unrecognised and therefore untreated heart 
disease is a major factor contributing to sudden cardiac death rates. 
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1.2.3 The increasing importance of sudden death in heart failure 
 
Sudden death has become the dominant mode of death in heart failure taking over 
from worsening and progressive heart failure. With the development of drugs that 
primarily have modulation of the renin-angiotensin and sympathetic nervous systems 
as their mechanism the relative importance of progressive heart failure has 
decreased28. 
 
 
1.2.4 Common risk factors 
 
The most powerful predictor of sudden cardiac death is poor left ventricular function. 
Other risk factors mirror those of coronary heart disease and include 
hypercholesterolaemia, hypertension, cigarette smoking, alcohol consumption, 
physical inactivity, obesity and diabetes 29 30. 
 
A multivariate model developed using prospective data on 4120 middle-aged men 
from the Albany and Framingham studies estimated the probability of sudden cardiac 
death. The model took into account risk factors of body mass, cigarette smoking, 
hypertension, hyperlipidaemia and left ventricular hypertrophy by 
electrocardiographic criteria. There was a 16 fold increase in risk from the lowest to 
the highest risk group for people without recognised heart disease with the annual 
incidence of sudden cardiac death 0.7% in the highest subgroup31. 
 
The risk of sudden cardiac death varies over time among people with known heart 
disease. The highest risk of out-of-hospital cardiac arrest is in the first 6 months after 
a major cardiovascular event, such as a myocardial infarction or new onset heart 
failure and then declines rapidly over the next 18 months. Survivors of cardiac arrest 
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or patients with ventricular tachyarrhythmias in the convalescent phase of an acute 
myocardial infarction have an incidence of sudden cardiac death in the first year 
following a ventricular fibrillation episode of 15%. 
 
Obesity is associated with an excessive occurrence of CHD, largely as a consequence 
of its association with atherogenic risk factors32. Obesity is more strongly correlated 
with sudden death incidence in men. Diabetes doubles the risk of atherosclerotic 
cardiovascular mortality with the rate for sudden death being slightly greater in 
women33.  
 
 
1.2.5 Arrhythmias  
 
Sudden cardiac death is often preceded by arrhythmia. According to the National 
Service Framework guidelines, cardiac arrhythmia affects more than 700,000 people 
in England8. An arrhythmia may be caused by an inherited problem or by an acquired 
condition that disturbs the electrical impulses that regulate the heart. The heart may 
beat too slowly, too quickly, or in an irregular way. The symptoms experienced by 
patients include palpitations, loss of consciousness, dizziness and breathlessness. In 
extreme cases, certain types of arrhythmia can cause sudden cardiac death. Acquired 
heart disease is the most common factor predisposing a person to arrhythmias. The 
main causes are atherosclerosis, hypertension, previous myocardial infarction and 
inflammatory or degenerative conditions. The ischaemia, scarring or abnormal tissue 
deposits found with these diseases can cause tachycardias (originating in either the 
atria or ventricles) by causing cells to fire abnormally or by creating islands of 
electrically inert tissue so that impulses circulate in a re-entrant fashion around these 
areas.  
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 A variety of other factors may predispose a person to develop arrhythmias. Prominent 
among them is the part of the autonomic nervous system that is involved in 
cardiovascular regulation. This control system alters the sinus rate. When sudden 
death occurs in the absence of evidence of organic heart disease it is conceivable that 
neurochemical and electrophysiological malfunction is responsible34 35. The National 
Service framework for the UK states that most sudden deaths in people under 30 years 
old are caused by inherited cardiomyopathies and arrhythmias8. 
 
 
1.2.5.1 Chemically induced arrhythmias 
 
Many chemical agents may provoke arrhythmias, sometimes with serious 
consequences. Known factors include high or low blood and tissue concentrations of a 
variety of minerals, such as potassium, magnesium and calcium. These play a vital 
role in the conduction of impulses in the heart. Addictive substances, especially 
alcohol, cigarettes and recreational drugs notably cocaine, can also provoke 
arrhythmias as can various medications including those used to treat arrhythmia36. 
 
1.2.6 Cardiomyopathies 
 
Hypertrophic cardiomyopathy can present at any age its prevalence is 0.2% and 
sudden death occurs in about 1% of patients annually37. About 70% of cases of 
hypertrophic cardiomyopathy are inherited as autosomal dominant with a high degree 
of penetrance and equal sex distribution. Hypertrophy of the ventricular septum 
occurs. The muscle fibres are short, thick and fragmented and there is fibrosis. About 
one third of cases have left ventricular hypertrophy38. Ventricular arrhythmias are 
common in patients in patients with either hypertrophic or diffuse cardiomyopathy 39. 
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Dilated cardiomyopathy results in an enlarged, flabby heart. It is associated with 
ventricular arrhythmias and sudden death. It may be idiopathic or caused by alcohol 
dependence, undiagnosed hypertension, viral infection, autoimmune disease and 
puerperal heart failure. Thyrotoxicosis may rarely present as dilated cardiomyopathy. 
There is also a rare X chromosome linked form40.  
 
 
Restrictive cardiomyopathy may be caused by a variety of conditions including iron 
storage diseases, scleroderma, amyloidosis and sarcoidosis. For sarcoid heart disease 
ventricular premature beats have been associated with sudden death41. 
 
 
1.2.7 Wolff-Parkinson-White Syndrome 
 
In this condition, one or more accessory pathways are present that can cause 
paroxysmal tachycardia by contributing to accelerated conduction from the atrium to 
the ventricle. Although disabling arrhythmias afflict only a minority of these patients, 
sudden death has been reported42 43. 
 
 
 
1.2.8 Genetic Long QT syndrome 
 
Prolongation of the QT interval is associated with ventricular arrhythmias, syncope, 
and sudden death. This syndrome may be acquired or congenital. Two rare clinical 
syndromes were originally recognised; firstly the Jervell-Lange-Neilson syndrome 
that is autosomal recessive, and symptoms also include deaf mutism44, secondly the 
Romano-Ward syndrome which is autosomal dominant with normal hearing. As well 
as a prolonged QT interval, both syndromes are characterised with frequent syncopal 
attacks that are often provoked by emotional or physical stress. There is a high 
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mortality with 20% dying in the first year after the first syncope and 50% within 10 
years. Several other genetic types have been identified corresponding to potassium 
and sodium ion dysfunction45.  One of these is the Brugada syndrome, which is 
associated with an abnormality in a sodium ion channel gene. The syndrome is 
estimated to be responsible for at least 4% of all sudden deaths  and the prevalence of 
the disease is estimated to be 5/10 000 inhabitants46 It is more common in South 
Asian subjects. In a community based study in Japan the Brugada-type ECG was 
found in 98 of 13,929 study subjects (0.70%, 95% confidence interval [CI]: 0.57% to 
0.86%). The typical coved-type with an rsR' pattern in V1 lead ("typical" Brugada-
type) was found in 0.12% of subjects (95% CI: 0.07% to 0.20%).  
 
 
1.3 Drugs causing QT prolongation; direct and indirect 
mechanisms 
 
 
1.3.1 Acquired Long QT syndrome 
 
Acquired QT prolongation is most commonly drug induced or secondary to 
hypocalcaemia, hypomagnesaemia or hypokalaemia. Drug induced prolongation of 
the QT interval may cause life-threatening ventricular arrhythmia47. Antiarrhythmic 
drugs are often implicated especially quinidine, procainamide and disopyramide. 
Prolongation of the QT interval is part of the therapeutic benefit of drugs like 
amiodarone or sotalol but the drug should be stopped if the QT interval exceeds 
500ms.  Torsades de Pointes (TdP, a form of multi-focal ventricular tachycardia) may 
occur if the QT interval exceeds 500ms48. Several other types of drugs can also 
prolong the QT interval including some commonly prescribed antibiotics, 
antidepressants, diuretics, antifungals, antihistamines, antimalarials, diuretics, lipid-
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lowering drugs, oral hypoglycaemics. They increase the QT interval by a variety of 
mechanisms.  
 
1.3.2 Definition of QT interval and Corrected QT interval 
 
The QT interval on the electrocardiogram (ECG) corresponds to the time taken to 
depolarise and repolarise the ventricular myocardium. The length of the QT interval is 
inversely proportional to heart rate. To remove the effect of heart rate, the QT interval 
is transformed (normalised) into a value known as the QTc interval. The c in QTc 
stands for correction. The most commonly used method for correcting the QT interval 
for heart rate is the one formulated by Bazett 49. Bazett's formula is QTc = QT/(√RR), 
where QTc is the QT interval corrected for heart rate, and RR is the interval from the 
onset of one QRS complex to the onset of the next QRS complex, (a single heart beat) 
measured in seconds. Bazett’s formula over-corrects at high heart rates and under-
corrects at low heart rates. There are several other more accurate methods, but they 
tend not to be used because they are complicated. The regression based approach is 
considered to be the most accurate50. The normal range of the QTc interval is 350 to 
430 ms for men below 55 years and for women it is 350 to 450 ms51. QTc 
prolongation can be defined as QTc values above 450ms for men and 470ms for 
women. Both the QT and QTc intervals commonly exceed 500ms among subjects 
developing TdP 52. 
 
 
1.3.3 QTc Prolongation and risk of sudden cardiac death 
 
There is controversy about the mortality risk posed by QTc prolongation in the 
general population. This is because good quality epidemiological studies that have 
investigated the risk reached different conclusions.53 
 18
 A recent prospective, population-based Rotterdam study of 6134 subjects age 55 years 
and older, that were enrolled and followed up for an average time of 6.7 years, 
demonstrated that subjects with an abnormally prolonged QTc interval, >450 ms in 
men, > 470 ms in women) were associated with a three-fold increased risk of sudden 
cardiac death after adjustment for relevant covariates, age, gender, body mass index, 
hypertension, cholesterol/high density lipoprotein ratio, diabetes mellitus, myocardial 
infarction, heart failure and heart rate54.  Positive findings were also found in the 
longitudinal Zutphen study from the Netherlands involving middle- aged and elderly 
men55 and from the Strong Heart Study56 that enrolled American Indians and in the 
Cardiovascular Health Study of community dwelling elderly subjects 57. The 
Caerphilly heart study indicated that QT dispersion is an independent predictor of 
cardiac death but that the QT maximum was not58. QT dispersion is defined as the 
difference between the longest (QTmax) and the shortest (QTmin) QT intervals within 
a 12 lead ECG59. QT dispersion is a measure of myocardial repolarisation 
heterogeneity60 and is predictive of ischaemia-related cardiac dysrhythmia in patients 
with ischaemic heart disease61. 
 
No association with baseline QTc prolongation and total mortality or sudden death 
was found in the population based Framingham study62. The Framingham study 
involved subjects aged 30 to 65 years with follow up extending over a 30 year period. 
The negative Framingham study is of particular concern because Framingham 
investigators have consistently provided excellent scientific studies.  
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The difference in the conclusions of the Rotterdam study and the Framingham study 
may be due to the difference between the ages at which subjects were enrolled. In the 
Framingham study the baseline electrocardiogram (ECG) was recorded in a majority 
of subjects at a relatively young age, probably before the development of subclinical 
cardiac disease whereas for the Rotterdam study the first of two baseline ECGs were 
recorded at age 55 years when subclinical disease is more likely to be present. 
 
The Rotterdam investigators were able to show a dose response effect between the 
duration of the QTc interval (borderline and and abnormally prolonged categories 
relative to normal QTc prolongation) and the risk of sudden cardiac death in the entire 
population. This dose-response effect adds considerable strength and significance to 
the association of QTc prolongation and the risk of sudden cardiac death in older 
adults. 
 
 
1.3.4 Possible mechanisms of observed risk association between QTc 
prolongation and sudden cardiac death 
 
The simplest explanation is that QTc prolongation, whatever the cause, is 
proarrhythmic, and this alone is sufficient to increase the probability of sudden 
arrhythmic cardiac death. Another possibility is that the length of the QTc interval is 
just a marker for the severity of underlying sub-clinical cardiac disease and that the 
risk is related to the underlying cardiac problem. The authors of the Rotterdam study 
tried to adjust for covariate risk factors, but perhaps adjustment was not complete. A 
third possibility is that the QTc prolongation in the general adult population is due to 
genetic variability, with the increased risk of sudden cardiac death being a direct 
consequence of gene-related QTc prolongation. Furthermore it is possible that the 
presence of one or more ion-channel gene polymorphisms could cause minor 
 20
alterations in ion-channel function contributing to a modest prolongation in cardiac 
repolarisation and an increased probability for fatal arrhythmias. For example, a 
D85N polymorphism in the KCNE1 gene, the beta-subunit of the IKs has been 
associated with drug-induced QTc prolongation. The frequency of this polymorphism 
is approximately 2% to 3% in the general population. By itself this polymorphism 
might have only minimal effects on the QTc duration in a general population. 
However, the presence of additional unrecognised ion-channel polymorphisms may 
have additive effects on the QTc duration such that individuals that carry several of 
these polymorphisms, might be at increased risk of sudden cardiac death63. Such 
polymorphisms are being investigated as modifier genes to explain the normal 
variation in the QTc interval that exists among healthy individuals64. 
 
Investigations into the genetic contributions to rhythm and conduction disorders have 
found genes or loci associated with primary rhythm and conduction disorders such as 
familial atrial fibrillation and atrio-ventricular block65. Some cardiac muscle problems 
such as cardiomyopathy, predispose to arrhythmia and have documented genetic 
components. 
 
 
1.3.5 The clinical significance of a long QT interval 
 
The lengthening of the QT interval on the ECG is a significant finding because it is 
associated with Torsade de Pointes (TdP), which is a dangerous polymorphic 
ventricular arrhythmia that can lead to sudden death.  
 
About 70% of patients who develop TdP have a prolonged QT interval. In contrast, 
only a few patients with prolonged QT interval go on to develop TdP 66 67. Therefore 
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despite the association it cannot be claimed that a prolonged QT interval causes TdP 
or sudden death. This will be discussed further with respect to specific drugs.  
 
For patients with TdP the most common QT interval or QTc is 600ms to 649ms. 
Other measures have been proposed to supplement QTc measurement and allow better 
prediction of risk of dysrhythmia such as QT dispersion which is the maximum 
difference in QTc values on a 12 lead ECG. This is considered to be a measure of 
heterogeneity and a predictor of dysrhythmia 68. 
 
1.3.6 Cardiac cells 
 
It is necessary to have an understanding of the properties and behaviour of cardiac 
cells before discussing the mechanisms by which drugs cause QT prolongation. 
Cardiac cells exhibit a charge capable of changing throughout the cardiac cycle. The 
mechanism that allows this dynamic process is the flow of positively charged ions 
(cations) in or out of the cell. During the resting state the cell is polarised. Its interior 
is negatively charged (-90mV) with respect to the exterior. The potassium ion (K+) is 
the dominant cation inside the cell. Its continuous outward movement through the cell 
membrane is what maintains the intracellular negativity. Like all living cells, the 
inside of the cardiac myocyte has a negative charge. This results in a voltage 
difference across the cell membrane called the transmembrane potential. Unlike most 
other cells, cardiac myocytes are excitable. When appropriately stimulated, channels 
in the cell membrane open, allowing ions to flow across the cell membrane. This 
results in the cardiac action potential. There are three main components to the action 
potential: depolarisation, repolarisation, and a resting phase69.  
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During repolarisation, the cardiac membrane potential returns to normal. During this 
phase, the myocytes cannot contract (refractory period). The resting phase is the 
period between action potentials. During the resting phase most myocytes have no net 
movement of ions across the cell membrane. In some cells, however, the resting phase 
is associated with a gradual increase in transmembrane potential (phase 4 activity). 
When this potential is high enough, the appropriate channels open and spontaneous 
depolarisation begins. The property of cells to increase transmembrane potential 
during the resting phase is called automaticity. This is the mechanism whereby the 
normal cardiac impulse is generated. Cells in the sinus node usually have the fastest 
phase 4 and initiate the cardiac impulse. The phases of this process are summarised in 
fig 1. 
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Fig 1. Phases of the cardiac action potential 
 
Phase 0 is depolarisation of the myocyte when sodium channels in the cell membrane 
open and positively charged sodium ions enter it, causing a rapid change in the 
transmembrane potential. This depolarisation spreads to adjacent cells and 
corresponds to ventricular depolarisation seen as the QRS complex on the ECG 70. 
Phase 1 corresponds to a period of rapid initial repolarisation, which is brief. The 
sodium influx in the fast channels has ended and the recovery process is now in place 
by the opening of transient outward potassium channels with efflux of potassium ions. 
Phase 2 is known as the plateau phase. There is reduction of the efflux of potassium 
ions and in addition Calcium ions (Ca++) and Sodium ions (Na+) are moving into the 
cell. The flow of outward currents through delayed potassium rectifier channels is 
almost equalled by inward flow of current through calcium slow channels. The return 
of the cell to its resting state is delayed. Calcium entry promotes contractibility. 
Phase 3 marks the return of the cell to negativity, which occurs because of the 
continued loss of potassium from the cell at a faster rate, and the ending of the 
opposing inward currents carried by Na+ and Ca ++. There are at least three distinct 
delayed Potassium rectifier currents. 
Phase 4 marks the return of the resting membrane potential of –90mV. Following Na, 
calcium will more slowly begin crossing the cell membrane (slow calcium channels). 
Repolarisation occurs as the cell recovers its intracellular negativity by the outward 
movement of K+ ions71.  
 
 
 
Many medications can cause acquired long QT syndrome including, antibiotics, 
antidepressants, antifungals, antihistamines, antimalarials, diuretics, heart 
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medications, lipid-lowering drugs, oral hypoglycaemics and psychotropic drugs. They 
increase the QT interval by a variety of mechanisms which are discussed below. 
 
 
1.3.7 Antiarrhythmic drugs 
 
The Cardiac Arrhythmia Suppression Trial (CAST) showed that treatment with class 
1c antiarrhythmic agents to suppress post myocardial infarction ventricular 
arrhythmias paradoxically increased mortality from sudden cardiac death72. This trial 
was designed to test the hypothesis that suppression of ventricular premature 
complexes (VPDs) in survivors of acute myocardial infarction would reduce 
arrhythmic death risk. Instead, a preliminary finding from CAST was that the 
encainide and flecainide groups had a 3.6 fold increase in arrhythmic death compared 
with their placebo group. These unfortunate results were especially surprising in that 
the CAST population represented patients in whom the risk of arrhythmic death was 
thought to be low. Subsequent studies came to similar conclusions for 1a, 1b, and pure 
class 3 antiarrhythmic drugs. 
 
Antiarrhythmic drugs bind to sites on cell walls and affect ion channel function by 
causing them to remain open or closed at any given time. These drugs can also 
promote arrhythmias and some of them can directly cause lengthening of the QT 
interval. The standard classification of antiarrhythmic drugs was developed by Singh 
and Vaughan Williams based upon the drug's electrophysiological mechanisms of 
action. Class 1 medications exert their effects by blocking the sodium channel 73 and 
are divided into 3 subgroups, 1a, 1b and 1c. Of particular interest to this thesis are the 
class 1A and class 3 drugs because they prolong repolarisation. Classes 1B, 1C and 2 
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do not prolong repolarisation.  The actions of all four classes are summarised below 
(Table 1).  
 
Table 1 Singh-Vaughan Williams Classification of anti-arrhythmic 
medication 
 
 
Class Action  Drugs  
1 Sodium Channel Blockade   
    1A High potency as sodium channel blockers. 
Blockade also of potassium channels. Prolong 
repolarization, (lengthen QT interval)..  
Quinidine, 
procainamide, 
disopyramide  
    1B Lowest potency as as sodium channel blockers. 
Little, if any change, in action potential.  Shorten 
repolarization (decrease QT) interval).   
Lidocaine, 
mexiletine, tocainide, 
phenytoin  
    1C Most potent sodium channel blockers. Little 
effect on repolarization (QT interval does not 
change). 
Encainide, 
flecainide, 
propafenone, 
moricizine(?)  
2 Beta-Adrenergic Blockade, slowing sinus rhythm, 
prolong PR interval. No effect on QT interval. 
Propanolol, esmolol, 
acebutolol, l-sotalol  
3 Block outward potassium conductance, 
prolonging the QT interval.   
Amiodarone, 
bretylium, d,l-
sotalol, ibutilide  
4 Calcium Channel Blockade, slowing sinus 
rhythm, prolong PR interval.    
Verapamil, 
diltiazem, bepridil  
Miscel 
laneous Miscellaneous Actions  
Adenosine, digitalis, 
magnesium  
 
 
 
 
1.3.8 Antiarrhythmic drug action 
 
 
Class 1 drugs enhance the fast inward depolarising Na+ current albeit in a variety of 
ways. Class 1A depresses phase 0, slows conduction and prolongs repolarisation and 
thus can directly prolong the QT interval. Quinidine is the most widely used 
antiarrhythmic drug that can induce TdP74.  
 
The Class 3 drugs are potassium channel blockers. They can prolong the QT interval 
and initiate early after depolarisations and precipitate torsades de pointes. These drugs 
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traverse the lipid bilayer as neutral molecules and equilibrate in the cytosol as 
positively charged molecules. In the resting state, the activation gate of the K+ channel 
remains closed. Upon depolarisation the activation gate opens and the drug enters the 
vestibule to block the channel. The channel then enters a long lasting closed state 
(inactivation), which increases the affinity of drug binding. Upon depolarisation, the 
activation gate closes (deactivation) and traps the drug within the channel vestibule. 
On subsequent depolarisations the channel is not available to conduct K+ because the 
drug remains bound 75 76 77. Potassium currents may be voltage gated or ligand 
activated. Of particular importance are the delayed rectifier (rapid) Ikr and the delayed 
rectifier (slow) Iks. Disruption to these channels can cause long QT syndrome. Class 3 
agents include amiodarone, sotalol and dofetilide. Amiodarone is much less likely to 
cause torsades de pointes than other drugs with a similar QT prolonging effect such as 
sotalol, procainamide and disopyramide 78 79. It is interesting to note that Amiodarone 
decreases QTc dispersion. Many class 1A drugs (primarily Na+ channel blockers) also 
show significant K+ channel blocking behaviour.  
 
 
1.3.9 Non-antiarrhythmic drug action 
 
1.3.9.1 Anti-psychotic medication 
 
 
It is not just antiarrhythmics that can directly cause QT lengthening. It is now 
apparent that most conventional and atypical antipsychotics can cause dose-related 
prolongation of the corrected QT interval (QTc), although there are important 
differences in the potency of individual agents80. Antipsychotic drugs, particularly 
thioridazine of the phenothiazine family, primarily block the rapid component of the 
delayed rectifier K+ channel (Ikr) causing lengthening of the myocyte action potential, 
QTc interval prolongation, early after depolarisations (EADs) and TdPs 81. Important 
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QT prolongation has been observed in people taking thioridazine or droperidol 82. 
Thioridazine has now been withdrawn from the market as have sertindole and 
droperidol 83. Chlorpromazine has been associated with a variety of ECG changes 
including QT prolongation84 and sudden death85 86. Other non-phenothiazine 
antipsychotics may also cause cardiac abnormalities including QTc prolongation. 
Pimozide moderately prolongs QTc even at low daily doses and has been linked to 
several sudden deaths both in clinical use87  and in overdose88. Haloperidol has been 
associated with prolonged QTc and TdP at higher clinical doses and in overdose and 
has been associated with sudden death89. Antipsychotics share little more than their 
overall therapeutic effects: they differ importantly in pharmacology and widely in 
chemical structure. Because of this, it is unlikely that all antipsychotics have the same 
effects on myocardial ion channels or on QT interval, or have similar pro-
dysarrhythmic potential. New electrophysiological and epidemiological data suggest 
there may not be a clear-cut cause–effect relationship between QTc prolongation and 
the development of ventricular tachyarrhythmias for all atypical antipsychotics. For at 
least one of these agents (sertindole), counterbalancing mechanisms may act to reduce 
the risk of proarrhythmic activity arising as a result of QTc prolongation. 
 
The mechanisms by which different antipsychotics affect cardiac conduction are 
complex and probably numerous. They share the ability to antagonise the rapid 
component of the delayed rectifier Ikr current90 . Ikr is encoded by the human ether-a-
go-go related gene (HERG) and experiments using HERG-transfected or cloned cells 
suggest a direct antagonistic effect for drugs such as haloperidol91, sertindole 92, 
thioridazine and chlorpromazine93, amongst others94 95. Some antipsychotics may 
 28
also interfere with cardiac calcium and sodium channels. How these different effects 
contribute to QT changes and the risk of TdP or sudden cardiac death remains unclear. 
 
1.3.9.2 Antidepressants 
 
Tricyclic antidepressants (TCAs) act primarily on sodium influx during phase 0 
(sodium fast channel). In overdose, TCAs may induce widening of the QRS 
complex96. TCAs may secondarily affect calcium influx (calcium slow channel) and 
potassium efflux during phase 3 – thereby lengthening the QT interval. Thus, TCAs 
may cause QT interval prolongation both by widening the QRS complex and by 
delaying repolarisation. The secondary effects of TCAs and the primary effects of 
thioridazine-like drugs may act together to lengthen the QT interval and stimulate 
TdP. Because the time taken for repolarisation is the major component of the QT 
interval, drugs impacting on it are more likely to significantly increase the QT interval 
than are drugs widening the QRS complex alone. 
 
1.3.9.3 Cisapride 
 
Cisapride is an oral prokinetic drug which is known to prolong the QT interval and 
cause TdP97. It is thought to be responsible for several cases of sudden death. It is 
likely that it does this in the same direct way as the class 1A antiarrhythmic 
procainamide to which it is structurally very similar. Cisapride also stimulates 
serotonin-4 receptors which can result in cardiac chronotropic activity and it has been 
postulated that this may be responsible for QT prolongation98. Cisapride was removed 
from general distribution in July 200099. 
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1.3.9.4 Other drugs 
 
Other non-antiarrhythmic potassium channel blocking drugs that can directly prolong 
the QT interval include terfenadine100, erythromycin 101 102,  and cocaine 103 104. The 
adverse effects of terfenadine appeared to depend on concentration, occurring at 
supraclinical doses or at normal doses in patients also taking drugs that inhibit 
cytochrome P-450 drug metabolism-such as imidazole antifungals and some 
macrolide antibiotics105. 
 
Some antibiotics (such as macrolides and fluoroquinolones), antimalarials and 
imidazole antifungal agents can cause QT prolongation and torsades de pointes 106 107 
108 109. Torsades de pointes is rare and does not occur with all antimicrobials that 
prolong the QT interval. Intravenous erythromycin prolongs the QT interval, causes 
dispersion of recovery across the ventricular wall, and occasionally induces torsades 
de pointes. Quinine prolongs the QT interval at standard doses, as does halofantrine 
particularly when it is combined with mefloquine. Ketoconazole prolongs the QT 
interval by directly blocking Ikr and by delaying the cytochrome P-450 dependent 
mechanism of other drugs that prolong the QT interval. 
 
I have described that Ikr blockade is an important mechanism for acquired long QT 
syndrome. It is worth emphasising that it occurs with a variety of unrelated drugs, 
including class 3 antiarrhythmics, quinidine, cisapride, terfenadine, astemizole, 
bepredil, sulphamethoxiazole, erythromycin and ketoconazole. 
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1.3.10 Indirect mechanisms of QT prolongation 
There are many ways by which a drug can indirectly cause lengthening of the QT 
interval. 
 
The overuse of diuretics can result in the loss of ions. A reduction of extra-cellular K+ 
concentration can cause the resting membrane potential of cardiac cells to become 
closer to the threshold level that a cell must reach in order to complete depolarisation. 
Thus cardiac cells are more likely to respond to an approaching wave front of 
activation. When this happens cells are said to become more excitable. Such cells are 
more likely to fire off spontaneously causing early after depolarisations (EADs) 
causing arrhythmia.  Hypocalcaemia is also associated with a prolonged QT interval. 
The loss of magnesium ions (Mg++) can reduce the efficiency of the repolarisation 
process because it is a component (with Adenosine Triphosphate ATP) in the active 
process of pumping sodium ions out and potassium into the cell that occurs in action 
potential phase 4. 
 
Drug interactions play a major role in causing QT prolongation and may also increase 
the risk of TdP. Drugs may interact by the following mechanisms 1) One drug may 
decrease the clearance of another drug that prolongs the QT interval resulting in an 
increase in its plasma concentration 2) Two drugs may cause QT prolongation 
independently with an additive effect, or 3) a drug may both decrease the clearance of 
the drug that prolongs the QT interval and prolong the QT interval itself.  
 
Several drugs that can directly cause QT prolongation are metabolised by the 
cytochrome p450 (CYP) enzyme which consists of several isoenzymes . One of these 
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isoenzymes is CYP 3A. Thus medications that inhibit CYP 3A can indirectly cause a 
prolonged QT interval by elevating active drug levels.  Torsades de pointes, a life-
threatening ventricular arrhythmia associated with QT prolongation, can occur when 
these CYP3A inhibitors are coadministered with drugs that can directly lengthen the 
QT interval and are metabolised by CYP3A such as terfenadine, astemizole, cisapride 
or pimozide 110. It has also been reported that grapefruit juice is a clinically important 
inhibitor of CYP3A. Drug interactions that lead to increased concentrations of 
cisapride can cause QT interval prolongation and ventricular arrhythmia111.  
 
Drugs that inhibit the CYP 3A system include the anti-arrhythmic, amiodarone 
macrolide antibiotics, (clarithromycin and erythromycin) antidepressants, (fluoxetine, 
setraline and fluvoxamine), antifungals, (fluconazole, ketoconazole and itraconazole) 
and others such as diltiazem. 
 
About 5% – 10% of Europeans are poor metabolisers (pharmokinetic factor) 112. The 
CYP isoenzyme 2D6 is most commonly involved. The Pfizer 054 study assessed the 
potential for metabolic inhibitors such as paroxetine to induce QTc interval 
prolongation by increasing antipsychotic drug levels. The metabolic pathways 
inhibited in the Pfizer 054 study were 2D6 (paroxetine) for thioridazine, risperidone, 
and haloperidol; 3A4 (ketoconazole) for ziprasidone, quetiapine, and haloperidol; and 
1A2 (fluvoxamine) for olanzapine. Aripoprazole is metabolised by both 2D6 and 3A4 
pathways113. 
 
Erythromycin can interact with many other drugs, usually by interfering with their 
hepatic metabolism through the cytochrome p450 enzyme system as indicated above. 
Particularly important is its concomitant use with astemizole and terfenadine which 
 32
has been associated with long QT, TdP and sudden death114. In addition there is some 
evidence that erythromycin may itself cause action potential prolongation by altering 
sodium channel function, like the class 1A antiarrhythmics115. 
 
 
 
1.3.11 Additional factors contributing to QT interval prolongation 
 
There are non-drug factors that contribute to QT interval prolongation. The QTc 
interval varies throughout the 24 hour cycle, with night time values about 20 ms 
longer than daytime measurements. Changes in sympathetic and parasympathetic 
(autonomic) tone determine these differences116 117. At birth, QTc interval 
measurements are the same for male and female infants118. Before puberty, the QT 
intervals and the patterns of ventricular repolarization in boys and girls are similar. At 
puberty, in boys the QT interval shortens, and a typical male pattern of ventricular 
repolarization develops119. At puberty the male QTc interval shortens by about 20 ms. 
This androgen driven difference remains until ages 50 to 55 years when, coincident 
with a decline in male testosterone levels, sex differences in QTc measurements 
narrow. We would expect 45% of cases of TdP to occur in women based on the usual 
cardiovascular risk factors; however, about 70% of cases are found in women. Elderly 
men and women tend to have longer QT interval measurements than their younger 
counterparts even when free of cardiovascular disease120. The QT prolonging effects 
of hypokalaemia, hypomagnesaemia and hypocalcaemia caused by overuse of 
diuretics have been discussed. Other factors can bring about these conditions 
including excessive vomiting and diarrhoea. Postprandial states, intensive exercise 
and agitation, Anorexia nervosa and anti-obesity surgery can also lower K+ levels. 
Liver disease can lead to inhibition of the cytochrome P450 system resulting in 
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reduced metabolism and thus increased concentration of QT interval prolonging 
drugs.  
 
 
1.3.12 QT prolonging drugs Conclusion 
 
Many drugs have been associated with QT prolongation and some have been linked to 
TdP and sudden death. It may not be clear for some medications if there is a direct 
relationship between the extent of drug-induced QT prolongation and the risk of 
dysrhythmia or death, although this is often assumed on firm theoretical and 
observational grounds. Drug induced QT prolongation is a common observation and 
the outcome can be death thus, the development of new drugs should include 
procedures to detect this side effect. 
 
In clinical practice, the adverse effects of QT prolonging drugs can be prevented by 
not exceeding the recommended dose; by restricting the dose in patients with pre-
existing heart disease or other risk factors; and by avoiding concomitant 
administration of drugs that inhibit drug metabolism or excretion, prolong the QT 
interval or produce hypokalaemia. The potassium concentration should be checked 
regularly and potassium sparing diuretics should be preferred121. 
 
 
1.4 Death Certification in the United Kingdom 
 
 
1.4.1 The importance of Death certification 
 
Death certification is important because it is the most practical reflection of the level 
of health in populations. It provides the basis for testable hypotheses concerning the 
determinants of variation of the causes of death. These determinants are used to define 
health problems, to identify the emerging problems of public health and to monitor 
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the efficacy of health programs. Thus, death certification has a crucial role to play in 
strategic health planning. In the United Kingdom, there is a legal requirement to 
record deaths. Thus, the advantage of mortality statistics over other statistics relating 
to health is that they are more generally available. Critically, their validity depends on 
their completeness and accuracy122. 
 
 
1.4.2 The certification and registration of death 
 
When a death occurs the registered medical practitioner concerned is required by law 
to issue a medical certificate of the cause of death. The certificate must state the date 
that the deceased was last seen alive, whether the body was seen after death, the 
length of time between onset of disease and death and if the certified cause of death is 
based on post-mortem evidence. This certificate is given to the “qualified informant” 
who is most usually a close relative of the deceased. This person must attend the 
Registrar’s office to give, orally, details of place and date of death, name, sex, date 
and place of birth of the deceased, and the deceased person’s occupation and place of 
residence. If no qualified informant is available the medical practitioner must send the 
certificate by post to the local Registrar of Deaths. Returns on deaths are sent weekly 
to the Office for National Statistics (ONS) for processing, where the “International 
Statistical Classification of Diseases and Related Conditions” is used to code the 
cause of death. A copy is sent to the Director of Public Health of the health district in 
which the dead person resided123. 
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1.4.3 The role of the Coroner 
 
There are more than half a million deaths each year in England and Wales, 70% of 
bodies are cremated and 30% are buried 124. Of the half million deaths each year in 
England and Wales 45% are referred to the coroner125. The coroner must enquire into 
deaths associated with accidental, violent, unnatural and sudden causes.  
 
 
1.4.4 History of death certification 
 
The format of medical certificates has changed over time. The most radical change 
occurred in 1927 when a two part medical certificate was introduced: in the first part 
the doctor recorded the disease or condition leading directly to death and causes 
antecedent to it, while the second part was reserved for other significant conditions 
contributing to the death, but not related to the disease or condition causing it. From 
1940 onwards the entry in the first part of the certificate was taken to be the 
underlying cause of death. Before then the underlying cause of death was selected by 
the General Register Office using a complicated set of rules, in which conditions of 
various types were given an arbitrary order of precedence, regardless of the order in 
which they were specified on the medical certificate126. 
 
Further changes to the methods of identifying the underlying cause of death occurred 
in 1984 when the Office of Population, Censuses and Surveys (OPCS) adopted a 
broader interpretation of that previously used, of a World Health Organisation (WHO) 
coding rule that when the cause of death in the first part of the death certificate was a 
direct sequel condition mentioned in the second part, the latter condition should be 
preferred as the cause of death. This resulted in an artificial decrease in the numbers 
of deaths from certain causes (e.g. bronchopneumonia) and corresponding increases in 
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other causes (e.g. chronic conditions such as diseases of the nervous system and 
mental disorders). The anomaly was reversed in 1993, when an overhaul of OPCS's 
computer systems led to the introduction of an automated system for coding, 
developed by the US National centre for health statistics, which followed the 
internationally agreed interpretation of the WHO's rules for selecting the underlying 
cause of death  126. 
  
Old age has been permitted as a cause of death since 1985 for people over 70 years. It 
was introduced because causes of death for the very elderly in terminal decline were 
being used and it was found that it was common practice to put bronchopneumonia as 
cause of death which had the effect of over-estimating the true effect of 
bronchopneumonia on mortality. 
 
The method that is chosen to arrive at the underlying cause of death is influential in 
deciding the eventual outcome. Changes in the method of certifying deaths have 
changed over time and remain subject to change so that historic mortality data files 
are not strictly comparable. 
 
 
1.4.5 Arriving at the underlying cause of death 
 
The certification of the cause of death falls into two sections. Part 1 is in three 
subsections and asks for the direct cause of death. Part 2 asks for the significant 
condition contributing to death, if any.  
 
The underlying cause of death is the condition that triggered the chain of events that 
led to the patient’s death, without which death would not have occurred.  
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It is important to know that the underlying cause of death must be written in the 
lowest completed line of part 1 of the certificate. Coders at the ONS make the 
assumption that the certifier has followed this practice; in which case the “general 
rule” in coding the cause of death applies. In guidelines issued by the World Health 
Organisation, this general rule must be overridden in certain circumstances, most 
commonly when the completion of Part 1 of the certificate does not follow a proper 
clinical sequence of events. Under these circumstances, coders follow other rules that 
allow them to select the underlying cause of death. 
 
In many cases it is not appropriate to complete all 3 lines in part 1 because an 
immediate or antecedent cause of death may not be identifiable in all cases. An 
underlying cause of death can stand alone as the only completed line in part 1. 
 
Diseases are coded according to the International Classification of Diseases (ICD). 
Every disease has a code number. The coding system is in operation throughout the 
world and allows a translation of different medical terms. This standardisation allows 
a comparison between different health authorities and countries. About every 10 years 
there is a revision. 
 
These issues concerning the certification of the cause of death and its coding are 
important because they determine ultimately the content of population level mortality 
data. 
 
 
 38
 
 
 
1.4.6 Assessing data quality 
 
Mortality notification has the advantage that it refers to a clearly identifiable event 
and is legally required. However some data may be unreliable because human 
witnesses differ in their reliability. If the qualified informant is only distantly involved 
in the life of the deceased then the information given by them may lack accuracy. 
Doctors also differ in their reliability. The medical reason given for death is subject to 
uncertainty, being based largely on clinical opinion in many cases. 
 
Various methods have been used to evaluate the quality of the cause of death 
statistics127. Traditionally, post-mortem findings were deemed as the gold standard to 
evaluate the accuracy of cause of death certification. However, because of the biased 
selection of cases and the decreasing number of post-mortems, fewer and fewer 
evaluation studies have used post-mortem findings as the standard128. The consensus 
of a panel of physicians has also been used as a method to evaluate the quality of 
death certification129. Most of the studies using this method were large cohort studies 
or randomised clinical trials and wanted to assure that the end point was not biased. 
Physician review as the standard has the disadvantage of being time consuming and 
costly130 131. 
 
 
1.4.7 Common errors 
 
British Home Office guidelines state … 
“The most frequently occurring errors in the completion of certificates are: - 
(a) Failure to complete all questions in full 
(b) Incorrect completion of forms 
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(c) Illegible handwriting; and 
(d) Discrepancies between forms as to the date and time of death”132. 
 
Physicians sometimes make the mistake of putting the mode of death on death 
certificates, possibly because medicine is often aimed at treating this. The mode of 
death should not appear on death certificates because of the lack of aetiological 
specificity133. Modes of death are physiological derangements or biochemical 
disturbances produced by causes of death. Examples include various arrhythmias,, 
cardiopulmonary failure, sepsis, and hypovolaemic shock. The cause of death, on the 
other hand, is aetiologically specific. Examples include diabetes mellitus, 
cerebrovascular infarction, lung cancer, and alcoholic liver cirrhosis. 
 
Other common errors include putting the causes of death in the wrong order and 
entering two or more diagnoses in the same line in the death certificate 134 135 136. 
 
The certifying physician may include erroneous information on certificates in an 
effort to conceal diagnoses that might cause distress to family members137 138. 
Maudsley and Williams found that 18.5% of family physicians surveyed would 
consider modifying a death certificate for this reason. The percentage of death 
certificates affected in this way is not known. 
 
 
1.4.8 Quantification of error 
 
The Shipman enquiry third report of 14 July 2003 cited a study that showed only 55% 
of death certificates were of an acceptable standard139. In 1993 Jordan and Bass 140 
reported that 31.9% of a sample of death certificates completed at a Canadian tertiary 
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care teaching hospital contained errors. The highest percentage of inaccurate 
completion occurred in the Department of Medicine, with 40.3% of certificates 
classified as unacceptable because of major errors. Other studies have shown that 16% 
to 33% of sampled death certificates contain major errors in the Cause of Death 
statement141 142. The rate of major discrepancies in autopsy series has been found to 
be as high as 30%143. A study designed to assess the efficacy of an educational 
program identified major errors in 32.9% of 146 certificates prior to the intervention. 
Significant improvement followed after the intervention with major errors decreasing 
to 15.7% of 83 certificates144. A less successful educational program that did not 
show a significant improvement had a pre-intervention major error percentage of 
22.4% and a post intervention major percentage of 15.1%145. 
 
The final step in the certifying process is coding by a trained person, known as a 
nosologist. It is thought to be objective and accurate146. 
 
 
1.4.9 Error in sudden death in epilepsy (sudep) 
 
The United Kingdom National Sentinel Clinical Audit of Epilepsy-related Death 147 
reviewed the records of individuals who died from an epilepsy related death, in the 
United Kingdom, between September 1999 and August 2000. During that time 2412 
deaths were reported where epilepsy was mentioned somewhere on the death 
certificate. 
 
They found that certification of death (with or without post-mortem) was inconsistent 
and, in some cases inappropriate. Of deaths certified without post-mortem as due to 
epilepsy, 38% were sudden and/or not witnessed and should have been subject to 
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post-mortem. They reported that 87% of 439 deaths involving a post-mortem were 
inadequately investigated. The main problems were with further investigations and 
certification. Not all pathologists requested further investigations and the procedures 
tend to be non-standardised. These investigations are important to eliminate other 
causes of death.  
 
The audit concluded that death certification was inadequate in 41% of deaths 
involving a post-mortem. The reasons included: 
 
- Phrasing of the cause of death. This was very variable. Although the term SUDEP 
has been in use since 1997, it was cited on the death certificate in just 10% of audited 
cases. 
 
- A cause was often cited (e.g. asphyxia, aspiration of stomach contents, status 
epilepticus) despite a lack of pathological evidence. 
 
- In some cases, every medical condition the person had was listed on the death 
certificate, even if this had not contributed to the death. 
 
- In general, problems with certification highlighted the difficulty of establishing the 
true number of epilepsy-related deaths from certification data. 
 
 
1.4.10 Conclusion to death certification section 
 
Many commentators are of the opinion that death certification should be standardised. 
The Shipman Inquiry recommended that “the separate system of certification prior to 
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cremation should be abolished”148. Death certification needs reform as does the 
coronial system. 
 
 
1.5 Accuracy of Post-Mortem reporting 
 
Post-Mortem examination is considered to be the gold standard for the critique of 
medical practice, providing a quality control tool for the retrospective evaluation of 
diagnoses and treatment. The post-mortem facilitates new insights into the 
pathogenesis of disease and effects of therapy, gives feedback to clinical research 
protocols, provides epidemiological information and occasionally consoles grieving 
families that death was inevitable149.  
 
A large amount of evidence has been gathered to directly evaluate the accuracy of 
death certification using the post mortem report as the reference standard. It is not so 
easy to assess the accuracy of the post mortem report because there is no other gold 
standard. There are some highly objective tests such as medical imaging that can be 
usefully employed as well as comparison studies that assess inter-rater reliability 
between pathologists. 
 
 
1.5.1 Post-mortem rates 
 
The post-mortem rate has been declining for decades150 causing a reduction in 
determining the accuracy of clinical diagnosis. There is a tendency for the discrepancy 
rate between clinical diagnosis and post mortem to increase with age, probably 
because of the greater difficulty in making correct clinical diagnoses due to lack of 
clear symptoms and the presence of multiple pathologies151. 
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To address concerns about declining autopsy rates in a large academic medical centre 
in America, a quality improvement service was set up that sought to increase the 
visibility of the service and improve reporting and increase the amount and quality of 
the data152. This resulted in an increase in the autopsy rate and an improvement in 
clinician perception of the service. 
 
 
1.5.2 The importance of the post-mortem report 
 
Many studies highlight the importance of the post mortem report.  
A one year prospective study of 568 deaths in England and Wales that had the aim of 
determining whether the cause of death could be accurately predicted without the 
need for a post mortem examination, recommended that it could not and thus that the 
present system be continued 153. Some natural diseases were frequently misdiagnosed, 
although ischaemic heart disease was found to be the most common and most 
accurately predicted cause of death. Before post mortem, pathologists predicted a 
cause of death in 61% to 74% of cases depending on the body being viewed in the 
mortuary or evaluated as a paper exercise. After post mortem it was found that the 
cause of death was only predicted correctly in 39% and 46% of cases. This study 
highlights the inaccuracies inherent in stating a cause of death without post-mortem. 
 
Post mortem reports sometimes identify causes of death not predicted from medical 
history, as illustrated in the following two studies. An investigation of 63 deaths 
occurring in a hospital after cardiac surgery concluded that the post mortem 
examination identified an undiagnosed cause of death in a significant minority of 
patients 8 (12.7%). In another study, it was revealed that post-mortem examination of 
110 patients who died following thoracic surgery showed an unsuspected cause of 
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death in 34 (31%)154. The authors stated that post-mortem remained the gold standard 
method for attributing cause of death. 
 
Post mortem reporting can identify drifting of medical diagnoses as shown by a 
comparison of ante mortem (in vivo) and post mortem diagnoses of coronary heart 
disease at a university hospital for 1965, 1975 and 1985155. The post mortems showed 
that there was a gradually rising trend in both true positive and false negative ante 
mortem diagnoses. The implications were that there would be a progressive lowering 
of the counted numbers of coronary heart disease in official figures. The authors 
stated that “improvements in clinical accuracy are needed before vital statistics data 
are accepted at face value and analysed for biological explanation”.  
 
Suspected causes of death and main clinical diagnoses were determined and compared 
with findings at post-mortem examination in 97 patients who died in the 
Gloucestershire Royal Hospital intensive care unit156. Complete agreement was found 
in 74 (76.3%). Discrepancies fell into 4 main groups; unrecognised haemorrhage 7, 
myocardial infarction 5, thromboembolic disease 5 and infectious complications 4. 
Important diagnostic discrepancies were found in 19.6% of patients who had a post 
mortem. The authors conclude that “despite technological advances in intensive care 
medicine the post mortem examination continues to have an important role in auditing 
clinical practice and diagnostic performance”. 
 
 
 
1.5.3 Limitations and inaccuracies of the post-mortem report 
 
Post mortem reports sometimes contain errors. One high profile example concerns 
work of the pathologist who concluded that a victim of Dr Harold Shipman had died 
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of natural causes despite hospital doctors recording in the medical records that Dr 
Shipman had given his patient an injection of 20 mg of morphine when she had a 
severe asthma attack at her home. Morphine causes respiratory depression and would 
have exacerbated the asthma. Home office pathologist Dr Kenneth Scott told the 
General medical council that the pathologist had made key mistakes in his post 
mortem report157.  
 
Limitations of the post mortem examination have been identified in several studies. 
The Hammersmith hospital, London reviewed death certificates following post 
mortem of 123 patients who had cardiac valve prosthesis found that prostheses were 
recorded in only 43 (35%) of them 158. The authors point out that these errors may 
lead to inaccurate reporting of the number of valves that fail. 
 
Post-mortem reports from 1994-1996 and 1998-2000 in Ireland that were available for 
245 sudden infant deaths found that the reporting quality was below the minimum 
accepted standard in 55.5% of cases 159. The quality of autopsy was at its best when 
performed in regional centres. The finding of additional pathological information was 
significantly related to the extent of the post mortem.  
 
Studies have shown that myocardial infarction has been recorded as the cause of death 
even when no active coronary lesion is present160. In this thesis this would have the 
effect of reducing the number of sudden deaths available to us because we exclude 
myocardial infarction deaths. Studies have shown that tests can be useful to detect 
sudden death from coronary thrombosis161 162.  
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Additional tests can be helpful in detecting other conditions such as infection and 
anaphylaxis163. 
 
 
1.5.4 Comparison of medical imaging with conventional autopsy 
 
Imaging techniques have a significant role in autopsy practice. They can identify 
many causes of death such as traumatic brain injury or disseminated cancer. They can 
locate a projectile within the body and show its path through soft tissue. They can 
answer specific questions, such as, whether there is a cardiac air embolus in a person 
who has suffered neck trauma164. Modern imaging methods such as photogrammetry, 
optical surface and radiological CT/MRI scanning in combination have produced full 
3-dimensional representations of internal body structures. In 2005 for the first time 
this technology was used to document forensic relevant injuries of the human body in 
combination with vehicle damages165. Other examples include post mortem 
angiographic method used in detecting coronary artery bypass graft (CABG)166, 
multi-slice computed tomography (MSCT) and magnetic resonance imaging (MRI) 
for head and neck structures 167 and the human arterial system including intracranial 
and coronary arteries enabling identification of vascular pathologies such as 
calcification, stenosis and injury168. Medical imaging findings in hanging and manual 
strangulation compared with autopsy concluded that MSCT and MRI revealed 
strangulation signs concordantly with forensic pathology findings169.  
 
However medical imaging has limitations. A study that assessed the accuracy of post 
mortem MRI found that it was not able to accurately image coronary artery lesions or 
to differentiate thrombus from clot and pulmonary oedema from pneumonic 
exudates170. When stenosis of the coronary arteries is identified with imaging there is 
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still doubt that it is the cause of death171. Supplementing the image with a clinical 
history and an external examination of the body may still not remove the need for an 
autopsy172. 
 
Thus, although imaging can identify some abnormalities relevant to sudden death 
further studies are needed to correlate MRI with post mortem findings before MRI 
alone can make a reliable cause of death. 
 
 
1.5.5 Conclusion to accuracy of post-mortem reporting 
 
There is no reference standard to judge the post mortem because the post mortem is 
the reference standard. However the post mortem report is subject to inaccuracies, 
some due to poor individual practice and others systemic. 
 
Imaging technology is useful in enhancing the post mortem report and picking out 
some of its flaws. For some conditions imaging technology can be better than the 
dissection of the body.  
 
Accurate post mortem reporting is essential to maintain and improve clinical practice 
and it has been shown that the accuracy of post mortem reporting improves when 
frequency increases. 
 
 
1.6 Summary of Chapter 1 
 
Sudden death is an important cause of mortality. Chapter one of this thesis has 
demonstrated that there are case reports and pharmacological evidence to show that 
drugs that can prolong ventricular repolarisation or cause torsades de pointes can 
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contribute to the mortality from sudden death. I have described the important clinical 
factors that make people more likely to suffer this type of death. In addition I have 
explored evidence whether deaths identified as sudden cardiac by post mortem report 
have been accurately classified.  
 
We know how many sudden deaths occur each year but we do not know how many of 
them are caused by medications that affect cardiac conduction, therefore we do not 
know how many cases of sudden death could be prevented by more judicious 
prescribing. This thesis has the aim of identifying drugs associated with sudden death. 
This study could inform further research on this topic by identifying medications and 
combinations of medications that are strongly associated with sudden death. 
 
In chapter two I will state the aims and of the study and in chapter three I will give a 
detailed description of the methods that I used to try to achieve those aims.  
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2 AIMS 
 
 
2.1 The aim of the study 
 
The aim of the study was to investigate the hypothesis that the use of drugs that can 
cause prolongation of the QT interval on the electrocardiograph are associated with an 
increased risk of sudden death from probable cardiac arrhythmia. 
 
 
2.2 Objectives 
 
1. To determine the extent of individual risk of sudden death in association with 
treatment by drugs which tend to prolong the electrocardiograph QT interval as 
specified in the International Registry for Drug-induced Arrythmias maintained by the 
University of Arizona, Tucson, Arizona, United States of America173. 
 
2. To examine possible differences in risk of sudden death between major registry 
drug classes. 
 
3. To assess possible differences in risk between individuals with and without 
established coronary heart disease. 
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3 METHODS 
 
3.1 Demographics of study areas 
The study was performed in the Birmingham, Solihull, Nottingham and Coventry 
Primary Care Trust areas. According to the 2001 census, cases were drawn from a 
combined population of 1,744,440 people out of which 977, 087 (56%) reside in 
Birmingham, 300,848 (17.2%) in Coventry, 266,988 (15.3%) in Nottingham and 
199,517 (11.4%) in Solihull. Details of the age and background of people resident in 
those areas at the time of the census are summarised in the fig 2 below. 
 
Fig 2. Age and ethnic characteristics of study areas. 
Solihull has the greatest proportion of people 75 years and older 15,271 (7.7%), 
followed by Coventry 22,341 (7.4%), Birmingham 68,079 (7.0%) and Nottingham 
(18,333 (6.9%).  
 
White people are the predominant racial group in all populations accounting for 
77.7% of the total. We did not categorise cases or controls according to race. We can 
describe the racial mix of the areas from which cases were obtained.  
 
Birmingham has a white population of 687,406 (70.35%). The largest minority ethnic 
group in Birmingham is Pakistani (10.65%) followed by Indian (5.71%) and Black 
Caribbean (4.9%). 
 
Coventry has a white population of (83.98%). The largest minority group in Coventry 
is Indian (8.04%) followed by Pakistani (2.05%) and Black Caribbean, 3,314 (1.1%). 
 
Nottingham has a white population of (84.91%). The largest ethnic minority group is 
Pakistani (3.64%) followed by Black Caribbean (3.44%) and Indian (2.28%). 
 
Solihull is 94.6% white with the largest ethnic minority group Indian (1.82%). 
 
3.2 Design of the study 
The design was a community based matched case-control study. The case-control 
study is a type of analytical study because the differences between cases and controls 
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can be regarded as potentially causal. Matching eliminates factors already known to 
be associated with the outcome. Thus it has an advantage over ecological and 
prevalence studies for which no causal link can be concluded. 
 
The case control design was chosen because sudden death is a rare event with an 
incidence of approximately 1 per thousand cases in the population of developed 
nations, because it is informative, quicker and less expensive than the alternative 
prospective design and because there were no United Kingdom based databases 
available that combined drug data with post mortem reports and mortality data to use 
in a cohort design.  
 
3.3 Case definition 
Cases were defined as individuals aged 20 to 84 years who had died suddenly in the 
community and who had a post mortem report in which the cause of death was 
consistent with a cardiac arrhythmia.  
 
3.4 Case selection 
Mortality files for all individuals who had died from the start of the study in August 
2003 and for whom a post-mortem examination was undertaken on behalf of the 
coroner’s office were obtained on a monthly or quarterly basis from 1st September 
2003 to 1st October 2006 from the Primary Care Trusts for Birmingham, Solihull, 
Coventry and Nottingham. The mortality files stated which individuals died in the 
community and which did not. I discarded all individuals that did not die in the 
community and then assessed the remaining records to identify suitable cases. A key 
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aspect of this thesis was the steps that were taken to select cases because they enabled 
the  identification of arrhythmic deaths with a high degree of probability. 
 
Individuals were excluded if their deaths occurred when they were less than 20 years 
of age or over 85 years. 
 
This community based study had at the outset the intention to exclude all hospital 
deaths The mortality files record the place were people die and if the death of an 
individual was recorded as occurring in hospital then they were excluded. This 
exclusion criterion was applied to ensure that the study was community based. People 
who were dead on arrival at hospital were excluded because their deaths were 
recorded as hospital deaths. Thus the mortality files may have underestimated the 
number of community based deaths by recording some of them as hospital deaths. 
 
Cases were chosen according to the principle that their cause of death may have been 
due to a cardiac arrhythmia. Cardiac arrhythmia does not leave defining evidence in 
the body so in order to identify these people a clear set of criteria was used to rule out 
other causes of death. These criteria were applied to the mortality files, which record 
the 1a, 1b, 1c and 2 causes of death. Individuals who had a known non-cardiovascular 
cause of death such as road traffic accident, suicide, pneumonia or stroke were 
excluded. Also excluded were cardiac causes of death, which may have been due to a 
mechanism other than death from cardiac arrhythmia in the absence of acute coronary 
artery thrombosis. Hence we excluded deaths from acute coronary artery thrombosis, 
myocardial infarction, haemopericardium, left ventricular aneurysm and heart failure. 
This is a narrower definition than that normally applied to SCD and thus could be 
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called SCD of probable arrhythmic cause. The original proposal was to include deaths 
from MI and analyse these as a separate group, but the funders did not agree to fund 
this element. Thus, patients with an MI were excluded even though MIs are known to 
cause arrhythmias.  
 
 
3.5 Exclusions from post-mortem reports 
The application of the above criteria left a set of provisional cases.  
Post mortem reports for provisional cases were obtained either from patient written 
records at the shared service agencies for the primary care trusts or on request from 
the Coroners’ offices. The additional information provided by the post mortem report 
would result in the exclusion of a provisional case if it were judged that there was 
evidence for a cause of death not compatible with that due to a cardiac arrhythmia. 
 
3.6 Definition of cardiovascular disease in this thesis 
Cases were categorised into one of two types, cardiovascular and non-cardiovascular 
and matched to controls categorised in the same way. This decision was taken because 
people with cardiovascular disease have an increased risk of sudden death and if not 
taken, the study would have classified as cases a much greater proportion of people 
(compared with controls) that had a history of cardiovascular disease. This would not 
be informative because it is already established that individuals with cardiovascular 
disease are at much greater risk of sudden death. There would also be a danger of 
confounding because some of the drugs that can prolong the QT interval are likely to 
be associated with both sudden death and cardiovascular disease. Thus matching for 
previously identified cardiovascular disease was an attempt to eliminate confounding 
factors in the design stage. 
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3.7 Criteria for being classified as having cardiovascular disease 
Cases and controls were categorised as having cardiovascular disease if they were 
taking medication for a cardiovascular condition or if any of the following criteria 
obtained from the medical notes applied: 
 
-any previous myocardial infarction; 
-any previous coronary revascularisation (PTCA/CABG); 
-a diagnosis of angina with medical treatment;  
-cardiac valve disease; 
-heart failure on drug treatment; 
-hypertension on drug treatment; 
-cardiomyopathy; 
-dysrhythmic treatment. 
 
If any one of the above conditions held, then that would be enough to justify a 
classification of cardiovascular disease. Any individual could meet one, several or all 
of the cardiovascular conditions. People were not graded according to severity of 
cardiovascular disease. Hypertension was included because it is classified as a 
cardiovascular disease albeit much milder than others such as myocardial infarction. 
Diabetes and dyslipidaemia were not included because these conditions are not 
classified as CVD, although because of the strong association between Diabetes 
Mellitus and CVD many patients are managed similarly. 
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3.8 Criteria for not having cardiovascular disease 
Cases were classified as not having cardiovascular disease simply if they did not meet 
the criteria above. Thus they were not taking cardiovascular drugs and had no history 
of cardiovascular disease. 
 
 
3.9 Process of obtaining controls 
 
Each case was matched to three controls at the general practice at which the case was 
registered. This was an efficient way of obtaining controls.  
 
Suitable controls were obtained by running a database search on the computerised 
medical notes. This process was straightforward and efficient. In order to exclude 
control patients that had moved away, people who had failed to consult their general 
practitioner within the previous 2 years were not included in the study. This step was 
essential to remove the bias of erroneously recording controls having fewer 
medications (none for people that have moved away) than cases. 
 
Cases and controls were matched for sex, age to within 5 years and cardiovascular 
disease. Researchers used the surgery medical records database to select the controls 
on the basis that they were the closest in age to the case, providing the other matching 
criteria were satisfied. At large general practices it was possible to match controls 
very closely for age, often to within a few days. At small single handed practices the 
difference would be weeks, months and occasionally years. 
 
The process of manually selecting controls as in this thesis can introduce bias. The 
requirement to select the 3-controls nearest in age to the case (whilst matching for 
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CVD and gender) removed the possibility of selection bias.  However, when matching 
for the broad definition of cardiovascular disease I was more likely to obtain the more 
prevalent hypertension rather than the rarer, more severe, less prevalent 
cardiovascular diseases such as MI.  
 
3.10 Sources of medical information for cases and controls 
Medical information was collected for cases and controls from two sources, the 
general practice computerized database and the written medical notes.  
 
The medical notes for the cases were usually seen at the shared service agency where 
they had been sent following the death of the person and less frequently at the general 
practice if they had not yet been sent away.  
 
It was not always possible to have access to the written medical notes of some cases, 
whilst the computerized medical notes were available for every case and control and 
were always viewed.  
 
3.11 Strategy for viewing medical notes 
Researchers proceeded on the basis that if written notes were viewed for cases then 
they must be viewed for every control for that case. If it was not possible to view 
written notes for a case then the written notes for a control were not viewed even 
though they were available. This policy avoided information bias.  
 
 It was not always possible to view written notes on cases because the PCTs were not 
always able to provide them.  
 57
3.12 Information obtained at GP surgeries 
The date of birth and sex of all cases and controls was recorded, as was the date of 
death of each case. The names of all drug prescriptions including dosage, frequency 
and route of administration in the periods 0-7, 8-30 and 31-90 days prior to the death 
of each case were recorded. Information for the controls was also obtained for these 
periods up to the date of death of their case. Information for the controls after the date 
of death of their case was not collected because such information could not occur for 
the cases because of their death.  
 
People who are ill are more likely to visit their doctor. Thus the dates and type of all 
general practice and hospital consultations in the 90 days prior to the death of the case 
were recorded to obtain a measure of morbidity.  
 
Information was obtained on the presence of cardiac conditions that are known to 
contribute to an increased risk for sudden death. This is detailed in fig 3. 
 
Fig 3. Cardiovascular conditions 
 
 
(1) Has the patient ever had a myocardial infarction and if so the date of the last one.  
 
(2) Treated angina in the last 3 years. 
 
(3) Ever had a coronary artery revascularization operation. Coronary artery bypass 
graft (CABG) or Percutaneous Transluminal Coronary Angioplasty (PTCA) 
 
(4) Heart failure in the past year. 
 
(5) Treated hypertension within the past 3 years. 
 
(6) Sinus bradycardia in the past year.  
 
(7) Heart block in the past year. 
 
(8) Atrial fibrillation in the past year. 
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Additional information that could contribute to sudden death was also recorded. 
Amongst these were the presence of electrolyte concentrations in the blood which 
predispose to QT prolongation such as low potassium (hypokalaemia), low calcium 
(hypocalcaemia) and low magnesium, (hypomagnesaemia) defined as lower than 
normal laboratory results. Also recorded was the presence of case reported conditions 
that are associated with sudden death; epilepsy, unexplained syncope, dizziness, liver 
disease, renal disease, syncope and recreational drug misuse. 
 
3.13 Method for ascertaining sudden death risk with QTc prolonging 
medication  
 
3.13.1 Drug exposure definition 
The exposure was defined as the use of QTc prolonging drugs, as specified in the 
most recent version of the International Registry for Drug-induced Arrythmias 
maintained by the University of Arizona, Tucson, Arizona, United States of America 
173. They have classified QT prolonging drugs into four categories. Types 1, 2 and 4 
are mutually exclusive. Type 3 includes every drug in types 1,2 and 4 and in addition 
includes some drugs that are not categorised as type 1,2 or 4. Not all of the drugs 
appearing on the registry are licensed, marketed or prescribed in the United Kingdom 
and of those drugs that are, not all were prescribed to patients on this study. 
 
3.13.2 Index date definition 
Every case was matched without exception to exactly 3 controls, constituting a set. 
For every individual in a set, an index date was defined to be the date of death of the 
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case. All medications taken by cases and controls were categorised as taken in the 
period 0-7 days prior to death of case, 8-30 days prior to death of case and 31-90 days 
prior to death of case.  
 
3.13.3 Classification of medications that can affect the QT interval 
 
The registry classifications are as follows: 
Type 1. Drugs that are generally accepted to have a risk of causing Torsades de 
Pointes. 
Type 2. Drugs that in some reports have been associated with Torsades de Pointes 
and/or QT prolongation but at this time lack substantial evidence for causing Torsades 
de Pointes. 
Type 3. Drugs to be avoided for use in patients with diagnosed or suspected 
congenital long QT syndrome. Drugs in lists 1, 2 and 4 are also included here. 
Type 4. “Drugs that, in some reports have been weakly associated with Torsades de 
Pointes and/or QT prolongation but that are unlikely to be a risk for Torsades de 
Pointes when used in usual recommended doses and in patients without other risk 
factors (eg, concomitant QT prolongation drugs, bradycardia, electrolyte disturbances, 
congenital long QT syndrome and concomitant drugs that inhibit metabolism). 
 
3.13.3.1 Registry type 1 drugs 
 
Type 1 medications are of the greatest importance to this study because they 
constitute the strongest exposure. Type 1 medications prescribed to people in this 
study were drawn from macrolide antibiotics, antiarrhythmics, antipsychotics and 
antinausea classes..  
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Table 2: Registry type 1 drugs 
 
Macrolide anti-biotics Clarithromycin, Erythromycin 
Anti-arrhythmics Amiodarone, Disopyramide, Sotalol 
Anti-psychotics Chlorpromazine, Haloperidol, 
Thioridazine 
Anti-Nausea Domperidone 
 
 
Macrolide antibiotics are usually prescribed for one week whereas other medications 
are typically prescribed as monthly repeats. Thus use was defined as current for 
macrolide antibiotics if they were prescribed within 7 days of the death of the case 
and use was defined as current for drugs that are prescribed monthly if they were 
prescribed within 30 days of the death of the case. 
 
3.13.3.2 Registry type 2 drugs 
Type 2 medications are drawn from many drug classes. Examples of type 2 
medication are alpha blockers, dopaminergic, anti-arrythmic, diuretic, antibiotic, anti-
mania, anti-hypertensive, anti-psychotic, anti-cancer, muscle relaxant and vasodilator 
drugs (Table 3).  
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Table 3 Registry type 2 drugs 
 
Alpha1 blocker Alfuzosin 
Dopaminergic Amantadine 
Anti-arrythmic Flecainide 
Diuretic Indapamide 
Anti-biotic Levofloxacin, Ofloxacin 
Anti-mania Lithium 
Anti-hypertensive Nicardipine 
Anti-psychotic Quetiapine Risperidone 
Anti-cancer Tamoxifen 
Muscle relaxant Tizanidine 
Phosphodiesterase Vardenafil 
Anti-depressant Venlafaxine 
 
 
3.13.3.3 Registry type 4 drugs 
Type 4 drugs are drawn from a wide variety of classes. Type 4 drugs prescribed to 
individuals on the sudden death study consist of tricyclic antidepressants, other anti-
depressants, anti-biotics and anti-fungal. 
 
Table 4 Registry type4 drugs 
 
Tricyclic anti-depressant Amitriptyline, Clomipramine, Dosulepin 
Imipramine, Trimipramine 
Other anti-depressant Citalopram, Fluoxetine, Paroxetine 
Sertraline 
Antibiotic Ciprofloxacin, Trimethoprim 
Antifungal Itraconazole 
 
3.13.3.4 Registry “type 3 only” drugs (not type1, type 2 or type 4)Type 3 
medications include all drugs in lists 1, 2 and 4 as well as medications that are 
uniquely classified as type 3. “Type 3 only” medications prescribed to people in this 
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thesis belonged to bronchodilator, decongestant, sympathomimetic, appetite 
suppressant and bladder antispasmodic classes.  
 
Table 5 Registry “type 3 only drugs” (not type1, type 2 or type4) 
 
Bronchodilators Salbutamol Terbutaline 
Decongestants Ephedrine Pseudoephedrine 
Sympathomimetics Salmeterol 
Appetite Suppressants Sibutramine 
Bladder anti-spasmodic Tolterodine 
 
 
3.14 Obtaining approvals and subsequent difficulties 
 
3.14.1 MREC approvals 
Initial MREC approval was granted by the West Midlands on the 30 April 1999. 
Following submission of a revised protocol in November 2000, West Midlands 
MREC re-approved the study on the 3 January 2001. They again re-approved the 
study on the 7 June 2004 ref MREC/98/7/58.  
 
3.14.2 LREC approvals 
In April 2000 funding approval was received from the Wellcome Trust. LREC 
approvals were obtained from City hospital and East Birmingham in December 2000 
and in January 2001 from North Birmingham and South Birmingham. In April 2001 
approval was obtained from Solihull LREC. 
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3.14.3 Pilot study 
At the end of December 2000 and beginning of 2001 cases were identified from the 
Birmingham Coroner’s records for a one-month pilot period. Controls were sought 
from general practices at which cases were registered and data extraction piloted. 
 
 
3.14.4 Permissions from PCTs outside the Birmingham area 
Permission was granted to conduct the study at the Primary Care Trusts (PCTs) of 
Birmingham, Solihull, Coventry and Nottingham. It was necessary to obtain the 
approval of the directors of public health and the research and development 
departments of the Primary Care Trusts. The Primary Care Trusts insisted that the 
researchers that would be looking at medical notes be subject to a Criminal Records 
Bureau (CRB) check and when this was successfully concluded the research nurses 
were granted honorary contracts.  
 
The information officers at the four Primary Care Trusts agreed to supply mortality 
records for all deceased patients from August 2003 until the conclusion of the study. 
The files were sent, in encrypted form as either a database or a spreadsheet. 
Researchers identified provisional cases from the files.  
 
The shared service agencies (SSAs) granted permission to researchers to view the 
medical notes of deceased patients on their premises. In addition to clinical 
information the written notes often contained the post mortem reports. 
 
 
 
 64
3.14.5 Subsequent general practioner committee objections 
 
Despite being granted MREC approval by the West Midlands on the 30 April 1999 
the study was not able to proceed due to a number of objections to the protocol by 
some Birmingham doctors sitting on the Local Medical Committee of general 
practitioners who were concerned that patient confidentiality would be compromised. 
They objected to researchers’ collecting information from the medical notes of the 
living controls without the consent of those patients. Some general practitioners were 
also concerned that the Data Protection Act of 1998 prevented them from allowing 
researchers to access patient notes without patient consent. 
 
 
3.14.6 Section 60 approval 
 
3.14.6.1 Obtaining Section 60 approval 
In order to persuade the Birmingham general practitioners committee to co-operate 
with the study a decision was taken by the research team to apply for section 60 
approval. Section 60 approval was a legal provision that allowed researchers to access 
patient medical notes without seeking the permission of either patients or their 
relatives and allows general practices lawful permission to give this access; the hope 
was that this would ameliorate the concerns of the general practitioner local 
committee. 
 
A submission was made to the Department of Health on the 11 June 2002 seeking 
support under section 60 of the Health and Social Care Act 2001 to allow access to 
patient identifiable data. 
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The argument was put forward that people who refuse to act as a control may differ in 
some important respects from those that participate. In particular, individuals that are 
being treated with conditions to which are attached a social stigma are more likely to 
refuse to take part in medical studies. Some of these conditions are associated with 
medications that can prolong the QT interval such as mental illness. If the study were 
to proceed solely taking consented controls then systematic bias could occur which 
would cast doubt on the results and conclusions of the study. It would not be possible 
to evaluate how strong any such bias would be.  
 
Section 60 approval from the Department of Health was granted on the 26 July 2002 
registration number 001/02/02 subject to the following three conditions:   
 
(1) Research nurses should be allowed to examine patient records in order that 
anonymous data can be collected for use by the study team. 
 
(2) Information about the research should be displayed in practice waiting rooms. 
 
(3) The research nurses responsible for examining patient records should have a 
contractual obligation of confidentiality. 
 
Confirmation of the approval was included on the register of activities carried out 
with section 60 support. 
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3.14.7 Eventual approval by the Birmingham GPs local medical 
committee 
Once section 60 approval was obtained a further submission was made to the 
Birmingham general practitioners committee who removed their objections.  
 
3.14.8 Objections to the study from some individual GP surgeries 
After permission was granted by each PCT for the study to commence and the 
Birmingham general practitioners committee had removed their objections all GPs 
were written to ask for their co-operation. The letter asked the senior partners to allow 
research nurses onto their premises to view patient medical records held in written 
form and on the computerised database. They were told that when a case was 
identified from the mortality files a member of the team would telephone the practice 
manager to ask for permission to attend the surgery to obtain the clinical information. 
They were asked to reply to us only if they had an objection. Only 8 objections were 
received at this stage. However more objections were obtained after surgeries were 
contacted when they had a case. The majority of medical practices (approx 90%) 
eventually gave their permission. Those that did not give their permission were most 
often single-handed practices. The stated reasons for not taking part were lack of time, 
computers and office space. 
 
3.14.9 Birmingham and Solihull change their permission to view medical 
notes 
From the outset of the study we could obtain written medical notes at the SSAs’ for 
almost all of the cases. Those few medical notes that we could not look at were those 
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that could not be found by the SSA because they were lost or because the general 
practice had not yet released them.  
 
Fifteen months after we started gathering data, Birmingham and Solihull SSA decided 
that we could no longer view medical notes without paying an expensive fee. This 
meant that we no longer had access to the medical notes and the post mortem reports 
at the SSA.  
 
3.14.10 The effect of no longer being able to view post mortem reports 
Post mortem reports for most cases were available with the medical notes at the 
shared service agency for the first 18 months of data collection. Those not available 
were requested from the coroners’ office. Post mortem reports were effectively denied 
to us when the Birmingham and Solihull SSA levied their charge.  
 
We assessed the impact of no longer being able to view post mortem reports with a 
review of those that we had at that time. Of 356 post-mortem reports representing 
71% of the collected cases we concluded that we would lose 10 (3%) additional cases 
that would not have been eliminated on viewing just mortality file data alone. In view 
of this small gain of additional information it was decided not to request post-mortem 
reports from the coroner. 
 
3.15 Case-Matching  
3.15.1 Case-matching in general 
Cases are people with the outcome variable. The selection of cases requires a suitable 
case definition. Care is needed that bias does not arise from the way in which cases 
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are selected. In general it is better to use incident rather than prevalent cases because 
unlike prevalence, incidence is not influenced by factors that determine the duration 
of the outcome variable. The outcome variable in this thesis is probable sudden death 
from cardiac arrhythmia which is a clearly defined incident outcome variable. 
 
Controls are people that do not have the outcome variable. Controls were selected 
independently of the exposure variables. 
 
Case control studies identify past exposure to suspect causative factors and by 
comparing cases with controls estimate an odds ratio. To avoid bias, the exposures of 
cases and controls should be measurable with the same accuracy174. 
 
3.15.2 Matching in this thesis 
Matching is a way of negating or reducing the effects of confounding variables 
through the process of ensuring that cases and controls are similar with respect to 
them. 
 
This thesis matched 3 confounding variables in the design stage: age, sex and 
presence of cardiovascular disease because they are strong independent risk factors 
for sudden death. 
 
There are other risk factors such as individual cardiovascular conditions, severity of 
cardiovascular disease, alcohol abuse and severe obesity and arguably many others 
but we limited the matching to just 3 criteria because there would not be enough 
statistical power in a study with the number of cases that the researchers expected to 
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obtain (about 1000) to analyse the subgroups. Information on other risk factors was 
gathered with the intention of controlling for them in the analysis and we did that.  
 
Matching strategy includes elements of design and analysis. In principle matching can 
be used in any analytic study design. However it can be difficult, expensive and time-
consuming to find a comparison group because potential controls may have to be 
excluded before finding one with the required set of characteristics175.  
 
This thesis matched on age, sex and presence of cardiovascular disease  thus there 
were four (2x2) combinations to consider when matching a case to a control. If 
additional factors had been matched then the process would have become 
progressively more difficult. 
 
3.15.3 Avoiding overmatching 
There are additional reasons to avoid matching to more than 3 factors. Excessive 
matching causes controls to be very similar to cases which can lead to important 
exposure factors being missed because they are approximately equally prevalent 
between the groups. Overmatching will reduce statistical efficiency if the matched 
variable is associated with the exposure but not the disease. Validity will be 
compromised if matching is done on a path variable between exposure and disease. 
 
The researchers were also aware that a decision to match to more than 3 factors would 
have resulted in a loss of cases for which a full matching was not possible, causing a 
further reduction in statistical power. An additional consideration was that there 
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would be an increase in the cost of researchers’ time when matching for extra 
subgroups.  
 
3.15.4 Matching to more than one control to increase statistical power 
When the number of cases is limited as in this thesis, the statistical power of the study 
to detect a real difference if it exists can be increased by matching to more than one 
control per case (referred to as R : 1 matching) where R is the number of controls per 
case. This thesis matched every case to 3 controls. 
 
As R increases the cost of obtaining additional controls remains the same but the 
increase in statistical power declines so researchers have the problem of deciding on 
the optimum point to stop. The general consensus amongst researchers is that it is not 
worth matching to more than 4 controls per case176.  
 
There is a hidden problem with obtaining extra controls for a study where the subjects 
are elderly. The population age structure is pyramidal, thus if large numbers of 
controls are obtained per case the average age of controls could become significantly 
younger than that of the cases.  
 
 
3.15.5 Other advantages of matching 
There are some circumstances when matching is highly desirable or even necessary. 
Matching in this thesis was a very efficient way to obtain controls. Matching to 
individuals in the same general practice enabled us to control for provision of health 
care. Unknown confounders cannot be controlled except when they are fortuitously 
highly correlated with those variables that are matched. 
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 3.15.6 Disadvantages of matching 
There are some serious disadvantages of matching. It is impossible to evaluate the 
effect of the matched factor on the outcome. Matching results in a greater similarity 
between cases and controls with respect to their exposure histories and this has the 
potential to cause an underestimate of the true association between exposure and 
disease.  
 
Stratified analysis cannot easily be used with matched data to control for additional 
confounders. In this thesis additional confounders were adjusted in the conditional 
logistic regression analysis but the effective sample size is reduced because the 
analysis is based on discordant pairs. 
 
3.15.7 Analysis of matched data 
 
Table 6 illustrates the presentation of data for the analysis of a 1 : 1matched-pair case-
control study. Unlike the two-by-two table for unmatched data, in which each cell 
represents the number of individuals with a certain exposure and disease status, the 
cells for a matched study denote the number of pairs that fall into each category. Thus 
cell ‘e’ indicates the number of pairs in which both the case and control are exposed 
and so on. In a matched-pair analysis the estimate of the magnitude of the association 
between the exposure and disease is based entirely on the ratio of the discordant pairs. 
So for the table above the odds ratio is   OR   =   f / g. The appropriate null hypothesis 
for 1 : 1 matching is that the expected values of  ‘f’ and ‘g’ are equal ie =  (f + g) / 2. 
If we have sufficient numbers a chi-squared test leads to  χ²   =   (f – g) ²  /  (f + g). 
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This is known as McNemar’s test. The test statistic is compared with a χ² distribution 
with 1 degree of freedom and a confidence interval can be calculated174. 
  (1±1.96/ χ)    
      95% CI   =   OR 
 
Table 6 Presenting data for matched pairs case control studies 
  Controls  
  Exposed Not Exposed 
Cases Exposed e f 
 Not Exposed g h 
 
 
 
3.16 Strategy for Analysis 
3.16.1 Statistical Power in this study 
Statistical tables were studied before the start of the study to inform the number of 
matched sets that would be required for different levels of significance, power, 
relative risk and proportion exposed. Thus about 500 sets (where each case is matched 
to 3 controls as in this study) are needed to detect a relative risk of 1.5 where the 
proportion exposed is 0.1, the significance is 0.05 and the power is 80%177.  
From the start of the study I was confident that more than 500 sets could be obtained 
but it was not possible to determine in advance an accurate figure for effect size for 
any given medication. It was also not possible to know before data collection began 
the proportion of cases or controls that would be on medications of interest. 
The analysis for this thesis is based on 789 sets. I used PASS statistical software to 
show that with this number of sets I could detect an odds ratio of 1.47 at a power of 
80% and significance level of 0.05 where the proportion of individuals exposed is 0.1.  
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3.16.2 Measure of effect size 
 
Conditional logistic regression odds ratios were calculated because they are the 
appropriate measure of effect size for this matched case-control design. 
 
3.16.3 Software used for analysis 
Stata 7 was used to calculate conditional logistic regression odds ratios. SPSS version 
14 was used for other analysis.  
 
3.16.4 Adjustments for covariates  
Comparisons were made between the use of suspect drugs of all classes for all cases 
and controls. Covariates that were imbalanced between cases and controls were 
identified and adjusted in the analysis of medications. This analysis was also done 
after stratifying for cardiovascular disease. Adjustment was made for those conditions 
that were shown to be significantly associated with sudden death, namely myocardial 
infarction, heart failure, low serum potassium, heart block, atrial fibrillation, epilepsy, 
syncope, impaired liver function, recreational drug abuse and alcohol abuse.  
 
3.16.5 Drug Comparisons in time periods 
Data obtained on prescribing in the 3 designated periods, 0-7 days, 8-30 days and 31-
90 days gave an additional means of checking the validity of the findings, the 
expectation being of reduced differences in the proportions using suspect drugs 
between cases and controls more distantly from the event. 
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4    Exploring methodological issues 
 
 
4.1 Study 1 Comparison between raters 
 
I undertook two separate comparisons, one for electronic medical databases and the 
other for paper notes to assess the agreement of information obtained by data 
collectors and to assess their accuracy. 
 
4.1.1 Introduction to the comparison study 
 
Two experienced research nurses extracted the information for the study from 
computerised medical records and written medical records. The level of agreement 
between the nurses was assessed through a comparison of data extracted from the 
same information source. There would be cause for concern if the level of agreement 
for extracted data were to be poor, as this would also cast doubt on its accuracy.  
 
4.1.2 A review of comparison studies in the literature 
 
A review of the literature was undertaken to understand how comparison studies were 
done, the number of cases reviewed, how agreement was measured, the levels of 
agreement that were obtained and the importance that the levels of agreement had for 
those studies. Keywords entered into medical database search engines were nurse 
inter-rater reliability, medical notes, medication, agreement and concordance. Papers 
that had comparison studies on cardiovascular disease and medication were the most 
relevant.  
A study with the aim of assessing the quality of care between hospitals for congestive 
heart failure and pneumonia via a review of medical notes confirmed diagnoses with 
clinical data from medical records. To assess the inter-rater reliability of nurse 
 75
abstracters, 32 random hospital records abstracted by one nurse were re-abstracted by 
two more nurses. Nurses were asked to score the thoroughness of history taking and 
physical examination by physicians, the use of common tests for patients with 
appropriate indications and the use of standard therapies. Intra-class correlation 
coefficients were 0.64 to 0.95 demonstrating very good to excellent agreement178. 
 
A review of the medical records of 420 patients in New York who had received a 
diagnosis of heart failure was used to evaluate the care that they received. Reviewers 
looked at medications, problems, progress, consultation letters, hospital discharge 
data, emergency department visits, laboratory results, radiographic data and old 
records from other physicians. To measure consistency across reviewers a second 
blinded record review was completed using 45 patient records selected randomly. The 
kappa statistic was used to assess inter-rater reliability for each review criterion. For 
these analyses 8 measures were used. The authors gave the 4 highest ratios, which 
vary from 0.57 for the measurement of left ventricular ejection fraction to the 
prescribed trial of angiotensin converting enzyme (ACE) inhibitors (0.80). The 
authors did not report information on the lowest 4 kappa figures other than they were 
less than 0.57179. The authors commented that heart failure is over diagnosed in 
primary care. 
 
The level of agreement between two physicians was evaluated in a study in which 
both physicians independently of each other extracted data from recorded interviews 
of two patients. The encounter for each new patient visit had 63 data elements and the 
encounter for each of the  follow-up interviews had 27 data elements. The results were 
in agreement on 92.2% of the elements with a kappa statistic of 0.82 overall, 0.9 for 
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one patient and 0.65 for the other indicating a moderate to high degree of 
concordance180. 
 
A study that sought to evaluate the reliability and validity of estimating the National 
Institute of Health Stroke Scale (NIHSS) from medical records compared handwritten 
notes from the medical records of 39 patients and their NIHSS stroke scores estimated 
by 6 raters blinded to the actual scores. Estimated scores were compared among raters 
with the actual measured scores. Inter-rater reliability was excellent with an intra-
class correlation coefficient of 0.82181. 
 
Agreement among 8 American research nurses, as calculated by the kappa statistic 
were found to be generally high for a study that sought to assess the validity of the 
medical record and patient questionnaire for measuring delivery of different health 
services182.  
 
Kappa scores were found to be poor to moderate in a study that looked at the 
reliability of medical record review for estimating death from medical errors. They 
varied from 0.40 to 0.41 for adverse events and from 0.19 to 0.23 for negligent 
adverse events. The study relied on nurse and physician reviews of medical records to 
detect the errors183. 
  
A study evaluated the inter-group and intra-group reliability of a scoring tool for the 
appropriateness of medication for use in primary care. The tool was scored by two 
groups of evaluators for each drug. There were 211 drugs taken by 30 patients each 
taking at least 5 drugs. The overall kappa scores between groups were moderate and 
the kappa scores within groups were good184. 
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 A study that had the aim of evaluating factors associated with child asthma 
medication reported that agreement between physicians and caregivers for reported 
medication was 78%  with a kappa of 0.54; 95% confidence interval: 0.45-0.63 185. 
 
Varying levels of agreement exist when comparing medical record with patient 
interview and pharmacy with kappa scores between 0.38 and 0.70 for a study that 
reported on medications in 2267 interviews, 1936 medical records, and 457 pharmacy 
records186. Greater levels of agreement were obtained for a prospective population 
based cohort study of people older than 55 years of age, with 80.6% agreement, the 
highest for B adrenoceptor blocking agents with kappa statistics of 0.97 for atenolol 
and metoprolol 187. 
  
 
4.1.3 Conclusion to the comparison study literature search 
For studies to have validity it is important that the information obtained is both 
accurate and reliable. There is no gold standard to assess the accuracy of the 
information that can be obtained. In general, reliability studies should be done early to 
identify problems with data collection and interpretation. It is rarely sensible to 
compare the results from different comparison studies because they are usually 
measuring different outcomes or the same outcome in different ways or measuring 
different populations as demonstrated above. 
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4.1.4 The Kappa statistic 
The simplest way to measure agreement is to calculate a percentage and this is often 
done. Many researchers prefer to give the kappa statistic because it corrects for 
chance. The kappa statistic can be used for two purposes, firstly to test rater 
independence and secondly to quantify the level of agreement between raters. The 
second use of kappa is used in this study. The kappa statistic is considered to be 
appropriate for testing whether agreement exceeds chance for binary and nominal 
ratings and so can be applied to the sudden death study because all of the diagnostic 
information is binary. Kappa can also be applied to assess agreement about 
medication for names of drugs, dosages and time periods given.  
 
The kappa calculation uses a term called the proportion of chance (or expected 
agreement). This is the proportion of times raters would agree by chance alone and it 
assumes that raters are statistically independent.  
 
Kappa scores vary between –1 and +1 that is between perfect disagreement and 
perfect agreement. A kappa score of 0 signifies that agreement is no better than 
chance. A scale has been proposed to describe the level of concordance… agreement 
0 - 0.20, “poor”; 0.21 – 0.40, “fair”; 0.41 – 0.60, “moderate”; 0.61 – 0.80, 
“substantial”; 0.81 – 1.00 “almost perfect”.  188 . 
 
Kappa has several flaws that are relevant to this study. It does not make distinctions 
between various types and sources of disagreement. Disagreement can exist simply 
because raters have interpreted information differently.  
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Kappa scores are seldom comparable across studies, procedures or populations 
because they are influenced by trait prevalence and base rates. Kappa scores for the 
comparison study in this thesis vary between the different diagnoses even when the 
total number of errors is the same because of the distribution of those scores in the 
2x2 contingency table. 
 
Kappa values obtained from samples with different base rates fluctuate and so may 
not be comparable thus if sample base rates differ from population base rates the 
result may not be generalisable. 189. 
 
There is wide disagreement about the usefulness of kappa statistics to assess rater 
agreement. Kappa statistics should not be viewed as the unequivocal standard or 
default way to quantify agreement; one should use and interpret this controversial 
statistic cautiously and one should consider alternative methods of agreement such as 
the intraclass correlation or log odds ratio and make an informed choice190. 
 
 
4.1.5 Comparison study methods 
4.1.5.1 Electronic database comparison study  
To assess the agreement on information held on medical practice electronic databases 
between the two nurse data extractors, computerised medical records for 28 deceased 
individuals from 6 general practitioner surgeries were abstracted by one nurse and 
were later re-abstracted by the other. Each record was viewed at the General 
Practitioner surgery at which the individual was registered and patient diagnoses, 
blood test results and medications were recorded. Both nurses were trained in data 
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abstraction and had previous experience in other studies. Only one of them had 
worked on a previous cardiology study. 
 
4.1.5.2 Paper notes comparison study 
To assess agreement on information held on written medical notes a second data 
extraction was done by the same 2 nurses on a different group of 24 patients from 
written medical records held at the Nottingham Shared Service Agency. Patient 
diagnoses and blood test results were recorded but not medications because few 
surgeries record medications in the written notes. 
 
4.1.5.3 Clinical information obtained 
The nurses recorded the presence or absence of 8 cardiovascular conditions, namely if 
the patient had ever had a myocardial infarction, treated angina within past 3 years, 
ever had a coronary revasculation, heart failure in past year, treated hypertension in 
past 3 years, sinus bradycardia in past year, heart block in past year and atrial 
fibrillation in past year. Also recorded was the presence or absence of 3 non-
cardiovascular conditions namely, ever had epilepsy, renal abnormalities in past year 
and liver abnormalities in past year and 2 symptoms that could be indicative of a 
cardiovascular condition, that is unexplained dizziness and unexplained syncope both 
in the past 1 year. They also recorded the presence of 4 blood results namely 
hypokalaemia, hypocalcaemia, hypomagnesaemia and hyperkalaemia all within the 
past year.  
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4.1.5.4 Medication information obtained 
The nurses recorded the names and dosage of all prescribed non-topical medications 
that were taken by the case in the 3 months prior to death. The dates of prescription, 
and length of time for which they were prescribed were viewed on the databases and 
from this information the nurses were able to record if the drug had been taken 7 days, 
1 month or 3 months prior to the death of the case. 
 
4.1.6 Results 
The results of the agreement of diagnostic criteria for the computerised database 
extraction on 28 cases are summarised in the table 7 with more detail for that of 
cardiovascular status in table 8. The result of the computer extraction for medication 
is given in table 9. The results of diagnostic criteria extracted from paper notes on a 
separate group of 24 cases are given in table 10 with more detail of cardiovascular 
status in table 11.  
 
With regard to the computerised database agreement for diagnoses on 28 cases (Table 
7), the worst agreement levels existed for atrial fibrillation, heart failure and 
hypertension. The worst kappa score was a moderate 0.47 which occurred for the 
diagnosis of atrial fibrillation one year prior to death where both raters agreed that 1 
case had it and 25 cases did not (one rater identified 3 cases and the other rater 
identified just 1 case). A moderate level of agreement (0.53) existed also for heart 
failure where the raters agreed that 3 cases had it and 21 did not. (one rater identified 
7 cases and the other rater agreed on just 3 of them). The third worst kappa score was 
0.65 for hypertension where the raters agreed that 11 cases had it and 12 did not (one 
nurse identified 16 cases of hypertension and the other agreed on 11 of them).  
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No individuals were identified by either of the raters as having myocardial infarction 
or heart block. There was perfect agreement (kappa = 1) for cardiovascular status, 18 
of the 28 cases were classified as cardiovascular by both data extractors (Table 8) 
despite diagnoses of cardiovascular subclasses not being in perfect agreement.  
 
For comparison of paper notes, kappa scores varied between substantial and perfect 
(Table 10). The raters agreed that 16 people could be classified as being 
cardiovascular cases and 6 could not, thus not agreeing about the cardiovascular status 
of 2 of them, for a kappa score of 0.80. There was perfect agreement for 3 
cardiovascular conditions “ever had a coronary revasculation”, “sinus bradycardia in 
past year” and “atrial fibrillation” in past year”. The worst level of agreement existed 
for heart failure for which there was a moderate kappa score of 0.63. One rater 
identified 4 individuals as having heart failure and the other rater agreed on just two 
of them. This was because the nurse that had worked on previous cardiology studies 
was able to recognise drugs given to people in heart failure and classify them 
accordingly in the absence of heart failure being mentioned in the medical notes. Thus 
heart failure was the cardiovascular condition that overall had the least agreement on 
both computerised database and paper notes. Furthermore it was the same rater that 
identified the most heart failure in the computer as well as paper notes study. There 
was excellent agreement for the paper notes extraction of the 4 blood tests there being 
only 1 blood test for 1 case on which the raters disagreed. 
 
The agreement for medications was evaluated according to three criteria, name of 
prescribed drug, dosage and time period prior to the death of the case (Table 9). The 
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percentage agreement for drug name was 92%, agreement on dosage was 97% and 
agreement on time period was 91%.  
 
Table 7 Computerised database agreement for diagnoses on 28 cases 
 
Diagnosis Differences % agreement Kappa score 
Cardiovascular 0 100 1 
Myocardial infarction 0 100 1 
Angina 2 92.86 0.7083 
Coronary revascularisation 1 96.43 Not calculable 
Heart failure 4 85.71 0.5294 
Hypertension 5 82.14 0.6534 
Sinus bradycardia 1 96.43 Not calculable 
Heart block 0 100 1 
Atrial fibrillation 2 92.86 0.4716 
Epilepsy 1 96.43 0.7812 
Renal 0 100 1 
Liver 0 100 1 
Unexplained dizziness 0 100 1 
Unexplained syncope 1 96.43 Not calculable 
Hypokalaemia 0 100 1 
Hypocalcaemia 0 100 1 
Hypomagnesaemia 0 100 1 
Hyperkalaemia 1 96.43 0.65 
 
 
 
Table 8 Computerised database agreement for cardiovascular status on 
28 cases  
 
  Rater 1 Rater 1 
  Cardiovascular Non-
Cardiovascular 
Rater 2 Cardiovascular 18 0 
Rater 2 Non-Cardiovascular 0 10 
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Table 9 Computerised database agreement for medication on 28 cases 
 
 Drug name Dosage for agreed 
drugs  
Time period for 
agreed drugs 
Agree 178 172 458 
Disagree 16 6 47 
% agreement 92% 97% 91% 
 
 
 
Table 10 Paper notes diagnoses for a separate group of 24 cases 
 
Diagnosis Differences % agreement Kappa score 
Cardiovascular 2 92% 0.7983 
Myocardial infarction 1 96% 0.8333 
Angina 1 96% 0.8333 
Coronary revascularisation 0 100% 1 
Heart failure 2 92% 0.625 
Hypertension 1 96% 0.9032 
Sinus bradycardia 0 100% 1 
Heart block 1 96% Not calculable 
Atrial fibrillation 0 100% 1 
Epilepsy 1 96% Not calculable 
Renal 0 100% 1 
Liver 0 100% 1 
Unexplained dizziness 1 96% Not calculable 
Unexplained syncope 0 100% 1 
Hypokalaemia 1 96% Not calculable 
Hypocalcaemia 0 100% 1 
Hypomagnesaemia 0 100% 1 
Hyperkalaemia 0 100% Not calculable 
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Table 11 Paper notes agreement for cardiovascular status on 24 cases 
 
  Rater 1 Rater 1 
  Cardiovascular Non-
Cardiovascular 
Rater 2 Cardiovascular 16 1 
Rater 2 Non-Cardiovascular 1 6 
 
 
 
4.1.7 Discussion 
4.1.7.1 Computerised database 
Kappa scores varied between moderate and perfect. Given the small sample of 28 
cases, confidence intervals are wide and a few errors can cause kappa scores to 
plummet dramatically.  
 
The nurse rater that identified the greatest number of hypertensive subjects also 
identified the least number of heart failure cases as well as the least number of atrial 
fibrillation cases. Thus although it is relatively easy to identify cardiovascular cases, 
as shown by the perfect agreement for overall cardiovascular status it is more difficult 
to agree on the diagnoses for cardiovascular subclasses.  
 
Given that one nurse was more experienced than the other in recognising heart failure 
and the difficulty in classifying heart failure as noted by James et al 179 it is 
understandable that this diagnosis had one of the worst levels of agreement. For the 
diagnosis of hypertension one rater had a policy of classifying an individual as having 
this condition only if they saw the written diagnosis whereas the other rater also 
looked out for appropriate treatment.  
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It became clear in a later briefing that the main reason for disagreement on diagnoses 
between nurses was the interpretation of the information in the medical record. For 
example how does one interpret the criteria “atrial fibrillation in the period one year 
prior to death”? Clearly there is no problem if the diagnosis is in the notes, especially 
if backed up by relevant treatment; but what if the diagnosis was 18 months prior to 
death? One rater may decide that the criteria had not been met but another may decide 
that it had been if the subject had been receiving relevant treatment such as warfarin 
or aspirin. But those treatments can be used for other conditions so a judgement would 
have to be made on the presence of those other conditions and the likelihood of the 
patient being treated for them. It is likely that agreement would have been better if the 
wording of the criteria had been more explicit such as “ever had a diagnosis of atrial 
fibrillation”. Another important consideration is that one of the nurses had extracted 
and interpreted cardiovascular information for a previous trial and it would not be 
surprising if this greater experience led to her diagnoses being more accurate.  
 
For the blood results hypokalaemia, hyperkalaemia, hypocalcaemia and 
hypomagnaesaemia there was only 1 case, when comparing computerised notes, on 
which the raters disagreed. 
 
Agreement was excellent for those conditions where the criteria were unambiguous. 
 
4.1.7.2 Paper notes 
There is perfect agreement for the paper notes diagnosis of atrial fibrillation and 
moderate agreement for the computerised database extraction which could be due to 
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the small sample size so that the moderate agreement hinged on only two individuals 
for which there was disagreement. 
 
Heart failure was the cardiovascular condition that overall had the least agreement on 
both computerised database and paper notes comparison and this was because of the 
difference in experience of the nurses and the difficulty of the diagnosis. The same 
rater identified the most heart failure in the computer as well as the paper notes study. 
The bias in the classification of cases as having heart failure does not alter the 
classification of cases as cardiovascular.  
 
There was excellent agreement for the paper notes extraction of the 4 blood tests there 
being only 1 blood test for 1 case in the paper notes on which the raters disagreed.  
 
Agreement was excellent for both database and paper notes extraction of 
unambiguous data. 
 
After a review of the medical records of 52 individuals (28 computer records, 24 
paper records) the raters disagreed about the cardiovascular status of only two of them 
thus it is essential to define clearly the criteria. 
 
For both computerised and paper notes, extraction agreement was excellent for those 
conditions where the criteria were unambiguous. 
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4.1.7.3 Agreement for medication 
The agreement for medications was evaluated according to three criteria, name of 
prescribed drug, dosage and time period prior to the death of the case (Table 9). 
Percentage agreement over 90% is considered to be acceptable191. A percentage 
agreement of 92% for drug name was found. Agreement on dosage and time period 
prior to the death of the case was evaluated only for those drugs that both raters had 
identified as being prescribed. The comparison of dosage was made only for those 
medications that both raters had agreed were given to the respective case and was 
97%. In order to assert that a drug had been prescribed to individuals in any of the 
three time periods prior to death, a calculation had to be made by each rater which 
took into account the date of death of the case, the dates on which drugs had been 
prescribed, the total numbers of tablets prescribed and the number of tablets to be 
taken each day. An error of 1 day in the calculation can make a difference when 
declaring that a case had a drug in a time period explaining why agreement was the 
lowest of the drug criteria at 91%. Kappa scores were not done for individual 
medications because of the small numbers of cases that received even the most 
commonly prescribed drug. 
 
4.1.8 Conclusion 
There was perfect agreement for the classifications cardiovascular and non-
cardiovascular. There was a good to perfect (kappa = 1) level of agreement for most 
diagnoses and never less than moderate and when moderate were for conditions that 
required interpretation. Thus we can be sure that the raters were almost always seeing 
the same information but sometimes experienced difficulties when they had to make a 
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judgement. It is helpful to data extractors if their instructions are worded as 
unambiguously as possible. 
 
There is evidence of bias between the raters for the classification of some 
cardiovascular conditions, most notably heart failure and hypertension due to 
differences in training and experience. Fortunately there is no evidence of bias 
between cases and controls in this thesis because the same nurse viewed notes for 
both cases and the associated controls.  
 
This thesis collected data using both electronic and paper records. Therefore actual 
agreement is likely to be higher than the kappas recorded here. 
 
4.2 Study 2: Compliance characteristics of participating 
practices 
Most surgeries and general practitioners granted access to study investigators for the 
purpose of viewing medical notes. As doctors who decline to take part in research are 
widely believed to differ from those that do, I explored the characteristics of GPs who 
did and who did not allow access to their patient records. 
 
4.2.1. Compliance characteristics of surgeries and GPs 
 
I stratified the decisions by surgeries that I approached for permission to view medical 
notes according to whether they were single handed or not and present it below (Table 
12). Single handed general practices were more than twice as likely to refuse access 
21/75(28.0%) compared with doctors working in multi-handed practices 
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33/276(12.0%). There was a significant difference between single handed and group 
surgeries t = 11.6, p = 0.001. 
 
Table 12 Comparing single handed with group surgeries 
 
 Compliers n (%) Non-Compliers n 
(%) 
Total 
Single handed 
surgeries 
54 (72.0%) 21 (28.0%) 75 (100%) 
Group surgeries 243 (88.0%) 33 (12.0%) 276 (100%) 
 
 
 
I found that the GP decisions to assist with the study were taken at surgery level. Out 
of a total 1210 general practitioners working in the 351 surgeries that I approached for 
access to medical notes, 1083 (89.5%) doctors worked in surgeries that granted 
access. 
 
4.2.2 Compliance characteristics of surgeries with respect to deprivation 
scores 
 
Deprivation scores were obtained for individual practices and summary statistics 
generated to compare compliant with non-compliant surgeries (Table 13). Townsend 
deprivation scores are calculated from four census variables, namely percentages for 
unemployment, car ownership, overcrowding and non-owner occupied housing. Index 
of Material Deprivation (IMD) scores are based on income deprivation, employment 
deprivation, health deprivation and disability, education skills and training 
deprivation, barriers to housing and services, living environment deprivation and 
crime A positive deprivation score for an area would indicate that the area is relatively 
deprived; a negative figure that the area is relatively better off. 
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 Table 13 Compliance characteristics of surgeries with respect to 
deprivation scores 
 
 Number 
of GPs 
per 
practice  
Practice 
List Size 
Townsend 
2001 
IMD 2000 
Score 
IMD 2004 
Score 
Compliers 
mean (SD) 
3.7 (2.4) 6115 (3527) 4.3 (5.1) 38.5 (19.5) 36.9 (19.0) 
Refusers 
mean (SD) 
2.4 (1.6) 4418 (2862) 5.0 (5.7) 39.9 (19.5) 35.6 (17.9) 
* IMD Index of multiple deprivation 
  
Table 13 shows that deprivation scores are positive irrespective of compliance 
characteristics which indicates that sudden cardiac death occurs more often in areas of 
social deprivation. The mean number of general practitioners was significantly larger 
at compliant practices, t = 3.83, p = 0.0002. The mean practice list size at surgeries 
that refused access was significantly smaller than that at compliant surgeries, t = 3.34, 
p = 0.0009.  Differences were not significant between complier and refuser surgeries 
for mean Townsend 2001 score, t = 0.911, p =0.36, nor were they significant for IMD 
2000 scores, t = 0.49, p = 0.63 or for  mean IMD 2004 scores t = 0.47, p = 0.64. Thus 
there is no clear difference in terms of social deprivation between surgeries that 
comply and those that do not.  
Refusal to allow access could not be due to GP workload or to lack of administrative 
support because the research nurse did all of the data extraction which took about one 
hour for each case control set and only required access to a computer at a time 
convenient to the surgery. 
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4.3 Study 3 Post Mortem reports 
 
 
4.3.1 Introduction 
 
Provisional cases were individuals who had a post mortem report and met the case 
definition on examination of the mortality files. The study team sought to further 
strengthen the case definition by examining post-mortem reports from the 
Birmingham coroner’s records in order to identify and exclude any unsuitable cases. 
The supportive coroner who was a collaborator on the study proposal retired prior to 
its start and his successor would not grant access to post mortem reports.  
 
Fortunately we were able to view many but not all post mortem reports at the PCTs 
although copies were missing for some deceased individuals. Later, 16 months into 
the study researchers were also prevented from viewing reports at the shared service 
agency for Birmingham and Solihull PCTs, when they decided to levy a charge to 
view written medical information. Researchers were able to sometimes view a copy of 
the post mortem report at the GP surgery at which the case was registered 
 
To prevent a considerable loss of cases it was decided to explore whether we could 
accept individuals for whom post mortem reports were not available for scrutiny.  
 
4.3.2 Aims 
The purpose of the study was to address the following questions: 
 
1. How successful were study investigators in obtaining access to post mortem 
reports? 
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2. What proportion of individuals who would be classifiable as cases on 
mortality file data would be excluded after taking the additional information 
that is in post mortem reports into account? 
 
4.3.3 Methods 
 
To address question 1 researchers recorded on the study database if a post mortem 
report had been viewed.  
 
To address question 2, a study team consisting of a consultant cardiologist and senior 
lecturer in medicine compared the levels of agreement for 1a, 1b, 1c, and 2 causes of 
death for 96 cases between, mortality file data and post mortem reports obtained from 
surgeries.  
 
4.3.4 Results 
  
The study team were able to obtain access to the post mortem reports of 463 (58.7%) 
cases out of the total 789. Although every one of the remaining 326 (41.3%) cases had 
a post mortem report investigators were not able to view them. 
 
The 96 cases for which photocopied post mortem reports were available met the 
eligibility criteria according to the causes of death on their mortality files but 4 
(4.17%) of them were excluded after assessment of the post mortem report. 
 
There was a very good level of agreement between causes of death on post mortem 
report and public health mortality file data. There were seven “cause of death” errors, 
one of them in the 1a cause of death category, three in the 1b causes of death category 
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and three in the 2 cause of death category. One of the errors in the 1b cause of death 
category had the potential for a case misclassification (Fig 4).  
 
One can probably make the assumption that the cause of death recorded on the post 
mortem is correct and the cause of death appearing on the mortality file is copied from 
it so when the two differ the error is in the mortality file. The disagreements in the 
causes of death between post mortem and mortality file data for the seven cases that 
have differences are explored in more detail for each case below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 95
Fig 4. Differences between post mortem report and mortality file causes 
of death 
 
Case 1 the mortality file missed out “hypertension” from the post mortem 1b cause of 
death “coronary artery atherosclerosis and stenosis and hypertension”. 
 
Case 2 the mortality file missed out “diabetes mellitus” from the post mortem 1b 
cause of death of chronic mitral valvar disease, systemic hypertension and diabetes 
mellitus.  
 
Case 3 the mortality file missed out “with thrombosis” from the post mortem 1b cause 
of death of “coronary artery disease with thrombosis”. 
 
Case 4 the mortality file missed out “hypertension” from the post mortem section 2 
cause of death.  
 
Case 5 the mortality file missed out “extensive oedema of lungs” from the post 
mortem section 2 cause of death. 
 
Case 6 the 1a cause of death on the mortality file was “sudden adult death syndrome” 
whereas that on the post mortem report was “unascertained”. 
 
Case 7 the mortality file had an insertion error in section 2 cause of death of “chronic 
obstructive airways disease, diabetes mellitus and hyperthyroidism” instead of no 
phrase. 
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4.3.5 Discussion 
 
I believe that the disagreement for case 3 had the potential for a misclassification and 
thus I consider it to be a serious error because the study excluded deceased individuals 
from being a case if they had a coronary thrombosis. The disagreements for the other 
6 cases would not affect the decision to include them as cases so I would classify 
these errors as minor. 
 
This study was concerned with the level of agreement between post mortems and 
mortality file data, not with how well the pathologists followed the guidelines for 
entering the causes of death on the post mortem reports. The instructions state that 
there should be only one diagnosis for each of 1a, 1b, and 1c causes of death. In this 
respect I observed that it was very common for pathologists to disregard the 
guidelines and I showed some examples for the cases above. 
 
For those post mortem reports that were viewed, the majority were seen at the PCT 
premises. Only a minority of medical practices scanned post mortem reports into their 
computers. It would be of benefit to researchers if more surgeries were to adopt this 
practice 
 
It was possible to view post mortem reports for 463 (58.7%) cases. It is possible that 
the study would have lost a small number of the 326 other cases if their post mortem 
reports had been available and the best estimate of the number that would have been 
lost would be 326 multiplied by proportion that was lost on review by the study team 
(4.17%), (table 4) that is 15 of them. It is unlikely that this relatively small loss would 
have had an impact on the findings of this thesis. 
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4.4 Summary of Chapter 4 
In chapter 4 I have explored aspects of the methods of this study. In study 1 I 
measured the agreement between myself and the other nurse for the extraction of 
information from patient medical records held at general practitioner surgeries in 
computerised database and paper form. I found it to be acceptable. Study 2 assessed 
the compliance characteristics of general practitioners and found that single handed 
surgeries (compared with group surgeries) were significantly less likely to grant 
researchers access to patient records. Study 3 stated the number of post mortem 
reports viewed and quantified the agreement between the causes of death on mortality 
files compared with the causes of death on post mortem files for the same individuals. 
It also quantified the number of provisional cases that would be excluded after taking 
into consideration the additional information held on post mortem reports into 
account.  
 
 
 
 
 
 
 
 98
5 Results 
 
 
5.1 Characteristics of cases and controls 
All 789 cases were successfully matched to 3 controls. Males outnumbered females 
by a ratio of 2:1. More than half of the cases (56.1%) had a documented history of 
heart disease. Close matching for age was achieved with the average age 67.80 (SD 
12.71) for cases and 67.79 (SD 12.70) for controls (Table 14). 
 
Table 14 Summary of matching factors, age, sex and cardiovascular 
disease 
 Cases n (%) Controls n (%) 
Males n % 524 (66.4%) 1572 (66.4%) 
Females n % 265 (33.6%) 795 (33.6%) 
History of cardiovascular disease 
n % 
443 (56.1%) 1329 (56.1%) 
No history of cardiovascular 
disease n % 
346 (43.9%) 1038 (43.9%) 
Age (mean, SD) 67.80 (12.71) 67.79 (12.70) 
Age <20.0    0      0 
Age 20.0 – 30.0    6 (0.76%)   18 (0.76%) 
Age 30.0 – 40.0   22 (2.79%)   65 (2.75%) 
Age 40.0 – 50.0   55 (6.97%) 164 (6.93%) 
Age 50.0 – 60.0 120 (15.21%) 361 (15.25%) 
Age 60.0 – 70.0 174 (22.05%) 520 (21.97%) 
Age 70.0 – 80.0 288 (36.50%) 864 (36.50%) 
Age >80.0 124 (15.72%) 375 (15.84%) 
 
 
 
5.2 Summary of previous medical conditions according to case control 
status 
Proportionally more cases than controls had a history of myocardial infarction, heart 
failure, low potassium, atrial fibrillation, epilepsy, syncope, impaired liver function, 
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drug misuse and alcohol abuse. Conditional logistic regression odds ratios (OR) to 
measure effect size were calculated and 95% confidence intervals (95% CI) to 
measure the statistical reliability of this estimate were calculated (Table 15).  
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Table 15 Summary of previous medical conditions by group 
 
Medical diagnosis Cases  
n (%) 
Controls  
n (%) 
Odds 
ratio 
(OR) 
95%Confidence 
interval  
(95% CI) 
Previous myocardial 
infarction 
83 (10.5%) 164 (6.9%) 1.71* 1.27, 2.30 
Angina 107 
(13.6%) 
297 (12.5%) 1.11 0.86, 1.44 
Coronary 
revasculation 
20 (2.5%) 89 (3.8%) 0.65 0.39, 1.08 
Heart failure 85 (10.8%) 103 (4.4%) 3.22* 2.29, 4.52 
Hypertension 399 
(50.6%) 
235 (52.2%) 0.73 0.51, 1.03 
Low serum 
Potassium 
22 (2.8%) 18 (0.8%) 4.08* 2.10, 7.90 
Low serum Calcium 3 (0.4%) 6 (0.3%) 1.50 0.36, 6.00 
Low serum 
Magnesium 
0 (0.0%) 1 (0.0%) ----- ----------- 
Bradycardia 8 (1.0%) 16 (0.7%) 1.52 0.64, 3.60 
Heart block 7 (0.9%) 9 (0.4%) 2.45 0.88, 6.81 
Atrial fibrillation 58 (7.4%) 102 (4.3%) 1.91* 1.33, 2.73 
Epilepsy 46 (5.8%) 33 (1.4%) 4.26* 2.71, 6.70 
Syncope 16 (2.0%) 26 (1.1%) 1.97* 1.02, 3.82 
Dizziness 36 (4.6%) 98 (4.1%) 1.11 0.75, 1.65 
Impaired renal 
function 
49 (6.2%) 113( 4.8%) 1.37 0.95,  1.99 
Impaired liver 
function 
26 (3.3%) 27 (1.1%) 3.0* 1.73,  5.21 
High Serum 
Potassium 
24 (3.0%) 54 (2.3%) 1.36 0.83, 2.24 
Drug misuse 8 (1.0%) 3 (0.1%) 11.08* 2.34, 52.57 
Alcohol abuse 100 
(12.7%) 
48 (2.0%) 8.59* 5.75, 12.82 
 * significant at α = 0.05. 
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Conditions found to be significantly associated with sudden death were used to adjust 
for the strength of the effect size between sudden death and medications (section 5.5). 
 
5.3 Analysis of consultations 
Table 16 counts the number of consultations given to individuals and cannot be 
analysed using conditional logistic regression unlike tables 17, 18 and 19 which count 
the number of individuals given at least one consultation. For the latter three tables 
crude conditional logistic odds ratios were calculated. They were not adjusted because 
there was no need to control for confounding variables in this analysis. My goal was 
to find if there was a link between consultation and sudden death irrespective of 
disease.   
 
 
5.3.1 Comparison of GP and hospital consultations in 3 months prior to 
death of the case 
The number and type of consultations for each individual in the three months prior to 
the death of the cases were recorded (Table 16). 
Table 16 Comparison of GP and hospital consultations in 3 months prior 
to death of the case 
  
 Consultations 
for Cases 
N 
Consultations 
for Cases 
Mean (SD) 
Consultations 
for Controls 
N 
Consultations 
for Controls 
Mean (SD) 
GP  1337 1.69 (2.30) 3969 1.68 (1.96) 
Hospital 
clinic 
261 0.33 (0.75) 820 0.35 (0.81) 
Hospital 
admission 
63 0.08 (0.32) 70 0.03 (0.19) 
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Cases have a significantly greater mean number of hospital admissions than controls t 
= 5.40, p < 0.0001. There is no significant difference between cases and controls for 
mean number of GP clinic conditions, t = 0.15, p = 0.88 or hospital clinic 
consultations, t = 0.84, p = 0.43. 
 
5.3.2 General Practitioner Consultations 
There are 497 cases and 1,544 controls that had at least one GP consultation in the 3 
months prior to the death of the case (Table 17). Conditional logistic regression odds 
ratios, significance values and confidence intervals were generated. There was no 
significant association with sudden death and occurrence of at least one GP 
consultation in the 3 months prior to death of the case. Analysing separately the 
samples with a history of cardiac disease and no history of cardiac disease does not 
alter this finding.  
 
Table 17 General Practitioner Consultations 
  Cases 
  N 
Controls 
 N 
OR 95% CI p 
Non 
Cardiac 
157 497 0.90 0.70,       1.15 0.403 
Cardiac 340 1047 0.88 0.68,       1.15 0.356 
All 497 1544 0.89 0.74,       1.07 0.214 
OR; Conditional logistic regression odds ratio. 
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5.3.3 Hospital Outpatient Consultations 
There is no significant association with sudden death and hospital outpatient 
consultations in the 3 months prior to death of the case. Analysing separately the 
cardiac and non cardiac samples makes no difference to the findings (Table 18).  
 
Table 18 Hospital Outpatient Consultations 
 
 Cases 
N 
Controls 
N 
OR 95% CI p 
Non 
Cardiac 
145 390 1.19 0.93,        1.51 0.164 
Cardiac 57 165 1.05 0.75,        1.46 0.796 
All 202 555 1.14 0.93,        1.38 0.200 
OR; Conditional logistic regression odds ratios.  
 
 
5.3.4 Hospital admissions 
Admissions to hospital within 3 months of death are significantly associated with 
sudden death in cardiac patients, odds ratio 3.28 (2.11,  5.08) (Table 19).  
 
Table 19 Hospital admissions 
 
 Cases 
N 
Controls
N 
OR p 95% CI 
Non Cardiac 12 18 2.08 0.057 0.98,        4.43 
Cardiac 42 39 3.28* < 0.001 2.11,        5.08 
All 54 57 2.98* < 0.001 2.0,          4.26 
OR; Conditional logistic regression odds ratios.  
* significant at α = 0.05. 
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5.4 Medications 
 
Cases on average take significantly more medication than controls, t = 5.66, p < 
0.0001. Cases take a mean of 4.82 (sd = 4.20) and controls a mean of 3.97 (sd = 3.45) 
medcations.  
 
5.5 Results for drug exposures 
Using a conditional logistic regression model I calculated odds ratios (OR) for the 
association of sudden death with current use of registry QT prolonging drugs and I 
also calculated them adjusted for significant medical conditions. Current use was 
defined as prescription 0-7days for antibiotics and 0-30 days for other drugs. To 
explore the impact of cardiovascular disease on these associations I then stratified for 
cardiovascular disease and calculated the corresponding odds ratios. 
 
5.5.1 Registry type 1 drugs 
Registry type 1 drugs consist of macrolide antibiotics for which current use is 
prescription in the period 0-7 days prior to death of index case and other drugs for 
which current use is prescription 0-30 days. 
 
 
5.5.1.1 Current use of macrolide antibiotics 
The risk of sudden cardiac death was significantly increased for erythromycin users, 
non adjusted OR 7.5 (1.46, 38.66) and adjusted OR 8.67 (1.46, 38.66). Sudden death 
risk was not significantly increased for combined macrolide use. No cases took 
clarithromycin so it was not possible to calculate an odds ratio or a confidence 
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interval. Numbers of exposed individuals are very small and so confidence intervals 
are wide which reflects the great imprecision in these estimates (Table 20).  
 
 
Table 20 Current use of macrolide antibiotics 
 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
95% CI 
Clarithromycin 0 4 ----- ----- ---- ---------- 
Erythromycin 5 2 7.5* 1.46, 38.66 8.67* 1.50, 49.92 
Macrolides 5 6 2.5 0.76,  8.19 2.42 0.68,   8.63 
OR; Conditional logistic regression odds ratios.  
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
 
 
5.5.1.1.1 Current use of macrolide antibiotics stratified for 
cardiovascular disease 
As there were only 2 prescriptions of antibiotics for non-cardiovascular patients, both 
for control patients, it is not possible to find if an association with sudden death exists. 
 
In cardiovascular patients the risk of sudden cardiac death was significantly increased 
for erythromycin users, non-adjusted OR 7.5 (1.46, 38.66) and adjusted 8.67 (1.50   
49.92) and for combined macrolide use non adjusted OR 3.75 (1.01   13.96) and 
adjusted 4.40 (1.08   17.91) (Table 21).  
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 Table 21 Current use of macrolide antibiotics for cardiovascular patients 
 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
 95% CI 
Clarithromycin 0 2 ----- ------ ----- ---------- 
Erythromycin 5 2 7.5* 1.46  38.66 8.67* 1.50,  49.92 
Macrolides 5 4 3.75* 1.01  13.96 4.40* 1.08,   17.91 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope 
impaired liver function, drug misuse and alcohol abuse. 
 
 
 
5.5.1.2 Current use of non-macrolide type 1 drugs 
Unadjusted odds ratios significantly above 1 are found for amiodarone OR 2.6 (1.24, 
5.46) and haloperidol OR 6.0 (1.10, 32.76). On combining drugs, significant 
unadjusted odds ratios are found for antiarrhythmics 1.89 (1.03, 3.47) and 
antipsychotics 3.86 (1.44, 10.36) and all 2.09 (1.31, 3.34). 
 
After adjustment; only combined antipsychotic use remained significantly associated 
with sudden death OR 3.65 (1.17, 11.40) (Table 22). 
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Table 22 Current use of non-macrolide type 1 drugs 
 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
#95% CI 
Amiodarone 13 15 2.6* 1.24,   5.46 1.70 0.74,    3.89 
Disopyramide 0 1 ---- ------- -------- ---------- 
Sotalol 4 11 1.09 0.35,   3.43 0.93 0.28,    3.07 
Antiarrhythmics 17 27 1.89* 1.03,   3.47 1.34 0.68,    2.61 
Chlorpromazine 3 5 1.8 0.43,   7.53 1.83 0.31,  10.73 
Haloperidol 4 2 6.0* 1.10, 32.76 3.74 0.54,  25.83 
Thioridizine 2 0 ---- ------ ------- ----------- 
Antipsychotics 9 7 3.86* 1.44, 10.36 3.65* 1.17,  11.40 
Domperidone 4 9 1.33 0.41,   4.33 1.32 0.41,    4.34 
Type 1  
(excluding 
Macrolides) 
30 43 2.09* 1.31,  3.34 1.64 0.98,   2.73 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
 
5.5.1.2.1 Current use of non macrolide type 1 drugs for patients without 
cardiovascular disease 
For people that do not have a diagnosed cardiovascular condition there is a significant 
association between sudden death and current use of  antipsychotic medication, 
adjusted OR 4.5 (1.27,  15.95) and unadjusted OR 4.97 (1.15, 21.55). When the anti-
nausea drug domperidone is included there is a weakened unadjusted significant 
association for all combined OR 3.0 (1.05,   8.55) (Table 23). 
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For non cardiovascular patients the combined type 1 antipsychotic medication is 
significantly associated with sudden death both before and after adjustment. When 
domperidone is also taken into account the crude odds ratio is significant but not the 
adjusted one. 
 
Table 23 Current use of non macrolide type 1 drugs for patients without 
cardiovascular disease 
 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
#95% CI 
Chlorpromazine 3 3 3.0 0.61,  14.86 3.07 0.43,  21.80 
Haloperidol 1 1 3.0 0.19,  47.96 1.96 0.05,  84.83 
Thioridizine 2 0 ------- -------- ---------- ---------- 
Antipsychotics 6 4 4.5* 1.27,  15.95 4.97* 1.15,  21.55 
Domperidone 1 3 1.0 0.10,   9.61 1.13 0.17,  11.01 
Type 1  
(excluding 
Macrolides) 
7 7 3.0* 1.05,   8.55 3.04 0.93,   9.91 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
 
5.5.1.2.2 Current use of non macrolide type 1 drugs for patients with 
cardiovascular disease 
There is a significant association between sudden death and amiodarone, unadjusted 
OR 2.6 (1.24, 5.46) but not between sudden death and sotalol. Both drugs are 
prescribed to control arrhythmia (Table 24). 
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No significant association can be found between sudden death and current use of 
antipsychotic medication but this could be because the number of prescriptions is 
small.  
 
On combining drugs, significant unadjusted odds ratios are found for antiarrhythmics 
1.89 (1.03, 3.47) and all type 1 drugs 1.92 (1.14, 3.23). After adjustment no 
significant odds ratios are obtained.  
 
Table 24 Current use of non macrolide type 1 drugs for patients with 
cardiovascular disease 
 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
95% CI 
Amiodarone 13 15 2.6* 1.25,    5.46 1.70 0.74,   3.89 
Disopyramide 0 1 ------- ---- ---- -------- 
Sotalol 4 11 1.09 0.35,   3.43 0.93 0.28,   3.07 
Anti arrhythmics 17 27 1.89* 1.03,   3.47 1.34 0.68,   2.61 
Chlorpromazine 0 2 ------- ---- ---- --------- 
Haloperidol 3 1 9.0 0.94,  86.52 4.71 0.45,  49.45 
Thioridizine 0 0 --------
-- 
---- ---- -------- 
Anti psychotics 3 3 3.0 0.61,  14.86 2.29 0.39,  13.45 
Domperidone 3 6 1.5 0.38,    6.00 1.41 0.35,   5.69 
Type 1 (excluding 
Macrolides) 
23 36 1.92* 1.14,    3.23 1.43 0.81,   2.52 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
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5.5.1.3 Use of type 1 drugs in time periods (0-7, 8-30, 31-90) days prior to 
death of index case 
 
I calculated unadjusted odds ratios for use of type 1 medications in time periods (0-7, 
8-30, 31-90) days prior to death of index case (Appendix 1).Apart from macrolide 
antibiotics there is very little difference between the numbers of medications 
prescribed in the three time periods and the associated odds ratios because with few 
exceptions the same people are being counted in all of them.No individual had 
received more than one type 1 drug in period 0-7 or period 8-30 days One control has 
received more than one type 1 drug (domperidone and erythromycin) in period 31-90 
days. No Case has received more than one type 1 drug.There was a significant 
association with amiodarone, combined anti-arrhythmics, combined anti-psychotics 
and combined type 1 medication in all time periods. 
 
To quantify the temporal nature of drug exposure in terms of risk of sudden death I 
compared drug use in 3 defined time periods (0-7, 8-30, 31-90 days) (Table 29).  
 
Significant associations with sudden death and type 1 medications are found in all 
three time periods. The hypothesis that medications are contributing to death is 
supported if odds ratios increase with approaching index date of death. This trend is 
clearly seen in the table 25 and associated graph (fig 5) for combined type 1 
medications. 
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Table 25 Comparing use of combined type 1 drugs in time periods (0-7, 
8-30, 31-90 days)  
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
All Type 1 (0-7 
days) 
33 47 2.12* 1.36,      3.32 0.001 
All Type 1 (8-30 
days) 
31 51 1.82* 1.17,      2.85 0.008 
All Type 1 (31-
90 days) 
35 67 1.58* 1.04,      2.38 0.030 
OR; Conditional logistic regression odds ratios.  
* significant at α = 0.05. 
 
 
 
Fig 5. Risk of sudden death according to time of drug exposure for type 
1 medications 
Risk of sudden death according to time of drug exposure 
for type 1 medications.
0
0.5
1
1.5
2
2.5
0-7 days 8-30 days 31-90 days
Time period of prescription to index date
O
dd
s 
Ra
tio
 
 
 
The trend for odds ratios for combined type 1 medications to become greater the 
closer to the index date was further investigated by examining subcategories of type 1 
drugs. The increase is mostly due to macrolide antibiotic use and to a lesser extent 
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antipsychotic use. Antiarrythmics and the antinausea domperidone show very little 
variation in their use over the three time periods  (Table 26) & (Fig 6). 
 
Table 26 All type 1 medication subcategories (Non-adjusted) 
 
 Antiarrythmics 
OR, (95%CI) 
Antipsychotics 
OR, (95%CI) 
Macrolides 
OR, (95%CI) 
Anti-Nausea 
(Domperidone)
OR, (95%CI) 
0-7 days 1.89(1.03, 3.47) 3.5(1.18,  10.4) 2.5(0.76,  8.19) 1.5(0.45,  4.98) 
8-30 days 1.89(1.03, 3.47) 3.0(1.05,    8.56) 1.5(0.45,  4.98) 1.0(0.27,  3.69) 
31-90 days 1.89(1.03, 3.47) 3.0(1.05,    8.56) 0.8(0.35,  1.89) 1.5(0.45,  4.98) 
 
 
 
 
 
Fig 6.Risk of sudden death according to time of drug exposure for 
subcategories of type 1 medications 
Temporal nature of non adjusted conditional logistic 
regression odds ratios with type 1 drug sub-categories
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5.5.2 Current use of registry type 2 drugs  
A very significant association p< 0.001 is found with sudden cardiac death and the 
anti-psychotic drug risperidone adjusted OR 6.0 (2.57, 14.02), unadjusted OR 6.02 
(2.48, 14.64) (Table 27).  
 
No evidence exists of an association with sudden death for current use of grouped 
type 2 medications. 
 
There was one prescription for the antibiotic levofloxacin in the period 0-7 days prior 
to death of the case which can be included in the 0-30 days table that defines current 
use for type 2 drugs.  
 
Several individuals have received more than 1 type 2 drug in the period 0-30 days 
prior to the death of the index case. 
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Table 27 Current use of type 2 drugs 
 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
# Adjusted 
95% CI 
Alfuzosin 3 27 0.33 0.10,     1.10 0.37 0.11,   1.27 
Amantadine 1 0 ----- ----- ---- -------- 
Flecainide 1 3 1.00 0.10,     9.61 1.01 0.10,  11.55 
Indapamide 12 50 0.71 0.37,      1.35 0.91 0.47,    1.77 
Levofloxacin 0 1 ----- ----- ---- --------- 
Lithium 4 8 1.42 0.45,      4.98 1.29 0.38,    4.41 
Nicardipine 1 2 1.5 0.14,    16.54 2.36 0.20,  27.12 
Quetiapine 0 3 ---- ----- ----- ----- 
Risperidone 16 8 6.00* 2.57,    14.02 6.02* 2.48,  14.64 
Tamoxifen 1 11 0.27 0.04,      2.21 0.28 0.04,    2.18 
Tizanidine 0 1 ---- -----  ------ 
Vardenafil 0 5 ---- ----- ---- ------ 
Venlafaxine 5 9 1.67 0.56,      4.97 2.26 0.70,   7.25 
Type 2 (0-30 
days) 
42 120 1.05 0.73,      1.51 1.19 0.81,   1.74 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
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5.5.2.1 Current use of type 2 drugs for non cardiovascular disease 
No significant associations between sudden death and type 2 medication given to non 
cardiovascular patients can be detected (Table 28). 
 
Two non-cardiovascular cases and four non-cardiovascular controls are on two type 2 
drugs. 
 
Table 28 Current use of type 2 drugs for non-cardiovascular patients 
 
 Cases  
N 
ControlsN OR 95% CI #Adjusted 
OR 
#Adjusted 
95% CI 
Alfuzosin 1 10 0.30 0.04,      2.34 0.34 0.04,   2.72 
Amantadine 1 0 ------ ------ ------ -------- 
Levofloxacin 0 1 --- ---- ------ -------- 
Lithium 3 7 1.29 0.33,       4.97 1.18 0.30,   4.69 
Risperidone 4 8 1.5 0.45,        4.98 1.63 0.47,   5.65 
Tamoxifen 0 4 ----- ------ ------ -------- 
Tizanidine 0 1 ----- -------- ------ -------- 
Vardenafil 0 2 ------ ------- ------ -------- 
Venlafaxine 1 5 0.60 0.70,       5.14 1.03 0.11,   9.35 
Type 2 (0-30 
days) 
8 34 0.68 0.31,      1.48 0.74 0.33,   1.65 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
 
5.5.2.2 Current use of type 2 drugs for cardiovascular patients  
 
There are 12 cardiovascular cases and no cardiovascular controls on risperidone 
(Table 29) and this is indicative of an association between sudden death and the 
 116
current use of risperidone. It is not possible to calculate an odds ratio because of the 
presence of the zero. 
 
There are no significant associations with sudden death and any other type 2 drug 
given to people who are classified as having cardiovascular disease. 
 
No cardiovascular case is on more than one type 2 drug. Four cardiovascular controls 
are on more than one type 2 drug. 
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Table 29 Current use of type 2 drugs for cardiovascular patients  
 
 Cases 
N 
Controls
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 95% 
CI 
Alfuzosin 2 17 0.35 0.08,     1.53 0.38 0.08,    1.80 
Flecainide 1 3 1.0 0.10,     9.61 1.08 0.10,  11.55 
Indapamide 12 50 0.710 0.37,     1.35 0.91 0.47,    1.77 
Lithium 1 1 3.0 0.19,   47.96 1.92 0.11,   33.06 
Nicardipine 1 2 1.5 0.14,   16.54 2.36 0.20,   27.12 
Quetiapine 0 2 ------ -------- ----- -------- 
Risperidone 12 0 ----- -------- ----- --------- 
Tamoxifen 1 7 0.43 0.05,     3.48 0.45 0.05,   3.68 
Vardenafil 0 3 ------- ------- ----- -------- 
Venlafaxine 4 4 3.0 0.56,     4.97 3.48 0.80,   15.22 
Type 2 (0-30 
days) 
34 85 1.22 0.80,     1.84 1.42 0.92,    2.20 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
 
 
5.5.2.3 Use of type 2 medications in time periods (0-7, 8-30, 31-90) days 
prior to death of index case 
I calculated non adjusted odds ratios for use of type 2 medications in time periods (0-
7, 8-30, 31-90) days prior to death of index case (Appendix 2). 
There is very little difference between the numbers of medications prescribed in the 
three time periods and the associated odds ratios, because as for type 1 medications, 
with few exceptions the same people are being counted in all of them. Some cases and 
controls were prescribed more than 1 type 2 drug in all time periods. 
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 I compared the risk of sudden death associated with registry type 2 medications in the 
three time periods (Table 30). The hypothesis that medications are contributing to 
death is supported if odds ratios are significant and increase in the time period that is 
closest to the index date. Odds ratios are not significant and there is no evidence of a 
trend with grouped type 2 medications in the table. 
 
Table 30 Risk of sudden death according to time of type 2 drug exposure 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Type 2 (0-7 
days) 
39 116 1.01 0.69,      1.47 0.962 
Type 2 (8-30 
days) 
40 119 1.01 0.70,     1.46 0.962 
Type 2 (31-90 
days) 
42 141 0.91 0.63,     1.30 0.590 
 
 
 
5.5.3 Registry type 4 drugs 
Registry type 4 drugs consist of antibiotics and antifungals for which current use is 
prescription in the period 0-7 days prior to death of index case and other drugs for 
which current use is prescription 0-30 days. 
There were 10 prescriptions for ciprofloxacin, 8 for trimethoprim and none for 
itraconazole in this period. 
 
5.5.3.1 Current use of type 4 antibiotics 
There was no evidence of an association with sudden death and current use of type 4 
antibiotics (Table 31). 
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One individual received both type 4 antibiotics in the time period 0-7 days prior to 
death of the index case. 
 
Table 31 Current use of type 4 antibiotics 
 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
95%CI 
Ciprofloxacin 2 8 0.75 0.16,     3.53 0.54 0.11,       2.73 
Trimethoprim 3 5 1.80 0.43,     7.53 1.29 0.26,       6.52 
Antibiotics 5 12 1.15 0.39,     3.35 0.80 0.27,       2.77 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
 
There was no evidence of an association with sudden death and current use of type 4 
antibiotics for non cardiovascular patients (Table 32). 
 
Table 32 Current use of type 4 antibiotics for non cardiovascular 
patients 
 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
95%CI 
Ciprofloxacin 0 2 -------- ------------ -------- -------------- 
Trimethoprim 1 0 -------- ------------ -------- -------------- 
Antibiotics 1 2 1.5 0.14,  16.54 1.5 0.14,  16.54 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
There was no evidence of an association with sudden death and current use of type 4 
antibiotics for cardiovascular disease patients (Table 33). One individual received 
both type 4 antibiotics in the time period 0-7 days prior to death of the index case. 
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 Table 33 Current use of type 4 antibiotics for cardiovascular disease 
patients  
 
 Cases 
N 
Controls
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
95%CI 
Ciprofloxacin 2 6 1.00 0.20,   4.95 0.69 0.13,      3.71 
Trimethoprim 2 5 1.20 0.23,   6.19 0.70 0.10,      4.98 
Antibiotics 4 10 1.21 0.37,   3.99 0.74 0.20,      2.80 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
 
 
5.5.3.2 Current use of type 4 antidepressants 
 
Antidepressant medications account for every type 4 drug where current use is 
defined to be the period 0-30 days.  
 
Crude odds ratios that indicate a significantly increased risk of sudden death are 
obtained for current use of citalopam 2.05 (1.01, 4.16), fluoxetine 3.11 (1.46, 6.65), 
paroxetine 3.0 (1.25, 7.21) and for combined type 4 medications 2.12 (1.55, 2.90) 
(Table 34).  
 
After adjustment, fluoxetine remains significantly associated with sudden death OR 
2.68 (1.12, 6.38) and so do combined type 4 medications OR 1.87 (1.33, 2.64) 
although the associations are less strong. Dosulepin which was not significantly 
associated with sudden death before adjustment becomes so after adjustment OR 2.41 
(1.07, 5.44). Citalopram and paroxetine are no longer significantly associated with 
sudden death after adjustment (Table 34). 
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 It is not possible to calculate an odds ratio for nortriptyline or trimipramine because of 
a zero in either the numerator or the denominator. Imipramine is the only drug that 
has an odds ratio less than 1 but there have only been 5 prescriptions. 
 
One case has taken two type 4 drugs in the period 0-30 days. 
 
Table 34 Current use of type 4 antidepressants 
 
 Cases 
N 
Controls
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
95% CI 
Amitriptyline 14 30 1.45 0.77,      2.74 1.41 0.73,   2.75 
Citalopram 13 19 2.05* 1.01,      4.16 1.54 0.69,   3.47 
Clomipramine 2 4 1.5 0.27,      8.19 1.69 0.29,   9.76 
Dosulepin 12 18 2.15 0.99,      4.67 2.41* 1.07,   5.44 
Fluoxetine 14 14 3.11* 1.46,      6.65 2.68* 1.12,   6.38 
Imipramine 1 4 0.75 0.08,      6.71 0.77 0.09,   6.93 
Nortriptyline 0 1 ----- ----------- ------ -------- 
Paroxetine 10 10 3.0* 1.25,      7.21 2.24 0.83,   6.06 
Sertraline 6 9 2.0 0.71,      5.62 1.75 0.55,   5.56 
Trimipramine 1 0 ---- ----------- ------ -------- 
Type 4 (Anti-
depressant) 
72 109 2.12* 1.55,    2.90 1.87* 1.33,   2.64 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
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Crude odds ratios that indicate a significantly increased risk of sudden death are 
obtained in non cardiovascular disease patients for current use of sertraline OR 7.5 
(1.46, 38.66) and combined anti-depressants OR 2.23 (1.37, 3.65). Sertraline is the 
only type 4 antidepressant that shows such a significant result for non cardiovascular 
patients but this may be due to chance as it works in the same way as other type 4 
antidepressants. Following adjustment the association for combined use remains 
significant OR 1.92 (1.12, 3.31) (Table 35). 
 
Table 35 Current use of type 4 antidepressants for non-cardiovascular 
patients 
 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
95%CI 
Amitriptyline 7 12 1.75 0.69,       4.44 1.92 0.72,    5.11 
Citalopram 5 7 2.14 0.68,       6.75 1.78 0.46,    6.84 
Clomipramine 1 3 1.0 0.10,       9.61 1.45 0.14,  14.51 
Dosulepin 4 6 2.0 0.56,       7.09 2.11 0.59,    9.63 
Fluoxetine 6 6 3.0 0.97,       9.30 2.38 0.59,    9.63 
Imipramine 1 2 1.5 0.14,     16.54 1.5 0.14,  16.54 
Nortriptyline 0 0 ----- ------- ------ -------- 
Paroxetine 1 5 0.6 0.07,       5.14 0.34 0.03,    3.46 
Sertraline 5 2 7.5* 1.46,     38.66 4.19 0.73,  24.02 
Trimipramine 1 0 ----- --------- ----- -------- 
Type 4 (Anti-
depressant) 
30 43 2.23* 1.37,     3.65 1.92* 1.12,   3.31 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
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Crude odds ratios that indicate a significantly increased risk of sudden death are 
obtained in cardiovascular disease patients for current use of fluoxetine, paroxetine 
and combined anti-depressants (Table 39). After adjustment the association for 
paroxetine remains significant OR 4.67 (1.35, 16.13) as does that for combined use 
OR 1.83 (1.18, 2.87). The association with fluoxetine after adjustment is no longer 
significant (Table 36). 
 
Table 36 Current use of type 4 antidepressants for cardiovascular 
patients 
 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted  
OR 
#Adjusted 
95% CI 
Amitriptyline 7 18 1.17 0.49,       2.79 1.11 0.44,  2.77 
Citalopram 8 12 2.0 0.82,       4.89 1.43 0.52,   3.94 
Clomipramine 1 1 3.0 0.19,     47.96 2.16 0.13,  35.97 
Dosulepin 8 12 2.25 0.85,       6.01 2.65 0.91,   7.69 
Fluoxetine 8 8 3.21* 1.16,       8.92 2.89 0.95,   8.81 
Imipramine 0 2 ----- -------- ------- ------ 
Nortriptyline 0 1 ---- -------- ------ ----- 
Paroxetine 9 5 5.4* 1.81,     16.11 4.67* 1.35,  16.13 
Sertraline 1 7 0.43 0.05,       3.48 0.61 0.07,   5.25 
Trimipramine 0 0 ---- ---------- ------- ------ 
Type 4 (Anti-
depressant) 
42 66 2.04* 1.35,       3.08 1.83* 1.18,   2.87 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
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5.5.3.3 Use of type 4 medications in time periods (0-7, 8-30, 31-90) days prior to 
death of index case 
I calculated non adjusted odds ratios for use of type 4 medications in time periods (0-
7, 8-30, 31-90) days prior to death of index case (Appendix 3). Risperidone is strongly 
associated with sudden death in every period. The difference between the numbers of 
medications prescribed in the three time periods is mainly due to antibiotic 
prescription. For antidepressant use with few exceptions the same people are being 
counted in all three time periods. Some cases and controls were prescribed more than 
1 type 4 drug. 
 
I have compared the risk of sudden death associated with registry type 4 medications 
in the three time periods (Table 37 & Fig 3). Odds ratios are significant. There was no 
temporal trend in odds ratio with sudden death and type 4 medication (Table 37) & 
(Fig 7). 
 
Table 37 Risk of sudden death according to time of type 4 drug exposure 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Type 4  
(0-7 days) 
66 117 1.78 1.29,       2.44 <0.001* 
Type 4  
(8-30 days) 
82 122 2.16 1.61,      2.91 <0.001* 
Type 4  
(31-90 days) 
85 145 1.89 1.42,          2.51 <0.001* 
* significant at α = 0.05. 
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Fig 7. Risk of sudden death according to time of drug exposure for type 
4 medications 
Risk of sudden death according to time of drug 
exposure for type 4 medications
0
0.5
1
1.5
2
2.5
0-7 days 8-30 days 31-90 days
Time period prior to death of index case
O
dd
s 
ra
tio
 
 
 
 
5.5.4 Current use of type 3 only drugs (not type1, type 2 or type 4) 
Conditional logistic regression crude odds ratios that are significantly associated with 
sudden death are obtained for salmeterol OR 1.62 (1.06, 2.47), inhaled salbutamol OR 
1.37 (1.04, 1.77) and combined type 3 only medication OR 1.40 (1.10, 1.78) (Table 
38). After adjustment only combined drug use remains significant OR 1.35 (1.0, 1.74) 
 
Odds ratios for terbutaline and oral salbutamol are raised but not significantly. Few 
individuals take them.  
 
It may be that the odds ratios above 1 seen with most type 3 only drugs are because of 
the association between sudden death and respiratory disease. 
 
 
Many cases and controls receive more than one type 3 only medication 
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Table 38 Current use of type 3 only drugs (not type 1, type 2 or type 4) 
 Cases 
N 
Controls
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
95% CI 
Ephedrine 1 0 ---- ------- -------- -------- 
Pseudoephedrine 1 4 0.75 0.08,    6.71 0.58 0.05,   6.18 
Salbutamol  
(Oral) 
8 13 1.85 0.77,    4.45 1.96 0.77,   4.98 
Salbutamol 
(Inhaler) 
88 198 1.37* 1.04,   1.77 1.31 0.99,   1.74 
Salmeterol 35 67 1.62* 1.06,    2.47 1.49 0.96,   2.32 
Sibutramine 0 1 ----- ------- ------ ------ 
Terbutaline 8 15 1.63 0.68,    3.90 1.81 0.71,   4.63 
Tolterodine 5 12 1.25 0.44,    3.55 1.47 0.47,   4.58 
Type 3 only 
(0-30 days) 
112 252 1.40* 1.10,   1.78 1.35* 1.04,   1.74 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
. 
5.5.4.1 Comparing current single use of salbutamol and salmeterol with 
joint use 
Non adjusted odds ratios for current use of combined salbutamol and salmeterol are 
significant OR 1.66 (1.03, 2.69). Odds ratios are not significant for single use (either 
in oral form or inhaler or both but excluding salmeterol) of salbutamol 1.30 (0.96, 
1.76) or single use (that is salmeterol but not salbutamol)of salmeterol 1.41 (0.61, 
3.27) Most people receiving salmeterol are also taking salbutamol so numbers of 
people taking salmeterol and not salbutamol are relatively small (Table39).  
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Table 39 Comparing current single use of salbutamol and salmeterol 
with joint use 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Salbutamol 
inhaler and 
oral only 
  (0-30) days 
67 159 1.30 0.96,   1.76 0.090 
Salmeterol 
only  
 (0-30) days 
8 17 1.41 0.61,   3.27 0.421 
Salbutamol 
and  
Salmeterol 
(0-30) days 
27 50 1.66* 1.03,   2.69 0.039 
  
 
5.5.4.2 Current use of type 3 only drugs for non-cardiovascular patients 
There are no significant associations between sudden death and type 3 medications 
given to people that are classified as not having cardiovascular disease (Table 40). 
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Table 40 Current use of type 3 only drugs for non-cardiovascular 
patients 
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
95% CI 
Ephedrine 0 0 ------
-  
------- ------- -------- 
Pseudoephedrine 1 2 1.5 0.14,   16.54 2.07 0.18,    24.4 
Salbutamol 
(Oral) 
0 6 ------ ------- ------ ------- 
Salbutamol 
(Inhaler) 
24 64 1.14 0.70,     1.85 1.33 0.81,    2.19 
Salmeterol 9 28 0.96 0.45,     2.06 1.06 0.49,    2.30 
Sibutramine 0 0 ------
- 
------- ----- ------- 
Terbutaline 2 5 1.20 0.23,     6.19 0.99 0.18,    5.29 
Tolterodine 2 6 1.00 0.20,     4.95 2.01 0.39,  10.45 
Type 3 only 
(0-30 days) 
28 85 0.99 0.63,   1.54 1.18 0.75,    1.87 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
 
 
 
5.5.4.3 Current use of type 3 only drugs for cardiovascular patients 
Significant non adjusted odds ratios are found in cardiovascular patients with oral 
salbutamol OR 3.43 (1.24, 9.45), inhaled salbutamol OR 1.51 (1.09, 2.09), salmeterol 
OR 2.15 (1.27, 3.64) and combined type 3 only drugs OR 1.63 (1.22, 2.18). After 
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adjustment all these odds ratios become smaller but with the exception of inhaled 
salbutamol remain significant (Table 41). 
 
Table 41 Current use of type 3 only drugs for cardiovascular patients  
 Cases 
N 
Controls 
N 
OR 95% CI #Adjusted 
OR 
#Adjusted 
95% CI 
Ephedrine 1 0 ------ ------- ------- ----- 
Pseudoephedrine 0 2 ------ ------- ------- ----- 
Salbutamol 
(Oral) 
8 7 3.43* 1.24,  9.45 3.29* 1.12,    9.61 
Salbutamol 
(Inhaler) 
64 134 1.51* 1.09,  2.09 1.30 0.93,   1.84 
Salmeterol 26 39 2.15* 1.27,  3.64 1.79* 1.03,   3.11 
Sibutramine 0 1 ---- ------- ----- --------- 
Terbutaline 6 10 1.86 0.65,  5.26 2.50 0.79,   7.89 
Tolterodine 3 6 1.5 0.38,  6.00 1.16 0.25,    5.29 
Type 3 only 
(0-30 days) 
84 167 1.63* 1.22,  2.18 1.43* 1.05,    1.95 
* significant at α = 0.05. 
# adjusted for previous MI, heart failure, low serum potassium, atrial fibrillation, epilepsy, syncope, 
impaired liver function, drug misuse and alcohol abuse. 
 
 
5.5.4.4 Use of type 3 only drugs in time periods (0-7, 8-30, 31-90) days 
prior to death of index case 
 
I calculated unadjusted odds ratios for use of type 3 only medications in time periods 
(0-7, 8-30, 31-90 days) prior to death of the index case (Appendix 4). 
There is very little difference between the numbers of medications prescribed in the 
three time periods and the associated odds ratios because with few exceptions the 
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same people are being counted in all of them. Some cases and controls were 
prescribed more than one type 3 only drug. Significant associations with sudden death 
for salbutamol inhaler and salmeterol and combined type 3 only medication were 
found in all time periods. 
 
I compared odds ratios in the 3 defined time periods (0-7, 8-30, 31-90 days. I found 
no evidence of a trend for increased association with type 3 only medication and 
sudden death (Table 42) & (Fig 8).  
 
Table 42 Comparing use of combined type 3 only drugs in time periods 
(0-7, 8-30, 31-90 days)  
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Type 3 only 
(0-7days) 
108 245 1.38* 1.08,    1.76 0.010 
Type 3 only 
(8-30 days) 
107 248 1.35* 1.05,    1.72 0.017 
Type 3 only 
(31-90 days) 
115 254 1.43* 1.13,    1.82 0.003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 131
Fig 8. Risk of sudden death according to time of drug exposure for type 
3 only medications 
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5.5.5 Exploring study results for confounding 
Significant associations between sudden death and medications may be due to 
confounding with factors related to medical conditions that provoke prescription of 
medication. To take into account these medical conditions it is useful to compare 
results for registry QT prolonging drugs with medications that are not on the registry 
that are prescribed for the same medical conditions.  
 
5.5.5.1 Comparing macrolide antibiotics with penicillin antibiotics 
 
It is possible that the association between sudden death and erythromycin use is 
confounded with infection. I explored this possibility by comparing macrolides with 
an antibiotic group that does not cause Torsades de Pointes. I chose penicillins 
because, as is the case with macrolides, they are typically prescribed for chest 
infection and if confounding exists it is likely to be to the same extent for both 
antibiotic groups. 
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There is a significantly high nonadjusted odds ratio for flucloxacillin 3.25 (1.08, 9.75) 
but not for amoxicillin 1.16 (0.63, 2.12) or for grouped penicillins 1.52 (0.91, 2.53) 
(Table 43). These results are similar to that of the macrolides.  
 
It is not unusual to obtain a significant odds ratio for an individual medication. Small 
numbers of individuals on drugs give imprecise results. 
 
Table 43 Risk of sudden death with current use of penicillin antibiotics 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Amoxicillin 15 39 1.16 0.63,     2.12 0.633 
Ampicillin 1 1 3.0 0.19,   47.96 0.437 
Flucloxacillin 7 7 3.25* 1.08,     9.75 0.036 
Phenoxymethylpenicillin 1 1 3.0 0.19,   47.96 0.437 
TOTAL 23 46 1.52 0.91,     2.53 0.107 
* significant at α = 0.05 
 
One case and two controls were on more than one penicillin drug in the period 0-
7days prior to death of the case. 
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5.5.5.1.1 Risk of sudden death with use of combined penicillin antibiotics 
within the three time periods 
 
I calculated odds ratios for sudden death for the grouped penicillins in the time 
periods prior to death (Table 44) and for grouped macrolides and compared them (Fig 
9). 
 
Odds ratios are not significant for grouped penicillins in any time period. There is a 
trend for increased association with sudden death nearer the index case date of death. 
 
Table 44 Risk of sudden death with use of combined penicillin 
antibiotics within the three time periods 
 
 Cases  
N 
Controls 
N 
OR 95% CI p value 
0-7 days 23 46 1.52 0.91,        2.03 0.107 
8-30 days 29 78 1.12 0.72,        1.74 0.605 
31-90 
days 
37 127 0.87 0.56,        1.26 0.459 
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Table 45 Risk of sudden death with use of combined macrolide 
antibiotics within the three time periods 
Odds ratios are not significant for grouped macrolides in any time period. There is a 
trend for increased association with sudden death nearer the index case date of death. 
 
 Cases  
N 
Controls 
N 
OR 95% CI p value 
0-7 days 5 6 2.5 0.76,         8.19 0.130 
8-30 days 4 8 1.5 0.45,         4.98 0.508 
31-90 
days 
7 26 0.81 0.35,         1.89 0.626 
 
Odds ratios are not significant for grouped macrolides or penicillins in any time 
period. Both grouped antibiotics show a trend for increased association with sudden 
death nearer the index case date of death. This trend is more pronounced for 
macrolides.  
 
Fig 9. Comparing risk of sudden death between macrolides and 
penicillins according to time of drug exposure 
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5.5.5.2 Comparing anti-arrhythmics 
I compared current use of registry type 1 anti-arrhythmics that are associated with 
torsades de pointes with those that are not (Table 47). Non adjusted odds ratios 
significantly greater than zero were found for current use of the type 1 anti-arrhythmic 
amiodarone OR 2.6 (1.24,   5.46) and for grouped type 1 anti-arrhythmics OR 1.89 
(1.03,   3.47) (Table 46). 
 
No significant effect was found for current use of the anti-arrhythmic flecainide OR 
1.0 (0.10, 9.61) or for verapamil OR 0.43 (0.17, 1.14) or for grouped comparator anti-
arrhythmics OR 0.48 (0.2, 1.17). 
 
Table 46 Risk of sudden death with current use of anti-arrhythmics 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Amiodarone 13 15 2.6* 1.24,     5.46 0.012 
Disopyramide 0 1 ---------- ---------- ---------- 
Sotalol 4 11 1.09 0.35,     3.43 0.882 
Type1 
Antiarrhythmics 
17 27 1.89* 1.03,     3.47 0.040 
Flecainide 1 3 1.0 0.10,     9.61 1.0 
Verapamil 5 33 0.43 0.17,    1.14 0.091 
Combined 
comparator 
antiarrhythmics 
6 36 0.48 0.2,      1.17 0.107 
* significant at α = 0.05 
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5.5.5.3 Comparing type 1 anti-psychotic medications 
To explore confounding confounding by mental illness I compared registry type 1 
anti-psychotics with antipsychotic medications that are not generally accepted to have 
a risk of causing Torsades de Pointes (Table 47). 
 
A significantly raised odds ratio was found for current use of the registry type 1 drug 
haloperidol OR 6.0 (1.10, 32.76) and for grouped type 1 antipsychotics OR 3.86 
(1.44, 10.36).  
 
Chlorpromazine and thioridazine are phenothiazines. The closest comparator to them 
in this thesis is fluphenazine and prochlorperazine because they are also 
phenothiazines which is why I chose them. 
 
 There are no significant odds ratios for any single or grouped comparator drug. 
Fluphenazine amd prochlorperazine are group 3 phenothiazines which are typically 
prescribed for nausea and vertigo rather than psychosis and thus are not an ideal 
comparator. 
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Table 47 Risk of sudden death with current use of registry type 1 
antipsychotics with comparator antipsychotics 
 
 Cases  
N 
Controls 
N 
OR 95% CI p value 
Chlorpromazine 3 5 1.8 0.43,      7.53 0.421 
Thioridizine 2 0 ---------- ---------- ---------- 
Haloperidol 4 2 6.0* 1.10,    32.76 0.039 
Type 1 
Antipsychotics 
9 7 3.86* 1.44,    10.36 0.007 
Fluphenazine 1 2 1.5 0.14,    16.54 0.741 
Prochlorperazine 8 21 1.14 0.51,      2.59 0.748 
Flupentixol 3 2 4.5 0.75,     26.9 0.099 
All Comparators 12 25 1.44 0.72,      2.87 0.299 
* significant at α = 0.05 
 
 
5.5.5.4 Comparing Type 2 anti-psychotic medications 
A highly significant unadjusted odds ratio was obtained for risperidone 6.0 (2.57   
14.02) and for quetiapine and risperidone combined 4.36 (2.03   9.40) A highly 
significant odds ratio was obtained for comparator drugs amisulpride 18.0 (2.17   
149.5) and for olanzapine 5.14 (2.02,  3.06) and for both both amisulpride and 
olanzapine combined 6.75 (2.94, 15.52) (Table 48). 
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Table 48 Risk of sudden death with current use of registry type 2 
antipsychotic medication compared with non registry antipsychotics 
 
 Cases  
N 
Controls 
N 
OR P 
value 
95% CI p value 
Quetiapine 
(type2) 
0 3 ------- ------- ------------ ---------- 
Risperidone 
(type2) 
16 8 6.0* 0.000 2.57,        14.02 0.000 
TOTAL 16 11 4.36* 0.000 2.03,          9.40 0.000 
Amisulpride 
(comparator) 
6 1 18.0* 0.007 2.17,       149.5 0.007 
Olanzapine 
(comparator) 
12 7 5.14* 0.001 2.02,        13.06 0.001 
TOTAL 18 8 6.75* 0.000 2.94,        15.52 0.000 
* significant at α = 0.05 
 
 
5.5.5.5 Comparing Arizona type 4 antidepressant medications 
Significant unadjusted odds ratios were obtained for citalopram, fluoxetine, 
paroxetine and for combined use (Table 34). 
 
The most commonly prescribed anti-depressant comparator in this sample is 
escitalopram. Results for the comparator drug are similar to individual type 4 
antidepressant drugs. The odds ratio for escitalopram  was raised but not significantly 
(Table 49).   
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Table 49 Risk of sudden death with use of a comparator antidepressant 
medication 
 
 Cases  
N 
Controls 
N 
OR 95% CI p value 
Escitalopram 4 7 1.71 0.50,     5.86 0.390 
 
 
 
5.5.6 Effect of taking more than one QT prolonging registry medication 
Individuals taking more than 1 QT prolonging drug may be exposed to an additive 
effect. The hypothesis that QT prolonging drugs are associated with sudden death is 
supported if associations between sudden death and multiple medication use are found 
and weakened if it is not because if our hypothesis is correct we would expect a dose 
response effect.  
 
There are proportionally more cases than controls on 1 or more QT prolonging 
medications. The difference increases as the number of medications increases (Table 
50).  
 
Table 50 Risk of sudden death with increasing concommittent current 
use of all registry QT prolonging medication 
 
Number 
Medications 
Cases n (%) Controls n (%) Ratio 
(%cases/%controls)
5      1        (0.1%)    0        (0.0%) ----- 
4      4        (0.5%)    2        (0.1%)  6.0 
3    16        (2.0%)   22       (0.9%)  2.18 
2    55        (7.0%) 111       (4.7%)  1.49 
1  180      (22.8%) 437     (18.5%)  1.24 
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I compared concommittent use of Arizona QT prolonging drugs with non Arizona 
drugs. 
 
5.5.6.1 Effect of taking more than one non registry medication 
For non registry drugs there is an increasing trend from one to seven drugs for cases 
to have proportionally more concomitant prescriptions. From seven to seventeen 
drugs there is no trend (Table 51). 
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Table 51 Risk of sudden death with increasing concomitant current use 
of all non registry drugs  
 
Number 
Medications 
Cases n (%) Controls n (%) Ratio 
(%cases/%controls)
> 15 7 (0.89%) 3 (0.13%) 7.00 
15 6 (0.76%) 2 (0.08%) 9.00 
14 6 (0.76%) 10 (0.42%) 1.80 
13 4 (0.51%) 3 (0.13%) 4.00 
12 12 (1.5%) 29 (1.2%) 1.24 
11 15 (1.9%) 43 (1.8%) 1.05 
10 30 (3.8%) 40 (1.7%) 2.25 
9 36 (4.6%) 67 (2.8%) 1.61 
8 42 (5.3%) 118 (5.0% 1.07 
7 53 (6.7%) 125 (5.3%) 1.27 
6 61 (7.7%) 188 (7.9%) 0.97 
5 64 (8.1%) 215 (9.08%) 0.89 
4 88 (11.2%) 271 (11.5%) 0.97 
3 76 (9.6%) 244 (10.3%) 0.93 
2 72 (9.1%) 244  (10.3%) 0.89 
1 37 (4.7%) 266 (11.2%) 0.42 
0 180 (22.81%) 499 (21.08%) 1.08 
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5.5.7 Summary of principal results 
Type 1 drugs are those with the greatest risk of torsades de pointes and they were 
associated with a doubling of mortality. Type 2 drugs, which have the next highest 
level of risk did not have a significantly raised odds ratio. A doubling of mortality was 
associated with type 4 medications, which are considered to have the least risk.  
 
The majority of individual drugs in all registry classes had odds ratios greater than 
unity but in every class there were drugs that had odds ratios under that.  
The most important finding is that drugs used for psychiatric purposes are associated 
consistently with sudden death. These drugs occur in all registry categories 
accounting largely for the unexpectedly strong effect in the type 4 drug class.  
 
Anti-psychotic medications had the strongest association with mortality. Significant 
effects for combined use of chlorpromazine, haloperidol and thioridazine and for 
single use of risperidone remained high after adjustment. 
 
Significant associations were found with combined use of anti-depressant medication 
and with single use of citalopam, dosulepin, fluoxetine and paroxetine.  
 
There was an increase in the magnitude of effect from type 4 anti-depressant to types 
1 and 2 anti-psychotic medication.  
 
There was a significant association of sudden death with the type 1 macrolide 
erythromycin. 
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A strong trend was found for increasing association with sudden death nearer the 
index case date of death for combined macrolide antibiotic use and only a weak trend 
for the comparator combined use of penicillins.    
 
A strong significant effect was evident for the non-adjusted analysis of current use of 
combined Arizona type 1 antiarrhythmics, the major contribution due to amiodarone. 
These drugs were given only to patients that were classified as having cardiovascular 
disease. After adjustment no significant odds ratios were obtained. There was no 
evidence of effect with comparator antiarrhythmics.  
 
The association with sudden death increased with concommittent use of Arizona QT 
prolonging medication. There were proportionally more cases than controls on 1 or 
more QT prolonging medication. These differences increased steadily in magnitude as 
number of medications per person increased. 
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6   Discussion. 
This chapter summarises the findings of this thesis and puts them into the context of 
the published literature.The strengths and limitations of the thesis are discussed and I 
will make recommendations. 
 
6.1 The findings of this thesis  
6.1.1 Exposure definition 
The exposure was defined as the use of QTc prolonging drugs, as specified in the 
International Registry for Drug-induced Arrythmias maintained by the Georgetown 
University173. This is an internationally recognised register, which ensures there is 
general agreement about the categories of drugs used in the analysis.  
 
6.1.2 Antipsychotics 
6.1.2.1 Current use of anti-psychotics 
Anti-psychotic medications were associated with the highest levels of mortality. For 
atypical antipsychotics, crude and adjusted associations were found with individual 
and combined drugs. There were only sixteen prescriptions for current use of typical 
antipsychotics and significance was obtained for the crude association between 
sudden death and haloperidol and the crude and adjusted association for combined 
antipsychotics.  
 
6.1.2.2 Stratifying antipsychotics for cardiovascular disease 
Combined use of chlorpromazine, haloperidol and thioridazine resulted in higher 
significant odds ratio in patients without cardiovascular disease but risk was not 
significantly raised in patients with cardiovascular disease. The opposite was true for 
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risperidone. It could be that these differences can be explained by drug prescribing 
habits or it could be that they are due to imprecise estimates because of the small 
number of prescriptions.  
 
6.1.2.3 Comparing antipsychotic use 
A powerful significant effect was found for current use of grouped registry type 1 
antipsychotics. These drugs are are associated with Torsades de Pointes. It is possible 
that the association between sudden death and antipsychotic use is confounded by the 
conditions for which they are prescribed. To explore this possibility I compared type 1 
antipsychotics with medications that are not generally accepted to have a risk of 
causing Torsades de Pointes. The comparator drugs were fluphenazine, 
prochlorperazine, and flupentixol. I did not find evidence of a significant effect for 
any single or grouped comparator drug. The group 3 phenothiazines are typically 
prescribed for nausea and vertigo rather than psychosis and they are often prescribed 
in low doses for these conditions and thus are not an ideal comparator.  
 
6.1.2.4 Antipsychotics; comparison with other studies 
The most important finding of this thesis was that medication associated with the 
greatest risk of sudden cardiac death was prescribed for serious mental illness. This is 
in line with the conclusions of other researchers.  
 
A population based case control study in Holland that made use of a database with 
medical records from 150 general practitioners identified 554 cases of sudden cardiac 
death in a period of just over 6 years up to April 2001. The study found that current 
use of antipsychotic medication was associated with a 3 fold increase in risk of 
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sudden cardiac death and that the risk was highest in users of butyrophenone 
antipsychotics typified by haloperidol192. Risk of sudden cardiac death was highest 
among recent users but remained elevated during long term use. This latter finding 
could indicate confounding with conditions related to antipsychotic drug use. The 
design of this study, its numbers and results were similar to that found in my thesis. 
The authors recognised that people with serious mental illness are at a higher risk of 
death than people in the general population and adjusted, as I did, for known risk 
factors. They also adjusted for history of myocardial infarction, angina, heart failure, 
hypertension and alcohol abuse as well as for additional factors, cerebrovascular and 
cardiovascular ischaemia, diabetes mellitus, arrhythmia, hypercholesterolaemia, and 
smoking. It is notable that the results of this study are broadly in line with the results 
of this thesis despite some differences in identified covariates. Many of the covariates 
are associated with each other which results in a law of diminishing returns when 
adding extra covariates to the model.  
 
A retrospective cohort study of 1487 sudden cardiac deaths in Medicaid employees in 
Tennessee USA found an odds ratio of 2.39 (95% confidence interval, 1.77-3.22) for 
antipsychotics. The authors found an increased risk for patients on antipsychotics that 
have cardiovascular disease OR 3.53 (95% CI, 1.66-7.51). I did not obtain this 
increased risk for cardiovascular patients in my thesis. Confidence intervals, 
overlapping with that in my thesis, are wide, reflecting lack of precision.  
 
The authors also found a lower risk for former use OR 1.20 (95% CI, 0.91-1.58), an 
analysis that I could not do because I did not have information on patients taking 
medication beyond 3 months prior to death of case193. 
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A Dutch population based case control study comprised 775 cases of sudden cardiac 
death and 6297 controls matched for age, gender, date of sudden death, and general 
practice. They found that the use of non-cardiac QTc-prolonging drugs in a general 
population is associated with an increased risk of sudden cardiac death194. The Dutch 
group had more cases taking Arizona type 1 medication but the differences were not 
great. This thesis agrees with the conclusion of the Dutch group that current use of 
antipsychotic QTc-prolonging drugs are associated with a significantly increased risk 
of sudden cardiac death. 
 
The findings in this thesis of significant effects before and after adjustment for 
combined use of chlorpromazine, haloperidol and thioridazine and single use of 
risperidone were expected because odds ratios for haloperidol and risperidone have 
been linked to high rates of cardiac arrest195. 
 
6.1.2.5 Atypical antipsychotics  
This thesis found a very strong association with the atypical antipsychotics 
risperidone and olanzapine and sudden cardiac death. The strength of my findings 
were surprising because risperidone, a type 2 drug, is not classified in the Arizona QT 
prolonging drug registry as a type 1 drug, the category considered to have the greatest 
risk and olanzapine is not categorised at all. It is unlikely that these results have arisen 
by chance because of the statistically high odds ratios. I could conclude that it is 
probably not plausible to believe that the strong association with sudden cardiac death 
and atypical antipsychotics is due to the direct action on cardiac tissue because it is 
not classified in the highest risk category. Alternatively, we should be mindful that we 
would expect fewer case reports linking the newer antipsychotics to sudden death 
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because they have been in use relatively recently. The very high odds ratios may be 
due to doctors selectively prescribing atypical antipsychotics to patients at higher risk. 
We may be seeing a strong confounding effect with factors associated with mental 
illness although this confounding effect was not noticeable with type 2 comparator 
drugs, venlafaxine or lithium. To try to remove the potential confounding effect of 
psychotic illness I also calculated the odds ratio of sudden death for the non QT 
prolonging drugs amisulpride and olanzapine with the same indication. I found 
powerful significant effects for amisulpride and olanzapine which were of similar 
magnitude to quetiapine and risperidone. These results imply the presence of strong 
confounding effects. 
 
Epidemiological studies have reported raised risk of sudden cardiac death in patients 
taking atypical antipsychotics. A retrospective cohort study in Pennsylvania USA  that 
involved 22,890 patients aged 65 years and older who received antipsychotic 
medication between 1994 and 2003 found that both atypical and conventional 
antipsychotic drugs were associated with a significantly high risk of death and that the 
risk of death was significantly greater in patients receiving the conventional 
medication196. A population based retrospective cohort study in Canada of 27,259 
matched pair adults with dementia found that new use of atypical antipsychotics was 
associated with a statistically significant increase in the risk for death 30 days after 
initial dispensing but that this risk was less than that of conventional 
antipsychotics197. Risperidone198 and olanzapine199 have been shown to prolong 
cardiac repolarisation and are likely to enhance risk for QT prolongation and 
proarrhythmia in patients under conditions of impaired drug elimination such as renal 
or hepatic insufficiency and those taking interacting drugs. 
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On stratifying for cardiovascular disease this thesis found a very significant finding 
with risperidone and sudden cardiac death in cardiovascular patients. No significant 
effect was found with non-cardiovascular patients. This finding may have arisen 
because of a confounding effect of cardiovascular disease. In other studies risperidone 
with weight gain in the first year of treatment leading to increased risk of 
cardiovascular disease200. This weight gain is greater than that associated with the 
older generation of antipsychotics.   
 
All antipsychotics are associated with sudden death in people with and without CVD. 
My finding that risperidone was more closely associated with SCD in CVD patients 
may indicate that alternative drugs should be used, however all antipsychotic drugs 
are a problem.  This thesis is a case control study with very small numbers and 
findings need to be confirmed in cohort studies. 
 
A recently published Tennessee Medicaid retrospective cohort study has found that 
current users of typical and atypical antipsychotic drugs had significantly higher 
incident rate ratios of SCD, approximately double that of non users and that there was 
no significant difference between typical and atypical drugs201. As in my thesis, 
deaths occurred outside of hospital. Sudden cardiac death was defined as a sudden 
pulseless condition that was fatal, that was consistent with a ventricular 
tachyarrhythmia, and that occurred in the absence of a known noncardiac condition as 
the proximate cause of the death. The end point excluded deaths of patients who had 
been admitted to the hospital, deaths that were not sudden, and deaths for which there 
was evidence of an extrinsic cause (e.g., drug overdose), a noncardiac cause (e.g., 
pneumonia), or a cardiac cause that was not consistent with a ventricular 
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tachyarrhythmia (e.g., heart failure). The primary analysis included 44,218 and 46,089 
baseline users of single typical and atypical drugs respectively and 186,600 matched 
nonusers so was considerably more powered than my thesis. This increasing body of 
evidence regarding atypical antipsychotics supports my findings.  
 
6.1.3 Antidepressants 
6.1.3.1 Current use of antidepressants 
Significant crude odds ratios were found for single use of citalopam, fluoxetine and 
paroxetine. After adjustment fluoxetine and dosulepin were significantly associated 
with sudden death. The significant adjusted result for dosulepin may be a chance 
finding due to the small number of prescriptions. I combined drug prescriptions to 
increase statistical power and found significant associations with sudden death before 
and after adjustment. The effect was diminished after adjustment which was expected 
because the effect of confounding variables was reduced.  
 
I found that the association with sudden death and the selective serotonin reuptake 
inhibitor antidepressants (SSRIs) was as great as that with tricyclic antidepressants. A 
plausible mechanism exists because blockade of the HERG channel has been found 
for both drug classes, in the tricyclic antidepressant doxepin202 and the SSRIs 
fluoxetine203 and citalopram204. 
 
I had taken care to eliminate confounding with suicide by not choosing as cases 
people that had died in this way as identified by coroners post mortem. and  recorded 
on the mortality files.  
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6.1.3.2 Stratifying antidepressants for cardiovascular disease 
Crude and adjusted odds ratios were significant for combined use of antidepressants at 
similar levels in both cardiovascular and non cardiovascular patients. Paroxetine and 
fluoxetine were significantly associated with sudden death in cardiovascular patients; 
the association with paroxetine but not fluoxetine remained significant after 
adjustment. Sertraline was found to be significantly associated with sudden death in 
non cardiovascular patients before adjustment but not after. Numbers are small at the 
level of most individual drugs so the estimates of effect size lack precision.  
 
A significant association between sudden cardiac death and depression is expected 
regardless of stratification for cardiovascular disease because a systematic review 
showed that depression confers a relative risk between 1.5 and 2.0 for the onset of 
coronary artery disease in undiagnosed individuals205. The review also concluded that 
depression in patients with existing coronary artery disease confers a relative risk 
between 1.5 and 2.5 for cardiac morbidity and mortality.  
 
6.1.3.3 Comparing antidepressant use 
I compared risk of sudden death between current use of Arizona type 4 anti-
depressants and the comparator drug escitalopram. Combined odds ratios for Arizona 
type 4 anti-depressant drugs showed a significant effect whereas that for escitalopram, 
although raised thus indicating confounding, did not show such a strong effect.  
 
An important result of this study is the consistency of the association between 
psychiatric medication and sudden death and the increase in magnitude from non-QT 
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prolonging comparator anti-depressant to Arizona type 4 anti-depressant to anti-
psychotic.  
 
6.1.3.4 Depression antidepressants and sudden cardiac death 
Major depressive disorder affects approximately one sixth of the general population 
during their lifetime206 An important finding of this thesis was that current use of 
antidepressants was associated with one of increased risk of SCD. This result is in 
agreement with other researchers. Meta-analyses of retrospective studies have shown 
an association between depression and fatal CHD or MI with a hazard ratio of 1.81 
(95% CI: 1.53 to 2.15) over 10.8 years in 124,509 individuals207 and with a hazard 
ratio of 1.64 (95% CI: 1.29 to 2.08) in 36,549 individuals208. The former study 
concluded that because of biased availability of adjustments, incomplete adjustments 
and reverse causality, depression could not be established as an independent risk 
factor. 
 
An important question is how much confounding in the connection with 
antidepressant use and SCD is due to depression. I would expect confounding with 
depression because individuals with depression have diminished cardiac vagal control 
and may be at risk of ventricular arrhythmias209. Depression has been shown to be an 
independent risk factor for all cause mortality after acute MI in a subset of 358 
depressed patients matched to 408 nondepressed patients followed up for 30 months 
on the ENRICHD clinical trial210. 
 
Recent prospective studies have been published that show a relationship with 
antidepressants and sudden cardiac death. Whang et al211 studied 63,469 women in 
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the Nurses Health Study without baseline coronary disease, stroke, or malignancy for 
cardiovascular events on follow-up between 1992 and 2004. Questionnaires were 
administered every 2 years. The authors found that major depression and 
antidepressant use predicted nonfatal MI, sudden cardiac arrest, and fatal CHD events 
on multivariate analysis. Hazard ratios were stronger for fatal than for nonfatal events. 
Stepwise regression analysis found a hazard ratio between major depression or 
antidepressant use and sudden cardiac arrest of 2.33 (95% CI: 1.47 to 3.70, p < 
0.001). Proportional hazards models showed that antidepressant use alone provided a 
higher hazard ratio for sudden cardiac arrest of 3.34 (95% CI: 2.03 to 5.50). The study 
indicates that there is an aetiological link between depression, treatment of depression 
and cardiovascular outcomes and provides evidence that depression is predominantly 
associated with sudden cardiac arrest via the use of antidepressant drugs. The 
relationship between antidepressants and sudden death could be due to an increase in 
ventricular arrhythmias.  
 
Further recent work in a population based study that followed up 970 randomly 
selected individuals for 10 years, concluded after adjustment for age, sex, 
Framingham CVD risk score and depression that tricyclic antidepressant use was 
associated with an increased risk of coronary heart disease events (adjusted hazard 
ratio, 2.10; 95% CI. 1.09 – 4.06)212. The Tennessee Medicaid study showed increased 
risk for tricyclic antidepressants that was dose related213.  
 
SSRI antidepressants have not been associated with sudden death in the literature until 
recently. Previous studies indicated that they were safe. The SSRI sertraline did not 
prolong the QT interval or elevate mortality in patients with acute coronary syndrome 
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in a 24 week follow up period214. A case control study that had 1080 cases and 4256 
controls concluded that SSRI use but not tricyclic use correlated with protection from 
a subsequent MI in inpatients that had a first MI215. Other studies gave cause for 
concern, SSRIs had been linked with ventricular arrhythmias, QT interval 
prolongation and arrhythmia216 and increased mortality217 in some small clinical 
studies. A randomised control trial that randomised 2481 post MI patients to treatment 
with SSRIs and cognitive behaviour therapy found that although the depression was 
improved the risk of death or recurrent MI was not affected218. The Nurses Health 
Study211 found that 61% of patients prescribed antidepressants used SSRIs and the 
authors stated that there was no difference in the results for SSRIs and other 
antidepressant drugs. 
 
Thus, recent evidence implying an aetiological link between both TCA and SSRI 
antidepressants and SDC are in agreement with my thesis. 
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6.1.4 Antiarrhythmics  
6.1.4.1 Current use of antiarrhythmics 
Significantly increased odds ratios were found for current use of the anti-arrhythmic 
amiodarone and for grouped registry type 1 anti-arrhythmics but not between sudden 
death and sotalol. Doctors tend to prescribe sotalol to patients at low risk because it 
has toxic effects. Sotalol is a beta blocker and this class of drug is known to have 
cardio-protective properties219.  
 
 
6.1.4.2 Comparing antiarrhythmics 
I compared risk of sudden death between current use of Arizona type 1 anti-
arrhythmics, amiodarone, sotalol and disopyramide which are medications associated 
with torsades de pointes, and non type 1 anti-arrhythmics, flecainide and verapamil 
and found no evidence of effect with comparator anti-arrhythmics, suggesting that the 
QT prolonging action increases risk of sudden death. Finding comparator drugs was 
difficult because of low numbers of prescriptions and because of the different 
mechanisms of action of the drugs such as verapamil which has a calcium channel 
blocking effect and is used in the treatment of angina and hypertension. These 
difficulties mean that the comparisons may not be robust.  
 
6.1.5 Macrolides 
6.1.5.1 Current use of macrolides 
There were only eleven current prescriptions for macrolide antibiotics, seven for 
erythromycin and four for clarithromycin. Current use of erythromycin was 
significantly associated with sudden death before and after adjustment however no 
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significant association was found with grouped macrolides.  Erythromycin in this 
thesis was only given to cardiovascular patients so it was not possible to stratify 
macrolides according to CVD status The results for current use of macrolides are not 
robust given such small numbers. 
 
6.1.5.2 Temporal patterns in drug use 
Changes in the numbers of prescriptions in the three month period prior to deaths of 
cases were apparent only for drugs prescribed on a weekly basis given for short term 
conditions, particularly antibiotics. Drugs that were prescribed continuously for longer 
periods of time such as psychiatric medication showed no significant changes in 
association with sudden death in the 3 month period for which data was collected. 
 
6.1.5.3 Temporal patterns in drug use in macrolide antibiotics 
I found that there was a significant association of sudden death with erythromycin in 
the period 0-7 days prior to death of case and no significant association in the period 
8-30 days or 31-90 days. If this trend of increasing association nearer to death of 
index case was caused by the QT prolonging effect of erythromycin then we could 
expect to see a similar pattern with clarithromycin but no such pattern was found, 
possibly because there were even fewer prescriptions for clarithromycin. If the trend 
was confounded by infection then it would be expected to be found in the non QT 
prolonging penicillin drugs. Such a trend was evident but it was more pronounced for 
grouped macrolides than for grouped penicillins. Odds ratios were not significant for 
the penicillins.  
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The confounding effect of infection was limited by the study design which chose 
cases that were community dwelling adults who did not die of respiratory disease. I 
would expect that any remaining confounding effect due to infection would apply 
equally to macrolide and penicillin antibiotic use. Thus the finding of a more 
pronounced trend for increased use of macrolide antibiotic use nearer to date of death 
of index case compared with penicillin use requires an explanation. It could be due to 
QT prolonging effect of macrolide antibiotics. 
 
6.1.5.4 Macrolides; a comparison with other studies 
This study found that current use of macrolide antibiotics was associated with one of 
the greatest risks of sudden cardiac death. However only seven patients had been 
prescribed erythromycin so the result is very imprecise. The association between 
sudden death and erythromycin is in agreement with that of other researchers; the 
Tennessee Medicaid cohort study showed that current use of erythromycin was 
associated with a doubling of risk220. They found, as I did, that there was no 
significant increase in the risk of sudden death among those who were currently using 
the comparator drug amoxicillin. 
 
A recently published study prospectively identified 1678 cases of sudden cardiac 
death in a 4 year period in Portland USA concluded that QTc prolonging drugs were 
predictors of SCD in coronary artery disease221. Subjects with known non-cardiac 
causes of death were excluded and cases were required to have documented coronary 
artery disease. A particular strength of the study was that cases had an ECG before 
and unrelated to the occurrence of SCD. A particular weakness of the study was that 
cases were on average 6 years older than controls and thus confounding with age 
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could have occurred. SCD was defined as a sudden unexpected pulseless condition of 
likely cardiac origin and if unwitnessed, SCDs were deaths within 24 hours of last 
being seen alive and in a normal state of health.  
 
6.1.6 Dose response effects 
The presence of a dose response effect is an indication, although not by itself 
sufficient, that an effect exists between exposure and outcome. I found that the risk of 
sudden death increased with concomitant use of Arizona QT prolonging medication. 
There were proportionally more cases than controls on 1 or more QT prolonging 
medication. These differences increased steadily in magnitude as the number of 
medications increases. There is also an increasing trend for cases to have 
proportionally more concomitant prescriptions for non Arizona medications which 
implies that prior to death cases were more sick than controls.  
 
Summary statistics show that on average cases are prescribed more medication than 
controls. There is also a greater range of prescribed medication for cases. Odds ratios 
significantly associated with sudden death are therefore more likely. 
 
6.2 Do people actually take the medicine that they are prescribed? 
Patients do not always take the medications that they are prescribed. A cross sectional 
observational study in America that had the aim of assessing the accuracy of 
medication histories for prescription, over the counter and herbal medicines for 
patients taking at least 5 medicines, concluded that little is known about the accuracy 
of computerised medication lists. Patient medical records do not identify medications 
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that patients are being prescribed but are not taking, nor do they identify medications 
that patients buy over the counter at pharmacies222.  
 
Poor compliance has been found in elderly patients223 and elderly patients with heart 
failure with shortcomings in patients’ knowledge regarding prescribed medication, 
despite efforts to give adequate information224. Compliance with medication regimens 
is worse for psychiatric disorders compared with physical disorders and worse for 
antipsychotic drug use compared with antidepressant use225.  
 
The implication for this study is that if there is an association between sudden cardiac 
death and QT prolonging medication then a high rate of non-adherence to medication 
is likely to artificially reduce the association between sudden death and QT 
prolonging drugs unless factors associated with poor adherence are linked to sudden 
cardiac death which if so could cause a bias leading to a stronger association with 
sudden death. People may be less likely to adhere to their medication for conditions 
when they do not perceive themselves as being ill, for example hypertension. Non 
adherence in drugs that are protective against SCD could increase death rates.     
 
6.3 Internal validity and generality 
Internal validity depends on study design, the measurements taken, the care with 
which they were done and the consideration of alternative explanations for perceived 
causal relationships. Generalisability is the extent to which research findings can be 
applied to a population and relies on internal validity. 
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The design was a case control study which is the weakest type of analytical study and 
although it can identify associations between exposure and outcome it cannot by itself 
be used as evidence to justify a causal relationship. It does however fulfil some of the 
criteria of causation226. The outcome, sudden cardiac death, cannot precede exposure. 
Significant strong associations were found with individual drugs and drugs grouped 
within classes. The concomitant use of medications was associated with increased 
risk. The hypothesis was plausible although the results were not always in accord with 
it. Alternative explanations for study findings were explored. The findings of this 
study were mostly consistent with the work of other researchers.  
 
Every case had their cause of death verified by a post mortem report. Matching in the 
design and adjustment in the analysis increased the strength and the power of the 
analysis. Methodological issues around data gathering were explored and although 
mostly reassuring, some problems around diagnoses of medical conditions in GP 
medical notes were identified and resolved. The issue of confounding was explored in 
detail and alternative explanations explored through comparing drug results with non-
QT prolonging comparators prescribed for similar indications. The cases and controls 
were drawn from four PCT areas in the Midlands, a large and ethnically diverse 
population of almost two million people with a predominantly white ethnic group. 
This population is more ethnically diverse than most other United Kingdom areas. 
Study results may be less generalisable to a population with a different ethnic mix. 
  
6.4 Strengths and weaknesses of the study 
A great strength of this study is that every case had a post-mortem report which is the 
reference standard for determining cause of death. Thus the error associated with 
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death certification data was greatly reduced. I was also able to obtain and analyse 
most post mortem reports to verify that the stated cause of death of the cases was 
accurate and consistent with cardiac arrhythmia. 
 
A major weakness of the study was that because of the small number of individuals 
prescribed QT prolonging drugs it was underpowered to find associations with many 
individual medications. Confidence intervals are wide reflecting the imprecision of 
the estimates. Precision was improved but still often remained poor after analysing 
drugs combined in their classes. Numbers were often too small to justify the 
breakdown into the CVD and non CVD subgroups. I have done the analyses to 
explore the data and to compare with other studies. 
 
It was a serious omission not to collect data on other known confounders such as 
diagnosis of mental illness, smoking and diabetes.  
 
It is not possible to completely eliminate confounding from case control studies so it 
is not possible to say with certainty if significant findings with medication in this 
thesis are associated with risk or are due to confounding factors. 
 
Matching in the design stage of the study eliminated the confounders, age and sex and 
mitigated against cardiovascular disease. This study obtained a perfect matching for 
sex and an extremely good matching for age with three days difference between mean 
average age of cases and controls.  
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There were limitations to matching for cardiovascular diseases because controls were 
not matched to cases on the basis of any individual cardiovascular condition or 
combination of cardiovascular conditions. Hypertension was by far the most common 
cardiovascular disease which led to a high prevalence of it in both cardiovascular 
cases and controls. Controls were more likely than cases to be put into the 
cardiovascular group on the basis of having hypertension. Cases were more likely to 
have serious cardiovascular conditions. 
 
It cannot be assumed that there is equality for sudden death risk between the different 
cardiovascular disease subgroups. Neither can it be assumed that equality for sudden 
death risk exists within the subclasses, for example one person’s hypertension may be 
more severe than another’s. Therefore in the design stage the study did not control for 
sudden death risk with respect to the severity of cardiovascular disease between or 
within the cardiovascular subgroups. The imperfect matching for cardiovascular 
disease was addressed in two ways. Firstly significant associations with 
cardiovascular disease were identified and subsequently adjusted in the analysis. 
Secondly the inclusion of a subgroup without diagnosed CVD enabled a comparison 
between the cardiovascular and non cardiovascular subgroups. 
 
Strong associations were found with sudden death and previous MI, heart failure, low 
serum potassium, atrial fibrillation, epilepsy, syncope, impaired liver function, drug 
misuse and alcohol abuse. All significant associations were used as covariates in the 
analysis. Odds ratios in the adjusted analysis were generally lower than those in the 
crude analysis which indicated that researchers had been successful in identifying and 
controlling for confounding factors beyond matching. Adjusted analysis did not 
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materially alter the combined odds ratios between sudden death and drugs in the 
Arizona registry classes.  
 
I undertook many analyses but did not undertake multiple test adjustments. 
Bonferroni adjustments would in principle be possible227 but given that there were 
153 individual and combined tests for current use of Arizona drugs, they would only 
allow comparison with p values below 0.00034 to be significant228 and would thus be 
of doubtful value given the reduction in power in an already underpowered study. In 
addition the main analyses were for the four Arizona groupings. 
 
Data on epilepsy was collected to determine if we could find an association with 
sudden unexplained death; we did find an association. It has been estimated that about 
30% of patients in the United Kingdom following seizure are given a diagnosis of 
epilepsy when syncope or arrhythmia is the appropriate diagnosis229. 
 
Cases are clearly more ill than controls, they are prescribed more medication, have 
more hospital visits and suffer in greater numbers with almost all cardiovascular 
conditions, notably past history of myocardial infarction and heart failure. These 
conditions make them more at risk of suffering a sudden death. However it is possible 
that doctors prescribe drugs with less risk to people that are sicker and thus considered 
to be more vulnerable to side effects. 
 
6.5 Conclusions 
My thesis identified and explored associations with medications that can affect 
cardiac conduction and sudden death and compared its findings with those of other 
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studies. Risk of sudden unexplained death from non cardiac drug treatment was 
concentrated in drugs used for psychiatric conditions. The argument that my findings 
may represent causal effects is strengthened by my further analysis that showed that 
differences were reduced but not eliminated after adjustment of odds ratios to take 
account of confounding diseases and because the separate analysis of individuals that 
had no prior clinical evidence of heart disease also mainly reduced but did not remove 
risks. 
  
The associations between sudden death and prior disease found in this thesis and by 
others29 30 indicate that cardiovascular disease was an important confounder for the 
association with QT prolonging drugs but in general with the exception of risperidone, 
adjustment in the analysis did not materially alter the results. It is possible that the risk 
of sudden death with the newer SSRI antidepressants and atypical antipsychotics is 
confounded by targeted prescribing of these drugs instead of the older drugs that have 
known toxicity. A strength of this thesis is that the cause of death was confirmed by 
post mortem examination for all cases, unlike other studies194 213 220 that investigated 
the association between SCD and QT prolonging drugs.  Prevalence for torsades de 
pointes is greater in women than in men so the unexpectedly high proportion of males 
in my thesis may be because men are more likely than women to have a post 
mortem230.    
 
6.6 Implications for clinicians and policymakers 
Although a causal relationship for an association between QT prolonging medication 
and SCD has not yet been proved, the observational evidence is increasing thus there 
is a need for prescribers to focus on risk factor management.  The prescriber’s role is 
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vital in deciding whether the benefit of prescribing medication is greater than the risk. 
Ultimately the purpose of epidemiological research into the effects of pharmaceutical 
agents is to identify and quantify benefit and risk. Researchers have a duty to inform 
all members of the team involved in the prescribing and administering of medication 
about the possible adverse effects of medications as well as their benefits to enable 
them to make the best possible decisions.  
 
It is important that prescribers are aware which drugs can prolong ventricular 
repolarisation and cause Torsades de pointes and know that the risk of these side 
effects varies between individuals according to sex, age and medical conditions. 
Excessive use of QT prolonging medication in any individual should be avoided 
provided that suitable alternative medications are available.  In this context the role of 
the Medicines and Healthcare products Regulatory Agency (MHRA) is vital231. It is 
responsible for issuing graded alerts to healthcare professionals and organisations and 
publishes in print and online. The MHRA works with the Department of Health to 
promote healthcare policy such as enabling trained nurses and pharmacists to become 
prescribers and to help patients make better choices with better information and 
improved labelling. The MHRA is responsible for pharmacovigilance. Healthcare 
professionals and patients are able to report side effects through the MHRA Yellow 
Card Scheme and this information is shared with pharmaceutical companies. It is 
important that all prescribers are trained and are fully aware of pharmacovigilence 
procedures. 
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6.7 Recommendations 
Case control studies are not capable of calculating absolute risk, which can be 
obtained from a cohort study. Recent cohort studies211 212 have provided evidence for 
an aetiological link between antidepressant use and sudden cardiac death. There is a 
need for further large cohort studies to test if findings are consistent with the case 
control studies in the literature. A cohort study could use routinely collected data 
connected to mortality data. The linkage of the general practice research database 
(GPRD) which contains the anonymised medical records of patients registered at 
more than 480 practices throughout the United Kingdom to mortality data gives the 
potential of a much larger sample for further study of individual drugs because the 
GPRD is the largest and most validated database of its kind in the world. The 
relationship between QT prolonging medication and sudden cardiac death may only 
be finally decided by randomised controlled trials of QT versus non QT medication.  
 
 
 
 
 
 
 
 
 
 
APPENDIX 1 
 
Use of type 1 medications in periods 0-7, 8-30 and 31-90 days before death of index 
case 
 
Table 52 Use of type 1 medications in 0-7 days before death of index 
case 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Amiodarone 13 15 2.6* 1.24,      5.46 0.012 
Sotalol 4 11 1.09 0.35,      3.43 0.882 
Disopyramide 0 1 ---- ----------- ---- 
Antiarrhythmics 17 27 1.89* 1.03,      3.47 0.040 
Clarithromycin 0 4 ---- ----------- ---- 
Erythromycin 5 2 7.5* 1.46,    38.66 0.016 
Macrolides 5 6 2.5 0.76,      8.19 0.130 
Chlorpromazine 3 5 1.8 0.43,      7.53 0.421 
Haloperidol 2 1 6.0 0.54,      66.2 0.143 
Thioridizine 2 0 ---- ----------------
-- 
---- 
Antipsychotics 7 6 3.5* 1.18,     10.4  0.024 
Domperidone 4 8 1.5 0.45,      4.98 0.508 
All Type1 (0-7 
days) 
33 47 2.12* 1.36,      3.32 0.001 
* significant at α = 0.05. 
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Table 53 Use of type 1 medications in 8-30 days before death of index 
case 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Amiodarone 13 15 2.60* 1.24,      5.46 0.012 
Sotalol 4 11 1.09 0.35,      3.43 0.882 
Disopyramide 0 1 ---- ---------------
---- 
---- 
Antiarrhythmics 17 27 1.89* 1.03       3.47 0.040 
Clarithromycin 1 2 1.5 0.14,      16.5 0.741 
Erythromycin 3 6 1.5 0.38,      6.00 0.566 
Macrolides 4 8 1.5 0.45,      4.98  0.508 
Chlorpromazine 2 5 1.2 0.23,      6.19 0.827 
Haloperidol 3 2 4.5 0.75,      26.3 0.099 
Thioridizine 2 0 ---- ------------- ---- 
Antipsychotics 7 7 3.0* 1.05,      8.56  0.040 
Domperidone 3 9 1.0 0.27,      3.69 1.0 
All Type1 (8-30 
days) 
31 51 1.82* 1.17,      2.85 0.008 
* significant at α = 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 2
Table 54 Use of type 1 medications in 31-90 days before death of index 
case 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Amiodarone 13 15 2.6* 1.24,    5.46 0.012 
Sotalol 4 11 1.09 0.35,    3.43 0.882 
Disopyramide 0 1 ---- ------------ ---- 
Antiarrhythmics 17 27 1.89* 1.03,     3.47 0.040 
Clarithromycin 2 5 1.2 0.23,     6.19 0.827 
Erythromycin 5 21 0.72 0.27,     1.92 0.507 
Macrolides 7 26 0.81 0.35,     1.89  0.626 
Chlorpromazine 2 5 1.2 0.23,     6.19 1.0 
Haloperidol 3 2 4.5 0.75,   26.93 0.099 
Thioridizine 2 0 ---- -------------- ---- 
Antipsychotics 7 7 3.0* 1.05,     8.56 0.040 
Domperidone 4 8 1.5 0.45,     4.98 0.508 
All Type1 (31-90 
days) 
35 67 1.58* 1.04,     2.38 0.030 
* significant at α = 0.05. 
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APPENDIX 2 
 
 
Use of type 2 medications in periods 0-7, 8-30 and 31-90 days before death of index 
case 
 
Table 55 Use of type 2 drugs in 0-7 days before death of index case 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Alfuzosin 2 26 0.23* 0.05,         0.97 0.046 
Amantadine 1 0 ---- ----------------- ---- 
Flecainide 1 3 1.00 0.10,         9.61 1.00 
Indapamide 12 48 0.74 0.39,         1.41 0.362 
Levofloxacin 0 1 ---- ----------------- ---- 
Lithium 4 8 1.5 0.45,         4.98 0.508 
Nicardipine 1 2 1.5 0.14,       16.54 0.741 
Ofloxacin 0 0 ---- ----------------- ---- 
Quetiapine 0 3 ---- ----------------- ---- 
Risperidone 14 8 5.25* 2.02,       12.51 0.000 
Tamoxifen 1 11 0.27 0.04,         2.11 0.214 
Tizanidine 0 0 ---- ----------------- ---- 
Vardenafil 0 4 ---- ----------------- ---- 
Venlafaxine 5 9 1.67 0.56,         4.97 0.360 
Type2 (0-7 
days) 
39 116 1.01 0.69,         1.47 0.962 
* significant at α = 0.05. 
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Table 56 Use of type 2 drugs in 8-30 days before death of index case 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Alfuzosin 3 27 0.33 0.10,       1.10 0.071 
Amantadine 1 0 ---------- --------------- ----------- 
Flecainide 1 3 1.0 0.10,       9.61 1.0 
Indapamide 11 50 0.65 0.33,       1.26 0.202 
Levofloxacin 0 0 --------- -------------- ----------- 
Lithium 4 8 1.5 0.45,       4.98 0.508 
Nicardipine 1 2 1.5 0.14,     16.54 0.741 
Ofloxacin 0 0 --------- --------------- ------------ 
Quetiapine 0 3 --------- ---------------- ------------ 
Risperidone 15 8 5.63* 2.38,     13.27 0.000 
Tamoxifen 1 11 0.27 0.04,       2.21 0.24 
Tizinadine 0 1 --------- ---------------- ------------ 
Vardenafil 0 5 --------- ---------------- ------------ 
Venlafaxine 5 9 1.67 0.56,       4.97 0.360 
Type2 (8-30 days) 40 119 1.01 0.70,     1.46 0.962 
* significant at α = 0.05. 
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Table 57 Use of type 2 drugs 31-90 days before death of index case 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Alfuzosin 5 29 0.52 0.20,       1.34 0.173 
Amantadine 1 0 ------- --------------- ------------ 
Flecainide 1 3 1.0 0.10,       9.61 1.0 
Indapamide 10 53 0.55 0.28,       1.10 0.092 
Levofloxacin 0 2 ------- --------------- ------------ 
Lithium 4 8 1.5 0.45,       4.98 0.508 
Nicardipine 1 2 1.5 0.14,     16.54 0.741 
Ofloxacin 0 7 ------- --------------- ------------ 
Quetiapine 0 2 ------- --------------- ------------ 
Risperidone 14 8 5.10* 2.13,     12.51 0.000 
Tamoxifen 1 12 0.25 0.03,       1.92 0.183 
Tizinadine 0 1 ------- --------------- ----------- 
Vardenafil 0 6 ------- --------------- ----------- 
Venlafaxine 5 8 1.875 0.61,       5.73 0.270 
Type2 
(31-90 days) 
40 130 0.92 0.64,       1.32 0.647 
* significant at α = 0.05. 
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APPENDIX 3 
 
Use of type 4 medications in periods 0-7, 8-30 and 31-90 days before death of index 
case 
 
Table 58 Use of type 4 drugs in 0-7 days before death of index case 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Amitriptyline 13 29 1.39 0.72,      2.69 0.323 
Ciprofloxacin 2 8 0.75 0.16,      3.53 0.716 
Citalopram 11 18 1.83 0.87,      3.89 0.113 
Clomipramine 2 4 1.5 0.27,      8.19 0.640 
Dosulepin 10 17 1.89 0.82,      4.33 0.134 
Fluoxetine 10 14 2.20 0.96,      5.05 0.062 
Imipramine 1 4 0.75 0.08,      6.71 0.797 
Itraconazole 0 0 ---- -------------- ---- 
Nortriptyline 0 1 ---- -------------- ---- 
Paroxetine 9 9 3.00 1.19,       7.56 0.020* 
Sertraline 6 9 2.0 0.71,       5.62 0.188 
Trimethoprim 3 5 1.80 0.43,       7.53 0.421 
Trimipramine 1 0 ---- -------------- ---- 
Type4 (0-7 
days) 
66 117 1.78 1.29,       2.44 0.000* 
* significant at α = 0.05  
 
 
 7
Table 59 Use of type 4 drugs in 8-30 days before death of index case 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Amitriptyline 14 29 1.50 0.79,       2.85 0.215 
Ciprofloxacin 4 10 1.26 0.39,       4.10 0.704 
Citalopram 13 18 2.17 1.06,       4.42 0.034* 
Clomipramine 2 4 1.5 0.27,       8.19 0.640 
Dosulepin 12 18 2.15 0.99,       4.67 0.052 
Fluoxetine 14 13 3.23 1.52,       6.87 0.002* 
Imipramine 1 4 0.75 0.08,       6.71 0.797 
Itraconazole 0 0 ---------
- 
---------------- --------- 
Nortriptyline 0 1 ---------
- 
---------------- --------- 
Paroxetine 10 9 3.33 1.35,       8.20 0.009* 
Sertraline 5 9 1.67 0.56,       4.97 0.360 
Trimethoprim 8 10 2.40 0.95,       6.08 0.065 
Trimipramine 1 0 ---------
- 
---------------- ---------- 
Type4 (8-30 
days) 
82 122 2.16 1.61,       2.91 0.000* 
* significant at α = 0.05. 
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Table 60 Use of type 4 drugs in 31-90 days before death of index case 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Amitriptyline 18 34 1.64 0.92,         2.91 0.093 
Ciprofloxacin 6 13 1.38 0.53,         3.64 0.510 
Citalopram 15 15 3.00 1.47,         6.24 0.003* 
Clomipramine 2 4 1.50 0.27,         8.19 0.640 
Dosulepin 12 19 2.02 0.94,         4.34 0.070 
Fluoxetine 14 13 3.23 1.52,         6.87 0.002* 
Imipramine 1 4 0.75 0.08,         6.71 0.797 
Itraconazole 0 1 ---------
- 
---------------- ---------- 
Nortriptyline 0 1 ---------
- 
---------------- ---------- 
Paroxetine 9 11 2.45 1.02,          5.92 0.046* 
Sertraline 5 9 1.67 0.56,          4.97 0.360 
Trimethoprim 6 25 0.72 0.30,          1.76 0.470 
Trimipramine 1 1 3.0 0.19,        47.96 0.437 
Type4 (31-90 
days) 
85 145 1.89 1.42,          2.51 0.000* 
* significant at α = 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 9
 
 
APPENDIX 4 
 
Results for all type3 only drugs in all time periods are shown below. 
 
Table 61 Use of type 3 drugs in 0-7 days before death of index case 
 
 Cases 
N 
 Controls 
N 
OR 95% CI p value 
Ephedrine 1 0 ----- -------------- ----- 
Pseudoephedrine 1 2 1.50 0.14,    16.54 0.741 
Salbutamol (Oral) 8 12 2.00 0.82,      4.89 0.129 
Salbutamol 
(Inhaler 
85 195 1.35* 1.03,      1.77 0.029 
Salmeterol 34 66 1.59* 1.04,      2.45 0.033 
Sibutramine 0 1 ----- -------------- ----- 
Terbutaline 7 14 1.50 0.61,      3.72 0.381 
Tolterodine 4 11 1.09 0.35,      3.43 0.882 
Type 3 only 
(0-7days) 
108 245 1.38* 1.08,      1.76 0.010 
* significant at α = 0.05. 
 
 
 
 
 
 
 
 
 
 10
Table 62 Use of type 3 only drugs in 8-30 days within death of index case 
before death of index case 
 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Ephedrine 0 0 ---- ------------- ----- 
Pseudoephedrine 1 4 0.75 0.08,       6.71 0.797 
Salbutamol (Oral) 7 13 1.62 0.64,       4.05 0.306 
Salbutamol 
(Inhaler 
84 196 1.33* 1.01,       1.74 0.042 
Salmeterol 35 66 1.64* 1.07,       2.52 0.022 
Sibutramine 0 1 ---- ------------- ------ 
Terbutaline 8 14 1.75 0.72,       4.24 0.217 
Tolterodine 5 12 1.25 0.44,       3.55 0.675 
Type 3 only (8-30 
days) 
107 248 1.35* 1.05,       1.72 0.017 
* significant at α = 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11
 
Table 63 Use of type 3 only drugs in 31-90 days before death of index 
case before death of index case 
 
 Cases 
N 
Controls 
N 
OR 95% CI p value 
Ephedrine 0 0 --- ------------ ----- 
Pseudoephedrine 0 6 --- ------------ ----- 
Salbutamol (Oral) 8 10 2.4 0.95,      6.08 0.065 
Salbutamol (Inhaler 89 198 1.40* 1.07,      1.82 0.014 
Salmeterol 40 70 1.78* 1.19,      2.66 0.005 
Sibutramine 0 1 --- ----------------
- 
--- 
Terbutaline 8 13 1.89 0.77,      4.66 0.166 
Tolterodine 5 14 1.07 0.38,      3.04 0.893 
Type 3 only (31-90 
days) 
115 254 1.43* 1.13,      1.82 0.003 
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